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Abstract 
Background: Cardiomyopathy (CM) frequently leads to heart failure which is 
associated with a high degree of mortality, morbidity and financial burden on 
healthcare providers. Confidence in the recognition of risk factors or in early diagnosis 
allows timely intervention, before heart failure develops. The right ventricle (RV) has 
historically been overlooked when assessing cardiac function and response to therapy 
but its importance is increasingly recognised. Cardiovascular magnetic resonance 
(CMR) is established as the gold standard for assessing the functional consequences of 
cardiovascular disease, being non-invasive and with high accuracy and reproducibility. 
It can also provide in-vivo tissue information which may be diagnostic before 
functional changes are apparent. With this backdrop I tested the hypothesis that CMR 
can provide early disease markers in patients at risk of heart failure in 3 unrelated 
conditions associated with heart failure including: Emery-Dreifuss muscular dystrophy 
(EDMD), anthracycline induced cardiomyopathy and cardiac iron overload in 
transfusion dependent patients. 
Methods and Results: Patients with 3 different clinical substrates for the development 
of CM were studied. In group 1, patients with EDMD were studied by CMR and echo. 
There was a significant reduction in inferior wall contractility using CMR tagging (-
0.062±0.02 versus -0.094±0.03 in the control group, p=0.048) and in echo derived early 
diastolic myocardial posterior wall velocity gradients (4±1.2 vs. 7.1±2.7 s-1, p=0.02). 
Bi-ventricular ejection fraction (EF) was normal and no late gadolinium enhancement 
(LGE) was detected. These findings demonstrated the relative insensitivity of EF in the 
detection of early disease and the need for careful follow up in these patients.  
In group 2, anthracycline mediated cardiotoxicity (AMC) was studied. The risk of heart 
failure rises with cumulative dose but not all individuals are susceptible.  In a cohort of 
patients with early breast cancer an increase in early gadolinium relative enhancement 
(EGRE) from baseline to day 3 correlated with a reduction in LVEF after a year 
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(R=0.34, p=0.01) suggesting a potential clinical role for EGRE in the prediction of late 
AMC.  
In group 3, patients with thalassaemia major (TM) were studied. The coefficient of 
variance (CV) for a new black blood T2* sequence was found to be significantly lower 
than the white blood sequence (1.47% vs 4.23%, p<0.001) and this was adopted for  
clinical use. The RV response to iron chelation therapy was examined in 3 clinical 
trials. Using deferiprone monotherapy RVEF increased from 69.6±5.2 to 72.2±5.3% 
(p=0.001) with a reduction in RV end-systolic volume (ESV) from 37.7±11.7 to 
34.2±11.3 mL (p=0.009). With deferiprone/deferoxamine combination therapy the 
RVEF increase from 60.2±7.2 to 63.8±5.9% (p<0.001) and RVESV decreased from 
60.8±24.2 to 50.6±17.3 mL (p<0.01). These improvements mirrored the LV response. 
However, the response to deferasirox monotherapy was different with no change in 
LVEF, but an increase in RVEF from 66.1±6.1 to 68.8±5.4 (p=0.001) driven by an 
increase in RV end diastolic volume (EDV) from 69.3±19.8 to 76.1±17.1 (p<0.001) 
with a reduction in RV mass from 32.8±7.8 to 24.7±5.6 (p<0.001) and LV mass 
(78.6±16.9 to 66.5±12.9, p<0.001). These results suggest a different pharmacological 
action to deferiprone and deferoxamine, and indicate a possible role of RV 
measurements in risk assessment. 
Conclusions: This thesis has demonstrated that CMR can be used to identify a variety 
of markers of early CM, namely that: Strain abnormalities in EDMD are not associated 
with identifiable fibrosis in EDMD, early inflammatory changes post anthracycline 
exposure can predict late functional changes and that CMR provides sensitive markers 
of therapeutic efficacy on RV function in iron overloaded patients.  
These data improve our understanding of the early effects of CM and demonstrate that 
novel CMR techniques may play a clinically useful role in earlier detection of 
ventricular abnormality, and assessment of differential treatment responses. 
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Chapter  1: Summary and Objectives 
Heart failure is a common late manifestation of cardiomyopathy (CM) that is 
distressing for the patient and associated with high morbidity and mortality. The 
recognition of causative factors and early disease may provide opportunities to slow or 
prevent the onset of symptomatic disease, however ejection fraction (EF), the most 
commonly cited index of cardiac function, often remains within normal limits early in 
the disease process. It is possible that other cardiac parameters may reveal abnormality. 
This thesis explores the use of cardiovascular magnetic resonance (CMR) in 3 groups 
of patients with known risk of CM with disparate causes for ventricular abnormality. 
Particular questions addressed are: 
 Can CMR can provide early disease markers in Emery-Dreifuss muscular 
dystrophy (EDMD). The leading hypothesis being that fibrosis plays a role in 
cardiac involvement? 
 Is there a link between anthracycline induced early inflammatory changes 
(CMR and urinary markers) and a late reduction in cardiac function? 
 Can the T2* sequence for tissue iron assessment in current clinical use be 
optimised to improve reproducibility and therefore reliability? 
 How does iron chelation therapy affect the right ventricle (RV)? 
The word cardiomyopathy is derived from Greek, and means heart muscle disease. The 
term was previously restricted to heart muscle disease of unknown aetiology, which 
was a reflection of the lack of knowledge of disease pathophysiology at the time. 
Diseases affecting the myocardium associated with inflammatory or metabolic 
disorders etc were termed specific heart muscle disease (SHMD). Our understanding of 
disease pathophysiology has been enhanced by recent advances in imaging technology, 
molecular science and genetics which has blurred this distinction and brought SHMD 
under the CM umbrella. Cardiomyopathies are now classified by their aetiology or 
dominant pathophysiology, although full consensus on terminology has yet to be 
achieved.  
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Non-invasive imaging modalities are well established for assisting in the management 
of patients with CM. Cardiovascular Magnetic Resonance (CMR) was first attempted in 
humans in 1983-4, and since then improvement in hardware and acquisition software 
has resulted in applications for functional assessment and tissue characterisation. The 
development of Steady State Free Precession (SSFP) sequences in which a non-zero 
state of magnetisation is maintained, has improved signal to noise coupled with reduced 
motion sensitivity and faster scan duration. With its superior intrinsic contrast and 
spatial resolution, and lack of ionising radiation, SSFP cine imaging is now considered 
the reference technique for cardiac functional assessment. CMR can also characterise 
myocardium with 2 techniques: a) using a gadolinium MR contrast agent, changes at a 
tissue level such as fibrosis and oedema can be identified before global abnormality 
occurs and b) intrinsic contrast from differential tissue relaxation properties such as 
occurs in iron deposition.  
The patient cohorts studied for this thesis have specific or acquired CM with well 
recognised aetiologies. In all these patient groups, previous reports have tended to refer 
to functional changes of the left ventricle (LV). The RV has been largely ignored 
however its importance is being increasingly recognised as a prognostic factor in CM. 
To address this, emphasis has been placed on changes in RV function in this work.  
EDMD is a rare neuromuscular disorder with cardiac involvement that usually requires 
pacemaker insertion. This has to date limited CMR investigation in later disease. 
Taking a well characterised cohort of patients from a specialist referral centre chapter 5 
first explores the hypothesis that fibrosis is a substrate for myocardial dysfunction as 
found in other muscular dystrophies. In this group in whom close follow-up using 
conventional echocardiography had uncovered no functional abnormality, atrial 
volumes CMR tagging and tissue Doppler echocardiography were added to ventricular 
volumetric analysis in an attempt to reveal early changes.  
Anthracycline CM and iron overload CM are examples of toxic CM. In anthracycline 
cardiotoxicity, population risk increases with dosage but individual reactions are 
idiosyncratic. Even at a low dose some patients develop CM, but other patients may be 
denied optimal treatment. The prediction of late complications may help tailor therapy. 
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Chapter 6 describes a 1 year follow-up study of patients receiving adjuvant 
chemotherapy for early breast cancer using CMR and inflammatory markers measured 
at three days post chemotherapy showing that CMR can predict late myocardial 
dysfunction. 
Iron overload CM occurs in patients requiring life-long transfusions, such as beta-
thalassaemia major, and can be reversed if appropriate iron chelation therapy is 
administered, but heart failure is still the commonest cause of death worldwide. 
Unfortunately liver iron concentration (LIC) and ferritin levels do not predict cardiac 
iron burden. CMR T2* can accurately show cardiac iron levels and therefore indicate 
patients at risk of heart failure and subsequent death. There are however technical 
challenges associated with the established white blood technique which may reduce 
diagnostic accuracy. Chapter 7 describes the validation of a new T2* sequence that has 
increased the diagnostic robustness of CMR iron overload assessment and has now 
been adopted into routine clinical use. 
A relationship between myocardial T2* and RV function has been established but there 
is no data on the response of the RV to chelation therapy. Deferiprone is known to 
improve LV function in patients with cardiac iron overload, both as a monotherapy 
improves and in combination with deferoxamine. Deferasirox does not improve LV 
function. Chapters 8 and 9 examine the effect on the RV of deferiprone and 
combination therapy respectively, the results as expected showing an improvement in 
RVEF associated with a reduction in RV end systolic volume (ESV). Unexpectedly the 
cardiac functional response to deferasirox monotherapy (chapter 10) showed an 
increase in RVEF associated with an increase in RV end diastolic volume (EDV) with a 
reduction in RV and LV mass but no improvement in LVEF. These results show 
differential effects on the RV of the iron-chelators, which have potential clinical 
impact.  
In summary, this work for this thesis has shown CMR to be a versatile imaging 
modality for exploring phenotypic changes in CM. Its strengths in characterising the 
myocardium have been used to define diagnosis, evaluate treatment efficacy and 
contribute to risk assessment for clinical outcomes, for both the left and right ventricles. 
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In particular strain abnormalities in EDMD identified using CMR and echo were not 
associated with macroscopic myocardial fibrosis. Early CMR inflammatory changes in 
AMC were related to early changes in urinary isoprostanes and late changes in cardiac 
function. RV functional improvement with deferiprone mono and combination therapy 
is associated with, but not dependent upon, improved LV function. The results for the 
deferasirox trial however suggest a different therapeutic effect with interesting 
ramifications.  
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Chapter  2: Cardiovascular Magnetic Resonance 
2.1 Basic principles of magnet resonance 
2.1.1 Nuclear spin 
Atomic nuclei are usually made up of positively charged protons and uncharged 
neutrons. Both possess quantum spin characteristics (angular momentum) that can 
cancel each other out resulting in a zero net nuclear spin. Isotopes with an uneven 
number of protons and neutrons have a net spin and are useful for MR if in sufficient 
abundance. This is due to the fact that a rotating charge (dipole) produces an electrical 
current which in turn generates a magnetic field in the direction of the axis of rotation, 
termed the magnetic moment. The magnetic moment is a directional force, the 
characteristics of which determine the effect of an external magnetic field. 
 
Figure 2-1 Proton spin velocity is constant however the angle of spin is random 
outside a magnetic field. 
Although nuclear rotational or spin velocity is constant the angle of the spin or axis is 
variable and the sum effect of the individual nuclei can be expressed as a vector. Out of 
a magnetic field nuclear spin orientations are random therefore net magnetisation is 
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effectively zero. The utilisation and manipulation of these spin vectors is the basis of 
magnetic resonance imaging. 
 Commonly used nuclei in MR are 1H, 31P, 23Na, 14N, 13C and 19F. Hydrogen is the 
most abundant element in the body being the major component of water and fat. In 
addition the nucleus of the hydrogen atom, consisting of one positively charged proton, 
gives the strongest MR signal when compared with other elements. 
Although an analogy can be drawn between a magnetic dipole and a bar magnet or 
electrostatics a magnetic dipole has a particular feature that is exploited for MR 
imaging, it precesses when placed in an external magnetic field.  In other words the 
spin direction rotates. 
2.1.2 Spin behaviour in a magnetic field 
When placed in a magnetic field, B0, the spin vectors of the nuclei align with the 
external field (designated the Z axis) in a direction dependant on their energy state.  
The low energy state is where the poles are aligned (parallel or spin up) and the high 
energy state (anti-parallel or spin down).There is a small excess of nuclei in the more 
stable lower energy state dependent upon external field strength, temperature and 
proton density. It is approximately 9 parts per million at body temperature and field 
strength of 1.5T which leads to a very weak net magnetisation or paramagnetism. 
Paramagnetism is the term used for substances that exhibit no magnetic properties 
outside a magnetic field but show a slight positive interaction within an applied field. It 
can also be called positive magnetic susceptibility. The result of this is a net 
magnetisation in the Z axis, termed Mz. The torque exerted by the external field affects 
the spin angular momentum causing a precessional motion, of the spin axis. This can be 
likened to the effect of gravity, acting as an off-centre force, on the spin of a gyroscope. 
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Figure 2-2 Spin vectors align with an external magnetic field and the torque 
exerted causes the spin vectors to precess. 
Precessional speed is proportional to the external field strength (but is much lower than 
the proton‟s rotational velocity). The stronger the external magnetic field, the higher the 
precession or Larmor frequency expressed by the equation ω = γ B0 where ω= Larmor 
frequency, γ= gyromagnetic ratio of the nucleus and B0 = field strength. The 
gyromagnetic ratio is a constant that relates frequency and external magnetic field 
strength and is the ratio of the magnetic moment to the angular momentum. It is 
different for each nucleus. For 1H it is 42.58 MHz/T. The Earth‟s magnetic field is only 
about 50 μT and nuclei precess at approximately 2 kHz. In MR scanners field strength 
is high, usually 0.5 to 7 Tesla (T). Nuclei therefore precess at radio frequency (RF) in 
MR systems. For example the precessional frequency for 1H at 1.5 T is approximately 
63MHz (which is why shielding against extraneous RF waves is necessary). 
2.2 Excitation and energy level transition 
  Nuclei in the lower and higher energy states are in equilibrium within the constant 
external field. Nuclei can undergo a transition from high to low or low to high by the 
absorption of a photon with exactly the same energy as the difference between the two 
states. This energy is related to its frequency by Planck‟s constant designated h, (where 
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h=6.626x10-34 Js) by the equation ∆E=hf where f is the precessional frequency. This in 
turn is related to the Larmor frequency ω by the equation ω=2πf. The fact that each 
isotope has a unique resonant or Larmor frequency which in turn is directly 
proportional to the external field can be utilised for imaging. The term nuclear magnetic 
resonance refers to the process by which the nuclei within a magnetic field absorb and 
emit electromagnetic energy. Applying an alternating voltage of the correct frequency 
to a radio-frequency (RF) coil creates a second, much weaker, alternating field (B1) 
which, in an MR system, is aligned perpendicular to the external field (B0). This is 
termed the RF pulse.  Before commencing a MR examination the system will calculate 
the precessional frequency (centre frequency) of the subject within the magnet bore to 
determine the frequency of the RF pulse to be utilised. The oscillating field is rotated at 
the Larmor frequency in the XY plane, perpendicular to B0.  This will change the net 
magnetisation vector which spirals from alignment with the B0 field into a rotational 
motion in the XY plane. (Ridgway 2010) The strength (amplitude) and duration of the 
RF pulse will determine the angle of the rotation, which is termed flip angle in MR 
imaging. This process is known as excitation. 
 
Figure 2-3 The RF pulse rotates net magnetisation from the from the Z axis into 
the XY axis. The angle of rotation is dependent upon the duration and amplitude 
of the pulse. 
Although within an external magnetic field the precessional frequency of individual 
nuclei will be the same their precession is out of phase such that transverse magnetic 
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vectors cancel. The alternating, or rotating, RF pulse however not only changes 
magnetisation along the Z axis. As the applied field is rotating at the Larmor frequency 
of the spins it creates phase coherence, i.e. they start to spin in phase thus generating 
net magnetisation transverse to the Z axis (designated Mxy). This happens 
simultaneously with the loss in magnetisation in the Z axis. The rotating transverse 
magnetisation induces a voltage which can be detected by a receiver antenna which is 
used to provide the raw data for the MR image.   
2.3 Longitudinal relaxation and T1 
When the RF field is turned off the spins revert back to their lower state or equilibrium 
spontaneously over a period of time emitting photons of energy at the Larmor 
frequency. Thus the net magnetisation realigns with the Z axis, the speed of which is 
determined by the surrounding protons (or tissue in the case of clinical MR imaging). 
This transition is termed longitudinal relaxation and is due to the exchange of energy 
with the environment or „lattice‟. Accordingly this process can be referred to as spin-
lattice relaxation. The process is exponential and the time constant describing this 
return to equilibrium of the longitudinal magnetization along the Z axis is termed T1. 
The value of the magnetisation is given by Mz = Mo(1-1/e) where Mo is the 
equilibrium value. At the time T1 63% of the original longitudinal magnetisation has 
recovered. Protons in large molecules such as lipids or proteins have fairly short T1 
values as they are tightly bound to adjacent molecules and more sensitive to field 
fluctuations (due to induced fields from neighbouring nuclei and unpaired electrons) 
This means they can exchange energy to their surroundings and change their spin states 
rapidly. In contrast, protons in water are more mobile and less affected by field 
fluctuation and therefore change their spin state less readily. The fact that different 
tissues have a unique T1 is utilised in MR imaging and provides intrinsic contrast. For 
example the T1 for normal myocardium has been measured to be between 1000ms and 
1100ms at 1.5T and between 1200ms and 1500ms at 3T.  For blood it is between 
1400ms and 1600ms at 1.5T and between 1600ms and 2100ms at 3T.(Stanisz 2005, 
Sharma 2006, Sibley 2011)  
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2.4 Transverse relaxation and T2 
After the RF pulse has ceased the spins also rapidly de-phase causing the transverse 
magnetization, and therefore the signal, to decay. This is termed free induction decay 
(FID) and is caused by the interaction between neighbouring spins (spin-spin 
relaxation). As with longitudinal relaxation the process is exponential and the decay 
time is defined by the time constant T2 where transverse magnetisation has reduced to 
37% of the maximal value (Mxy(t) = MxyMaxe-t/T2). The decay is dependent upon 
how the proton is bound, protons in fat and other solid tissues will generally dephase 
much more quickly than those in liquids. The loss in phase coherence thus loss in signal 
is accelerated by the proximal fluctuating magnetic fields,  generally due to protons in 
large molecules, frequently encountered in biological systems. These localised non-
uniformities cause a slight change in the precessional frequency reducing phase 
coherence and transverse magnetisation.  The combination of T2 and other dephasing 
factors is termed T2* substituting T2* for T2 in the previous equation. T2* is always 
shorter than T2 which is always shorter that T1. Different scan acquisition sequences 
utilise the difference in these relaxation parameters for different tissues to provide 
image contrast. 
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Figure 2-4 The 90° RF pulse rotates net magnetisation from the Z axis into the XY 
plane. Longitudinal net magnetisation returns to equilibrium slowly, the time 
constant T1 represents when 63% of the original magnetisation has recovered. 
Transverse magnetisation returns rapidly to baseline through a process termed 
free induction decay and is represented by the time constant T2* when it has 
reduced to 37% of the maximal value. 
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2.5 The MR scanner 
The MR system is composed of four basic functional units. These are; 
•The magnet, which for modern medical systems is a superconducting electro-magnet. 
•The RF system which consists of RF transmit and receive antennae and amplifiers 
•A gradient system to induce field gradients in all three spatial directions for spatial 
encoding. 
•A computer system for acquisition and image processing. 
 
Figure 2-5 Diagrammatic representation of a MR system 
2.5.1 Main magnet 
MR systems can be in the form of a tunnel or an open system and there are specialised 
systems for scanning extremities or for animal work. Tunnel based systems are used for 
CMR as the magnetic field tends to be stronger and more homogeneous. 
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A clinical MR system consists of a super-conducting magnet (electromagnet) which 
induces a static homogeneous magnetic field. It is made from coils of conducting wires 
(niobium/titanium alloy in copper). It is cooled by liquid helium to almost absolute zero 
at which point the wires lose electrical resistance thus once the required field strength is 
attained no further electric input is necessary (hence the term super-conducting). 
Homogeneity of the field is of paramount importance as inhomogeneities cause 
distortion in spatial encoding. The system must be shielded from extraneous magnetic 
or RF activity which will interfere with scanner performance. In addition shielding will 
prevent magnetic and RF interference from the scanner affecting nearby equipment. 
The system is therefore placed in Faraday cage which blocks radio waves.  
Newer scanners also have active magnetic shielding integral to the scanner. These use 
additional coils at each end of the magnet to reduce the fringe fields for safety reasons. 
2.5.1.1 Shimming 
As the perfect magnet does not exist homogeneity is improved by a process termed 
shimming. Passive shimming involves placing ferromagnetic material around the main 
magnet, usually during scanner set-up. Active shimming uses shim coils to induce 
small currents to compensate for small induced inhomogeneities during scanner use. 
2.5.2 Gradient Coils 
Spatial localisation is determined by using the gradient coils. These coils are placed in 
each spatial direction and superimpose linear variation to the main magnetic field. This 
in turn alters the resonance frequency and spin phase in proportion to the local field 
allowing spatial differentiation. The performance of the gradient coil is very important 
as it affects image quality and the ability to perform rapid imaging. Gradient 
performance is determined by the peak gradient and slew rate (the gradient switching 
speed measured in mT/m). Generally amplitude and slew rate increase with increasing 
main magnetic field strength but the gradient system itself is a determinant factor. 
Gradient systems can be upgraded without changing the main magnet. It is the vibration 
of the gradient coils and their surroundings during switching that causes the 
characteristic noise of the MR scanner. 
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 The rapid gradient changes can induce electrical currents in nearby conducting 
materials (Eddy currents) which in turn can affect the gradient fields and hence the 
image quality. This can be countered by active coil shielding or manipulating the coil 
currents to offset Eddy currents. 
2.5.3 RF Coils 
The RF pulses that energise the protons in the magnetic field are produced by the body 
coil within the bore of the magnet. The body coil is a transmit-receive coil (i.e. 
comprises transmit and receive antennae) which produces the excitation pulse as well 
as receiving the MR signal (from net spin in the XY direction). The RF system also 
incorporates transmit and receive amplifiers to ramp up the signals. The body coil has a 
large measurement field but low signal to noise ratio (SNR). A stronger signal is 
detected by placing a coil closer to the area of interest. In addition smaller volume 
samples give a better SNR. For this reason smaller surface or volume coils, either 
transmit-receive or receive only, tend to be used for focused examinations. Volume 
coils encompass the body part to be scanned whereas surface coils are placed directly 
over the area of interest. The trade-off for smaller coils is that signal uniformity 
decrease rapidly away from the coil itself thus limiting the scan field. Array coils, 
which are made up of small coil elements which can be summated, combine a higher 
SNR with a larger measurement field. For CMR the receiver coil is usually an array of 
four or more coils placed directly on the chest.  
2.5.4 Image formatting 
The received analog signal needs to be digitised by an analog to digital converter for 
processing. The digital data are then stored, according to phase and frequency, in a 
temporary spatial domain termed k-space. K-space is filled with the raw data during the 
scan, usually one line per TR and with the same number of rows and columns as the 
final image. 2D Fourier transformation of the raw data in k-space produces the image. 
The centre data in k-space contribute to the rough shape of the structure and contrast. 
The more marginal k-space points determine resolution. Other than linear filling, k-
space can be filled centrically, radially, spirally and in numerous other ways. 
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Figure 2-6 , k-space is a matrix which is filled by the raw frequency and phase 
information. This is then Fourier transformed to produce the image. 
2.6 Sequences used in CMR 
2.6.1 The fundamentals of image acquisition 
Simplistically a magnetic resonance image can be thought of as a proton map. Image 
formation relies on the correlation of signal intensity and spatial information derived 
from proton density coupled with spin manipulation. Once the sample (or patient) has 
been placed within the main magnetic field a complex interaction between operator, 
computer system, gradient fields and RF pulses produces a bounty of imaging 
possibilities. By manipulating the acquisition protocols the intrinsic contrast potential 
of the modality can be exploited to show gross anatomy, function and tissue 
characteristics.   
2.6.1.1 Slice selection 
If a patient is in a uniform magnetic field all proton spins would be similarly excited by 
the applied RF pulse and image formation impossible. Similar to most other medical 
imaging modalities MR acquires tomographic images. The first step in obtaining an 
image is to select the focal plane. This is achieved by activating the slice encoding, or 
select, gradient. As previously stated the precessional frequency is proportional to the 
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applied external field strength. By applying a gradient perpendicular to the desired 
image plane, protons in every plane will precess at a different frequency determined by 
the local field strength. A slice select RF pulse is applied at the same time as the 
gradient. Only the protons precessing at the same frequency as the applied RF pulse 
will absorb energy and therefore a signal is only generated within that selected slice. 
The thickness of the slice is determined by the range of frequencies within the RF 
pulse, the bandwidth, and the slope of the slice select gradient (a steeper gradient 
excites a thinner slice). Slice orientation is defined by changing the centre frequency of 
the RF pulse to correspond to that of the desired location. 
 
Figure 2-7 Slice selection: The gradient coils induce a magnetic gradient along the 
Z axis. Precessional frequencies will vary along the direction of the gradient. Only 
the protons precessing at the same frequency as the applied RF coil will be excited. 
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2.6.1.2 Phase encoding 
The tomographic section or slice has now been isolated but it is not yet possible to 
determine from where within the slice a particular signal comes from. The next step is 
to sort the signals according to their origin within the slice. While the spins are still in 
the transverse plane after the RF pulse and slice select gradient a gradient field is 
applied briefly in the chosen phase encoding direction, usually designated the y axis. 
The phase change along the column depends on the polarity and amplitude of the 
gradient. After each phase encoding a frequency encoding is acquired.  A series of 
phase encoding gradients are applied sequentially with differing gradients. The symbol 
used in sequence diagrams to represent phase encoding is a diagrammatic 
representation of the change in gradient magnitude and polarity (figure 2-8). The 
number of steps is dependent on the field of view (FOV) and desired resolution (which 
is proportional to the number of phase encoding levels used). The phase encoding for 
each column along the y axis is performed separately, therefore to complete the slice 
acquisition the complete process of slice select, phase encoding and frequency 
encoding needs to be repeated.  These phase encoding steps are termed repetitions and 
there are usually between 128 and 256 for cardiac imaging. The duration is termed the 
repetition time (TR).  The resultant difference in the phase of the magnetisation vector 
along the y axis is used during Fourier transformation.  
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Figure 2-8 A gradient in the Y axis produces incremental phase encoding steps. A 
compressed representation of the above diagram is used to depict the phase 
encoding steps in a sequence diagram. 
 
2.6.1.3 Frequency encoding 
A frequency encoding gradient is applied to spatially encode in the other perpendicular 
direction to phase encoding. The frequency encoding gradient (or readout gradient) is 
applied during signal acquisition. It imparts a changing precessional frequency along 
the direction of the gradient thus providing spatial information in for this example the x 
axis. If the final image has 256 pixels across in the frequency encode direction then 256 
frequencies are differentiated within the signal, i.e. one frequency per pixel is defined.  
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The phase and frequency encode gradients are always applied perpendicular to each 
other and the slice selection gradient direction.  However, the three gradients can be 
rotated to any angle to allow any slice plane to be acquired.  This constitutes an 
advantage of gradient based MR technology over other imaging modalities. The 
sequence of pulses is repeated, usually 128 or 256 times, with different phase encode 
amplitudes, to generate an image. The timing between repetitions is termed the 
repetition time (TR). 
 
Figure 2-9 Gradient induced phase encoding along the Y axis and frequency along 
the x axis provides spatial information. 
2.6.1.4 Contrast manipulation 
Image contrast is largely dependent upon T1 and T2 and how much relaxation of each 
has occurred before readout and subsequently applying the next excitation. If the TE is 
very short and very little dephasing has occurred T2 will have little effect on tissue 
contrast. If in addition the TR is short tissue with a longer T1 will not have regained 
much longitudinal magnetism to be used for the next excitation.  This will result in low 
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signal in the final image. The contrast in this case will be determined by the T1 of the 
constituent tissues and the acquisition is described as T1 weighted. Lengthening the TE 
allows T2 to cause dephasing for longer which will reduce signal from tissues with a 
shorter T2. If the TR is also long longitudinal relaxation will have recovered for most 
tissues and T1 plays little part in the image contrast. The image contrast is now 
dependent upon the TE and therefore T2 and is said to be T2 weighted. Proton density 
weighted contrast is achieved by having a short TE and long TR eliminating most of the 
effects of T1 and T2 and signal strength is dependent upon the number of proton 
present. The type of weighting selected depends on what is to be demonstrated by the 
image. Further contrast manipulation can be obtained by using a contrast medium such 
as Gd-DTPA which reduces the T1 and gives a bright signal on T1 weighted images. 
2.6.1.5 Cardiac gating 
Motion artefacts due to respiratory motion can be eliminated by breath-holding if the 
acquisition is short enough. There is still a problem with cardiac motion and unless the 
acquisition time is extremely fast blurring of the image will occur. Cardiac gating 
synchronises the beginning of the acquisition with the R wave of the electrocardiogram 
(ECG). 
2.6.2 Basic sequence steps 
An example of a very simple imaging sequence is shown below. Using the three 
perpendicular gradients the imaging slice is selected and spatially encoded. Firstly a 
slice select gradient is applied along with a RF pulse of sufficient amplitude and 
duration to rotate the net magnetisation through 90° into the XY plane. Spatial 
encoding is achieved by the application of a phase encoding followed by a frequency 
encoding gradient in the other two perpendicular planes. The resultant FID signal can 
be detected using a RF receiver coil. 
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Figure 2-10 A schematic diagram of a basic sequence showing the order of steps to 
produce the image. The FID decay signal is sampled by a receiver coil. The 
graphic depicting the phase encoding represents the multiple phase encoding 
steps. 
Although the FID can be utilised as a signal for imaging, the problem with this basic 
scan sequence is that signal decay, especially in a biological system, is very rapid due 
to dephasing caused by field inhomogeneities. In addition the magnetic field gradients 
used to create the signal further disrupt the FID.(Ridgway 2010) The time in which a 
signal can be detected after the RF pulse is therefore limited to just the latter part of the 
signal, resulting in a relatively poor SNR. This can be compensated for by generating 
an echo by applying field gradients or a 180° refocusing RF pulse. 
2.6.2.1 Gradient echo sequences 
Gradient echo (GRE) sequences are produced by the application of bipolar gradient 
pulses. The first gradient causes protons to lose phase coherence along the direction of 
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the gradient which causes the FID signal to drop.  Applying a second gradient of the 
same amplitude and in the same direction but of opposite polarity will re-phase the 
spins with a resultant reappearance of the signal (echo). If the gradient continues to be 
applied spins will once again lose coherence and the signal will drop again. In a 
standard gradient echo acquisition the basic pulse sequence is repeated with different 
phase encoding gradients until k-space is filled. For gradient echo imaging the slice 
select pulse is usually between 5° and 60° and this factor, along with the lack of a 180° 
refocusing pulse, permits a much shorter TR. Contrast and  signal strength are 
determined by the flip angle and longitudinal magnetisation. A larger flip angle gives 
more T1 weighting. Spoiler gradients can be applied at the end of the sequence to de-
phase remaining spins and ensure only longitudinal magnetisation is present when the 
next RF pulse is applied. Alternatively RF phase cycling (RF spoiling) can be used to 
minimise the transverse magnetisation. 
 
Figure 2-11 The gradient echo sequence uses gradients of opposite polarity to 
dephase then rephase the spins to produce a gradient echo. 
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Gradient mediated refocusing is fast and is therefore suitable for dynamic imaging.  As 
the TR is very short the low flip angle is necessary. Basically the images become T2* 
weighted but as the TE is also very short this is not a problem. The trade off is loss in 
SNR and an increase in signal loss and magnetic susceptibility artefacts induced by 
magnetic field inhomogeneity compared with spin echo sequences. This factor however 
plays a positive role in CMR based tissue iron overload evaluation. FLASH imaging 
(fast low angle shot) is an example of this type of sequence and was used for CMR 
functional imaging before balanced steady state free precession (SSFP) acquisition 
methods became available. 
2.6.2.2 SSFP imaging 
SSFP is used to describe a gradient echo sequence whereby a non-zero steady state is 
achieved for both longitudinal and transverse magnetisation. The flip angle tends to be 
higher than other GRE sequences. The TR is shorter than T1 and T2. Transverse 
magnetisation is not lost or spoiled but rephased at the time of the next excitation. This 
is added to the transverse magnetisation induced by the following RF pulse. Repeating 
this process results in a decreasing Mz component until a steady state is achieved for 
both longitudinal and transverse components. The steady state is maintained by the 
relationship between flip angle and TR. T2* and T1 properties determine contrast.  This 
is influenced by the TR which is selected to optimise contrast in the selected slice. 
TrueFISP (true fast imaging with steady state precession) is an example of a SSFP 
sequence and is available on Siemens scanners. SSFP sequences are rapid with 
excellent blood to myocardial contrast due to the relatively low myocardial signal 
compared with high signal from blood and fat. They are therefore ideal for cardiac 
imaging. There are problems with susceptibility artefacts although these can usually be 
counteracted by shim and RF frequency adjustments. 
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Figure 2-12 SSFP sequences use gradients of alternating polarity to maintain a 
steady state of transverse magnetization. 
2.6.2.3 Spin echo sequences 
Spin echoes are generated by applying a RF pulse that rotates the magnetisation 
through 180° after the run time τ following the 90° pulse.  
 
Figure 2-13 Diagrammatic representation of a spin echo sequence. 
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This results in a recovery of phase coherence lost by magnetic field inhomogeneities 
and therefore transverse magnetisation which reaches its maximum at a time 2τ 
producing what is termed a spin echo. In other words it removes the T2* effects 
therefore relaxation is dependent upon the T2 of the tissue. This time to maximal signal 
is termed the spin echo time and this is normally arranged to coincide with the imaging 
echo time (TE). The frequency encoding gradient is applied once again during the spin 
echo and the signal from the echo is read out. 
 
Figure 2-14 The 180° pulse re-phases the protons thus prolonging transverse 
relaxation and therefore signal. 
The disadvantage is the increase in scan time due to the additional step and the 
requirement to wait for Mz to recover prior to repeating the sequence. 
2.6.2.4 Multi-slice spin echo sequences 
Spin echo sequences are routinely used for anatomical imaging. Most investigations 
involve the exploration of entire body parts or organs requiring multiple tomographic 
sections. If each slice was acquired separately the time burden would be huge as T1 
needs to recover to ensure sufficient longitudinal magnetisation for the next excitation. 
To get around this the next slice is selected and excited while the first recovers and so 
on through the stack of planes to be imaged. This process is repeated until k-space is 
filled for each slice. 
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2.6.2.5 Turbo spin echo 
Scan time can be further reduced by inducing a chain of 180° pulses after the 90° pulse 
in a multi-echo sequence. This produces a series of echoes of reducing amplitude while 
T2 relaxation continues allowing several lines of k-space to be filled per excitation. The 
T2 is generally long enough for a relatively large number of echoes to be collected. For 
an echo train length (or turbo factor) of 5 the scan will take 1/5 of the time which is 
useful for cardiac work as it generally can be acquired during a breath-hold. 
2.6.2.6 HASTE sequences 
These are rapid single shot acquisitions in which an image slice can be obtained in less 
than one second. The acronym stands for Half Fourier Acquisition single Shot Turbo 
spin Echo (HASTE). A single 90° pulse is followed by as many 180° as there are lines 
of k-space to be filled. Further sequence acceleration is attained by partial k-space 
filling. If just over half of k-space is acquired, based on a couple of reasonable 
assumptions, it is possible to calculate the remaining k-space at the expense of signal to 
noise. An image can be acquired every cardiac cycle meaning that the sequence is 
insensitive to respiratory motion. This acquisition is useful for obtaining an overview of 
gross anatomy and for subsequent scan plane set up. 
2.6.3 Prepulses 
2.6.3.1 Inversion recovery sequences 
Inversion recovery (IR) sequences are sequences in which the 90° pulse is preceded by 
a 180° inversion pulse.  The initial pulse flips the magnetisation through 180° in the Z 
axis. Ensuing relaxation is thus only T1 recovery as there is no x-y magnetisation.  This 
recovery proceeds for a time known as the inversion time (TI). This is in the order of 
T1 after which the imaging sequence is applied. IR sequences therefore usually have a 
long TR but short TE such that image contrast depends mainly upon the TI. The 
prolonged T1 time separates the recovery curves of different tissues thereby creating 
very good T1 contrast. Manipulation of the inversion time is utilised for assessment of 
tissue viability post contrast injection. 
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2.6.3.2 STIR 
Short TI (sometimes called short Tau or inter-pulse time) inversion recovery sequences 
suppress the signal from fat by selecting a TI where the magnetisation of fat is zero so 
none is available to flip into the XY plane. On the resultant image fat will appear dark 
but fluids that tend to have a long T1 and T2, will be bright. This makes the sequence 
sensitive for the detection of fluid which is useful for the detection of inflammation. 
2.6.4 T2* sequences 
2.6.4.1 Bright blood 
2.6.4.1.1 Multiple breath hold single echo 
Gradient echo are faster than spin echo sequences consequently motion artefacts are 
reduced. They are also very sensitive to local field inhomogeneities which are increased 
by the presence of iron particles. Based on these factors a gradient echo sequence was 
developed in this unit.(Anderson 2001)   For the pilot study a 10mm thick single mid 
ventricular short axis slice was imaged at nine different echo times (TE 5.6-17.6) 
during nine separate breath-holds. The longer the echo time the less transverse 
magnetism there is left to give a signal. With increasing iron levels protons dephase 
earlier due to the increased local field inhomogeneity so that signal is lost even with 
shorter echo times for the most iron overloaded tissue. The acquisition is gated to the 
R-wave so that images are acquired during diastole where cardiac motion should be 
minimal. Although the reproducibility of this technique is generally good there can be 
problems with miss-registration due to breath-hold position inconsistencies. It is also 
time consuming as each scan lasts about 10-15 seconds and needs to be repeated for 
each TE. 
2.6.4.1.2 Single breath hold multi echo 
Improved gradient performance has lead to the subsequent development of a single 
breath-hold multi-echo sequence. This has addressed the issues associated with the 
multiple breath-hold sequence allowing all the images to be acquired during one breath-
hold. (Westwood 2003) Instead of having one echo time per acquisition a series of 
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gradients are applied resulting in a train of echoes with increasing TEs. This means that 
the T2* decay and therefore iron loading can be assessed in one short acquisition. 
 
Figure 2-15 The multi-echo sequence uses a train of different echo times that are 
acquired during a single breath-hold. 
2.6.4.2 Black blood T2* 
The reproducibility of the single breath-hold sequence is very good (Westwood 2003) 
but contrast between the myocardium and blood pool may be sub-optimal and despite 
flow compensation, artefacts from blood and motion may compromise accuracy. A 
black blood sequence which suppresses the blood signal has been developed to improve 
image quality. (He 2007) To achieve blood signal nulling a double inversion recovery 
(DIR) preparation is used.  A non selective 180° pulse is applied on the R wave which 
inverts the spins within the RF coil volume. The inversion time is set to null the blood 
signal. The second selective 180° pulse restores magnetisation within the selected slice. 
This means spins outside the slice are inverted but magnetisation is restored within 
selected slice. Blood motion within the heart is rapid. In the time between inversion and 
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acquisition the blood within the selected sliced is replaced by that previously inverted 
and is nulled at the time of imaging and appears black on the image. 
2.6.5 Myocardial tagging 
The use of spin tagging to produce saturated bands within the myocardium was first 
described in 1988. (Zerhouni 1988) This concept was further developed to produce a 
series of parallel saturation bands throughout the image using spatial modulation of 
magnetisation (SPAMM). (Axel 1989) 
2.6.6 Imaging using a contrast agent 
Gadolinium is a lanthanide element. It is the most commonly used intravenous MR 
contrast agent. This is due to the affect on the relaxation time in the tissues permeated.  
The T1 relaxation time is reduced which increases signal intensity (SI) on T1 weighted 
images. Although highly toxic, the Gd3+ ion can be chelated with 
diethylenetriaminepentaacetic acid (DTPA) to form Gd-DTPA. This is a very stable 
compound with retained paramagnetic properties. It is generally safe however there 
have been reports of nephrogenic systemic fibrosis (NSF) and nephrogenic fibrosing 
dermopathy (NFD) occurring in patients with severely impaired renal function. This is 
thought to be due to the prolonged time the compound is in the body and the 
subsequent breakdown of the chelate. Gadolinium containing contrast agents have been 
classified as high, medium and low risk for the development of NSF according to 
current evidence. As a consequence risk minimising measures have been advocated. 
Renal function should be assessed prior to receiving a high risk compound and is 
advisable with medium and low risk agent, particularly in patients of ≥ 65 years. The 
use of a high risk agent is contra-indicated in patients with severe renal impairment, if it 
is necessary to use a medium/low risk agent the minimal dose should be used and not 
repeated within 7 days. There is no supporting evidence that haemodialysis plays a role 
in the prevention of NSF in patients not already undergoing this treatment. A full list of 
risk minimisation measures can be found on the MHRA website. (MHRA 2010) First 
pass imaging is used for CMR angiography and myocardial perfusion. Late Gd-DTPA 
enhancement highlights areas of tissue damage and fibrosis. 
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2.6.7 Acquisition acceleration 
2.6.7.1 Echo planar imaging 
Echo planar imaging (EPI) is an ultra fast imaging technique that can use a single 
excitation pulse to fill k-space and therefore acquire the entire image. Alternatively, 
hybrid EPI can be applied to acquire a number of echoes or k-space lines after each 
excitation.  For both, a bi-polar gradient induces a train of gradient echoes, the number 
of which is termed the EPI factor. The T2* is relatively short limiting the readout to a 
maximum of between 64 and 128 echoes. Data rows in k-space are filled in alternating 
directions. Applying the phase encoding gradient for a short “blip” prepares for the 
filling of the next line in k-space. Image acquisition can be as short as 50 ms which 
generally makes the acquisition relatively motion insensitive. As EPI is the read-out 
part of the sequence contrast can be obtained by combination with selected preparation 
pulses. EPI is used frequently for myocardial perfusion imaging which requires the 
collection of a number of complete image slices every cardiac cycle. 
2.6.7.2 Parallel imaging 
The duration of a MR acquisition is largely dependent upon the phase encoding step 
which in turn depends on the gradient switching rate. The speed of image generation 
can be accelerated by using a parallel acquisition technique using an array coil.  This is 
achieved by reducing the phase encoding steps and filling missed data rows by using 
individual coil information or interpolated data. There is some loss of SNR with 
parallel imaging but this is offset by the ability to obtain more data in a limited time 
span, for example a breath-hold. 
2.7 Clinical applications 
2.7.1 History 
The phenomenon of nuclear magnetic resonance (NMR) was first described by Rabi in 
the 1930s and further explored in the 1940s by Bloch and Purcell. (Rabi II 1938, Bloch 
1946, Purcell 1946)The combination of a magnetic field and RF waves were observed 
to cause atoms to emit a radio signal. In 1971 Damadian noted that the signal from ex-
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vivo cancerous tissue differed from that of normal tissue and later in the 1970s the first 
in vivo scan was performed. (Damadian 1971, Damadian 1977) Since the early 1980s 
the development and use of magnetic resonance imaging for clinical purposes has 
exploded (the word nuclear was dropped because of negative associations). Attempts at 
cardiac imaging were originally disappointing due to cardiac motion and respiratory 
artefacts. The development of better hardware and gradient performance led to faster 
scanning with the possibility of the data being acquired within a breath-hold. ECG 
triggering meant cardiac motion was no longer such a problem. MR imaging of the 
heart became a sub-specialty akin to echocardiography and is now referred to as 
cardiovascular magnetic resonance (CMR). The society for cardiovascular magnetic 
resonance (SCMR), set up in 1996, has its own academic journal and the British society 
of CMR (BSCMR) was established in 2004 with 62 active centres within the UK 
(BSCMR newsletter June 2011). 
2.7.2 Overview 
CMR does not use ionising radiation which is a major benefit over radionuclide or 
fluoroscopy based imaging modalities. This is an important consideration when 
sequential studies are required, particularly in children. Additionally spatial orientation 
is not limited and there is not the tissue attenuation problem associated with 
radionuclide or echo imaging. Any part of the heart can be imaged in any plane due to 
the use of gradient technology. The 3D contiguous data sets provided by CMR are of 
particular importance in the evaluation of complex anatomy in congenital heart disease. 
CMR is less operator dependant than echo but does require a thorough knowledge of 
anatomy. Intrinsic contrast can be manipulated to highlight disease pathology. Injecting 
a contrast agent gives even more possibilities. Negative aspects include the relatively 
long duration of most imaging protocols and therefore time needed to acquire an image. 
Temporal resolution for cine imaging is not as good as echocardiography and is 
generally not real-time which means it may not be the investigation of choice for 
looking at valve motion for example.  Patients need to be within the tunnel bore for the 
duration of the examination which can be problematic for patients who are 
claustrophobic or have difficulty lying flat due to breathlessness or musculoskeletal 
discomfort. In addition the magnetic field is a potentially dangerous environment. A 
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strong field can turn ferrous objects into projectiles and although extremely infrequent, 
this has on occasion resulted in death. There are certain contra-indications to having a 
scan such as the presence of ferrous objects in areas of the body that may be damaged 
by field induced movement. These include cerebral clips or occular metal fragments. 
Having an implanted non MR compatible pacemaker or defibrillator has been regarded 
as an absolute contra-indication however MR compatible pacemakers are now 
available. Generally well seated metallic implanted devices are considered safe. 
Scanning critically ill patients can cause problems as monitoring may be challenging 
and the patient must be removed from the scan room to administer cardio-pulmonary 
resuscitation.   
Despite the perceived risks and challenges associated with CMR its use has become 
established in clinical cardiology and its use is increasing continually. It is considered 
the investigation of choice for cardiac functional assessment and myocardial viability. 
In fact CMR is now the gold standard for cardiac volumetric and mass measurement 
and the assessment of systolic functional parameters. Spin echo imaging plays a 
relatively small role in CMR compared with imaging of other body regions. This is due 
to the images being degraded by cardiac and respiratory motion. Manipulation of spin 
echo sequences, as described previously, can shorten acquisition times sufficiently to 
provide useful information, for example TSE, however most sequences used to 
visualise the heart use gradient echo technology. Apart from the description of 
congenital malformations most information required from CMR pertains to function. 
2.7.3 CMR for functional assessment 
This is where SSFP sequences play centre stage for the accurate depiction of volumetric 
parameters and regional abnormalities. The availability of 3-D data cine sets allows 
assessment of global function of both left and right ventricles. The analysis of tagged 
data gives information on the myocardial velocity derived strain parameters which are 
analogous to those derived using tissue Doppler imaging. Initially analysis was largely 
visual or by performing time consuming manual tag tracking. Harmonic phase MRI 
(HARP) uses the fact that image phase is related to motion and spatial derivatives are 
calculated for each pixel to produce displacement maps. Regional cardiac motion is 
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thus decoded during Fourier transformation and information on global function and 
regional strain derived. When superimposed on LAX and SAX cine images in plane 
motion can be characterised as longitudinal, radial or circumferential. Resultant systolic 
and diastolic strain patterns are sensitive to early functional change as the sub-
endocardial region is more prone to deformational abnormality than the sub-
epicardium. 
2.7.4 Tissue characterization 
Turbo spin-echo sequences with T1 and T2 weighting can be used with and without fat 
suppression to visualise fibrous or fatty infiltration within the myocardium. The fat will 
appear bright on the image. Fibro-fatty replacement of the myocardium is one of the 
features of arrhythmogenic right ventricular cardiomyopathy but it also occurs with 
ischaemic heart disease, Chagas‟ disease and neuro-muscular disorders and may 
represent the end point for myocyte injury. (Vatta 2007) STIR sequences highlight 
areas of increased fluid identifying regions of inflammation.  
2.7.4.1 Late enhancement 
The use of Gd-DTPA in acute ischaemia was first described in 1984 using an animal 
model. (McNamara 1984) The ischaemic zone showed a well defined segment of high 
intensity after Gd-DTPA injection compared with normal tissue. In a later clinical study 
of acute MI an increased signal was noted in the infarcted area 5-10 days post event but 
not in chronically infarcted tissue however the group used spin-echo sequences at 0.35 
or 0.5T and each scan took at least 2 hours. (Eichstaedt 1989) With the improvement in 
scanner hardware and acquisition software late enhancement with Gd-DTPA has 
become the investigation of choice for the identification and sizing of myocardial 
infarcts. Gd-DTPA based contrast agents pass through the normal myocardium fairly 
rapidly, not crossing normal cell membranes. It accumulates however where the 
interstitial space is increased due to cell damage, loss of cell membrane integrity and 
fibrosis. Segmented inversion recovery GRE sequences show small areas of damage 
not detectable by other imaging techniques. (Mahrholdt 2002) The high spatial 
resolution permits differentiation between viable and non-viable tissue and delineates 
transmurality. (Kim 2000, Simonetti 2001) This has been shown to identify patients 
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who will benefit from revascularisation therapy. Standardisation of protocols has 
provided a robust and reproducible technique. (Wagner 2006) Late enhancement with 
Gd-DTPA has also been reported in patients with necrosis and fibrosis associated with 
a myocarditic process. The pattern of distribution can distinguish the injury from that 
associated with ischaemic changes. (Friedrich 2009)  A wide range of cardiomyopathic 
aetiologies have shown characteristic patterns of LGE. In dilated cardiomyopathy 
(DCM) the majority of patients have no LGE but those that do, tend to have a mid-wall 
distribution unlike IHD and these patients have a worse outcome. (McCrohon 2003, 
Assomull 2006) Mid-wall LGE has also been reported in patients who have received 
anthracycline treatment for cancer. (Perel 2006) In hypertrophic cardiomyopathy 
(HCM) the extent of LGE is also associated with outcome. (Moon 2003) These findings 
potentiate appropriate intervention, for example the implantation of a defibrillator. LGE 
has been reported in patients with muscular dystrophies.(Varghese 2004, Silva 2007, 
Mavrogeni 2009) Cardiac involvement in the myopathic process leads to fibre necrosis 
and fibro-fatty replacement. Pre-clinical detection of cardiac fibrosis can determine the 
need for therapeutic intervention. 
2.7.4.2 Iron overload assessment 
Loss of signal on MR images due to tissue iron was first noted in the 1980s (Stark 
1983, Brasch 1984). This is due to the fact that iron in the form of ferritin and 
haemosiderin shortens proton relaxation times, in particular T2. This is termed 
susceptibility induced relaxation. The relaxation time is inversely proportional to iron 
concentration. Initial studies used spin-echo sequences and iron burden was assessed by 
either measuring T2 or comparing signal intensity with skeletal muscle which does not 
accumulate iron to give a signal intensity ratio. (Chezmar 1990, Mavrogeni 1998, 
Jensen 2001) Liver imaging and iron assessment was reliable with good correlation 
with biopsy results. It was less successful for the heart as the spin echo sequences used 
required long acquisition times and were motion sensitive causing image degradation 
by respiratory and cardiac motion artefacts.  Gradient echo CMR can measure the 
relaxation parameter T2* decay over a range of echo times. The first T2* sequence 
described was a multi breath-hold mid-ventricular short axis acquisition with zero delay 
R-wave triggering resulting in end-diastolic imaging. (Anderson 2001) A single breath-
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hold sequence was later developed which reduced the scan time, improved image 
registration between images, and had good reproducibility. (Westwood 2003) Signal 
decay caused by field inhomogeneities induced by tissue iron can be plotted, a decay 
time constant of <20ms is considered to be indicative of iron overload. (Anderson 
2001) This technique has become the mainstay of clinical evaluation and follow-up of 
thalassaemia major (TM) patients. 
Indeed, over the last decade, there has been a marked reduction in deaths attributable to 
tissue iron overload within the UK which coincides directly with the introduction of 
T2* CMR as a diagnostic tool. (Modell 2008) Prior to CMR use, efficacy of chelation 
therapy and dose adjustment of was based on LIC or ferritin levels. Despite apparently 
optimal therapy patients still developed heart failure and with the use of CMR it 
became clear that these parameters do not reflect myocardial iron burden. Life 
expectancy for patients in high income countries with good compliance to therapy is 
now over 50 years, although survival in low income areas is still poor. (Telfer 2009). 
The protocol has been installed onto CMR scanners from different vendors at multiple 
sites throughout the world with reproducible results, (Kirk 2010) and has been used to 
investigate the cardiac efficacy of chelating agents in multi-centre trials. (Pennell 2006, 
Tanner 2007, Pennell 2010, Pennell 2011)  A more recently developed DIR black blood 
sequence with mid diastolic timing showed good reproducibility in a pilot study as 
blood signal is suppressed thus reducing artefacts, a systematic review of comparative 
reproducibility forms part of this thesis. 
The involvement of iron in anthracycline cardiotoxicity has been reported in several in 
vivo and in vitro studies. The suggested mechanism is the impairment of iron 
metabolism pathways leading to the accumulation of iron in Cardiomyocytes and the 
reaction of anthracyclines with iron producing free radicals. (Minotti 1998, Minotti 
2001, Kwok 2003, 2004, Xu 2005, Cardinale 2008) Reports of the efficacy of iron 
chelators in preventing anthracycline induced heart disease are conflicting. (Hershko 
1996, Kwok 2000, Bryant 2007a, Bryant 2007b, Kaiserova 2007, Popelova 2008, 
Popelova 2009) There is a consensus however that a better understanding of the 
pathogenesis of anthracycline induced cardiomyopathy and the role of iron is needed 
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and to date no study has reported the follow-up of patients using CMR assessed iron 
loading. 
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Chapter  3: Classification of Cardiomyopathy 
3.1 Background 
The classification of heart muscle disease is complicated and often contradictory, 
because there are a large number of heterogeneous conditions, with a lack of 
consistency in inclusion. (Richardson 1996, Maron 2006) In 1980 the World Health 
Organisation (WHO) and ISFC reported that the term cardiomyopathy (CM) should be 
restricted to diseases involving heart muscle of unknown aetiology, (WHO 1980) and 
other diseases affecting the myocardium, for example those associated with 
inflammatory or metabolic disorders, should be termed "specific heart muscle disease". 
Over the past 30 years however our understanding of the interaction between genotype 
and other factors has lead to a blurring of this distinction and this definition is now 
considered obsolete. Causative mechanisms have been implicated for diseases hitherto 
of unknown aetiology, and most workers in the field now consider CM to be "disease of 
the myocardium", but with the notable exception of myocardial dysfunction related to 
ischaemia (although the term ischaemic cardiomyopathy is remarkably persistent 
especially in the USA). 
Improved phenotypic description due to improvements in imaging technology over the 
past few decades can take a large proportion of credit for this partial solution to the 
conundrum, as the sensitivity for identifying clinically silent abnormalities has greatly 
improved. Advances in genetic linkage and molecular studies have also taken our 
understanding forward. For example, channelopathies are due to ion channel protein 
mutations causing life threatening arrhythmias. The cellular substrate for the disease 
cannot be made by biopsy or autopsy, but they are now considered cardiomyopathies 
by some expert panels. (Maron 2006)  
Hypertrophic cardiomyopathy (HCM) was first described over 100 years ago but was 
largely ignored until the late 1950s when Brock and Teare made surgical and 
pathological reports. (Brock 1957, Teare 1958) The later discovery of more than one 
affected individual within a family led to genetic linkage studies and screening within 
families. Many genes are now implicated and we now know that patients carrying a 
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mutated gene can be phenotypically normal suggesting incomplete penetration, late age 
of expression or an extraneous catalyst mechanism.  
Until fairly recently dilated cardiomyopathy (DCM) was considered „idiopathic‟ with 
no identifiable aetiology. Again it was noted that there tended to be more than one 
affected individual within a family which instigated family screening programs. A large 
study in London (Keeling 1995) showed that 29% of asymptomatic relatives of DCM 
patients had abnormal echocardiograms and 20% had left ventricular enlargement as 
defined by echocardiographic criteria. Of these, 27% became symptomatic over the 
following 3 years. Events included 1 sudden death and one relative requiring cardiac 
transplantation. In another study anti-heart antibodies were found to be an independent 
predictor of progression to disease in asymptomatic relatives with normal 
echocardiographic examinations. (Caforio 2007) It is now known that approximately 
25% of DCM patients have a genetic causation (about 40 genes implicated) with new 
genes regularly being discovered. (Michels 1993, Keeling 1994, Goerss 1995, Baig 
1998)  
Overall, a pragmatic approach is to divide the cardiomyopathies that are driven by 
primary genetic defects into main groups according to the dominant clinical 
manifestations, for example  hypertrophic (HCM), dilated (DCM), restrictive and 
arrhythmic (ACM) and in 2008 the European working group on myocardial and 
pericardial diseases proposed a new classification outlined in the table below.(Elliott 
2008) 
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Table 3-1, Classification of cardiomyopathies proposed by the European working 
group on myocardial and pericardial diseases. 
 
 
3.2 Specific cardiomyopathy 
Although there is still not complete consensus regarding classification, in the light of 
the discovery that CM appears to be the product of gene mutation with or without a 
trigger mechanism, cardiac disorders previously termed specific heart muscle disease 
have now been accepted under the CM umbrella and given either the label specific CM 
(Richardson 1996) or mixed/ acquired CM. (Maron 2006) These include CM due to 
general systemic disease including connective tissue and infiltrative processes, 
peripartum CM and sensitivity and toxicity reactions. In this thesis, I have concentrated 
my research into patients with 3"specific" CMs of very different aetiology, namely 
Emery-Dreifuss muscular dystrophy (EDMD), β-thalassaemia major (TM) and patients 
receiving adjuvant anthracycline therapy for breast cancer. In all these CMs there are 
significant research questions. 
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3.2.1 Emery-Dreifuss muscular dystrophy 
3.2.1.1 The muscular dystrophies 
The muscular dystrophies (MDs) comprise a heterogeneous group of genetically 
transmitted diseases characterised by progressive muscular weakness and atrophy. 
(Emery 1998, 2002b, a) They are classified (as outlined in table 3-2) according to their 
clinical presentation, distribution of muscle weakness, age of onset, disease 
progression, protein mutation and inheritance pattern. Recent advances in genetic 
mapping have shown links to numerous loci and additional genetic information is being 
accumulated rapidly. Cardiac involvement is common in the inherited MDs. The X-
linked Duchenne MD (DMD) is the commonest (affecting 1 in 3,500 male births) and 
one of the most severe forms. It is due to a mutation in the dystrophin gene and 
dystrophin is usually absent in DMD patients. Onset is in early childhood and some 
degree of cognitive impairment is usual. Disease progression is rapid, affected 
individuals usually die in their early 20s. Becker muscular dystrophy (BMD) is also due 
to a dystrophin gene mutation but here dystrophin is reduced. Muscle weakness is 
similar to DMD but progression is slower and less severe.  The incidence of BMD is 
approximately 1 in 18,450 males. Myocardial hypertrophy and DCM are common in 
both forms. EDMD, caused by mutations in genes encoding for the nuclear membrane 
and laminar proteins emerin and lamin a/c, is much less common and can be X-linked 
(EDMD1), autosomal dominant (EDMD-2) or rarely autosomal recessive.(Hermans 
2010) The incidence of EDMD1 is approximately 1 in 100,000 males, the incidence of 
EDMD 2 is unknown. EDMD is characterised by relatively mild muscular weakness 
(humero-peroneal distribution) with early joint contractures and spine rigidity. 
Although skeletal involvement is less severe than in the dystrophinopathies, EDMD is 
associated with DCM and there is a high risk of sudden cardiac death, especially in 
EDMD2. For this reason, and the lack of prospective studies in the literature, a cohort 
of patients with EDMD2 were systematically reviewed using CMR and 
echocardiography. 
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Table 3-2Classification of the Muscular Dystrophies 
Name Mutation Symptoms Cardiac complications 
Duchenne (DMD) Dystrophin Early onset ,severe muscle 
weakness 
DCM, often masked by 
severity of skeletal 
weakness 
Becker (BMD) Dystrophin Less severe and slower 
progression than DMD 
DCM 
Emery-Dreifuss 
(EDMD) 
Lamin, Emerin Proximal muscle weakness, 
contractures 
DCM, arrhythmias 
Fascioscapulohumeral 
(FSHD) 
Unknown Face, proximal upper arrhythmias 
Myotonic (DM) Myotonic protein 
kinase 
Distal than proximal arrhythmias 
Epidermolysis bullosa Plectin Generalised weakness, skin 
blistering, contractures 
n/a 
Oculopharyngeal 
(OPMD) 
Poly-A-binding  
protein 2 
Throat, eyelids n/a 
LGMD1A-2J 
(Limb girdle) 
Various Proximal muscle weakness Cardiac symptoms may 
occur 
Miyoshi 
(distal) 
Dysferlin Posterior leg, can eventually 
affect upper extremities 
n/a 
Laing 
(distal) 
Unknown Anterior leg, possible proximal 
extension, neck flexors 
n/a 
Tibial 
(distal) 
Titin Anterior leg, can eventually 
affect upper extremities 
Cardiac symptoms may 
occur 
Welander Unknown Distal upper, eventually lower n/a 
Nonakel 
(distal) 
Acetylglucosamine 
epimerase 
Anterior leg, possible proximal 
extension 
n/a 
Myofibrillar/ Desmin 
(distal) 
Desmin Distal then proximal lower 
extremities 
DCM 
MDC1A-C 
(Congenital) 
Various Proximal limb, cognitive, 
seizures 
n/a 
Muscle-eye-brain 
(Congenital) 
POMGnT1 
glycotransferase 
Mild, generalised weakness, 
cognitive 
n/a 
Bethlem  
(Ulrich syndrome) 
(Congenital) 
Type VI collagen Proximal, early contractures n/a 
Rigid spine 
(Congenital) 
Selenoprotein N1 Spinal extensor contractures, 
spine rigidity, restrictive lung 
disease 
n/a 
Fukuyama 
(Congenital) 
Fukutin Proximal upper, distal lower, 
face, neck 
n/a 
Α7 intergrin 
(Congenital) 
Α7 intergrin Mild generalised weakness n/a 
 
 
3.2.1.2 The nuclear envelope 
The nuclear envelope comprises a double layer of membranes which separate the 
genetic material in the nucleus from the cytoplasm. The nuclear envelope pores allow 
communication between the nucleus and cytoplasm. Each membrane is composed of a 
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lipid bilayer. The outer membrane is covered with ribosomes and is in continuity with 
the rough endoplasmic reticulum, reforming it after cell division. The inner membrane 
is connected to the dense fibrillar nuclear lamina which plays an important role in 
maintaining the architecture of the nucleus. (Verhaert 2011) The protein emerin is an 
integral component of the vertebrate inner nuclear membrane and may play a role in 
anchoring the cytoskeleton to the membrane. The intermediate filament protein lamins 
A and C closely interact with emerin to form the nuclear lamina. A deficiency of either 
emerin or lamin A/C produces the characteristic slowly progressive distal skeletal 
muscle wasting and contractures of EDMD. 
3.2.1.3 Genetics of Emery-Dreifuss muscular dystropy 
EDMD is a genetically heterogeneous form of muscular dystrophy. (Bonne 2000) First 
described in the early 1900s, it was initially considered to be a milder form of DMD. 
Evaluation of a large family with X linked EDMD in 1966 led to its distinction as a 
separate disease (EDMD 1), and in the 1980s an autosomal dominant form was 
described (EDMD 2), and a 3rd form has also been described. (Emery 1966, Miller 
1985, Bonne 2000, Raffaele Di Barletta 2000) 
The first gene responsible for EDMD to be identified was the emerin gene, located on 
chromosome Xq28 and encoding for the ubiquitous nuclear envelope protein emerin. It 
is found in most cell types however it is most highly expressed in skeletal muscle.  
EDMD1 is a result of mutations in genes coding for emerin. More recent studies 
identified defects in the LMNA gene encoding for two other nuclear envelope proteins, 
Lamins A and C, responsible for both the autosomal dominant and autosomal recessive 
forms EDMD 2 and 3. (Bonne 1999, Raffaele Di Barletta 2000)   
Since the discovery of the LMNA gene mutations it has become clear that a number of 
mutations within this gene are responsible for a large series of allelic disorders. 
(Wehnert 2002, Mercuri 2004) These include limb girdle muscular dystrophy 1B 
(LGMD1B) and a form of dilated cardiomyopathy with conduction defects (DCM-CD) 
(Muchir 2000)  the Dunnigan-type familial partial lipodystrophy (FPLD) (Shackleton 
2000), a form of autosomal recessive axonal neuropathy (Charcot-Marie-Tooth disease, 
AR-CMT2) (De Sandre-Giovannoli 2002), mandibuloacral dysplasia (MAD) (Novelli 
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2002), Hutchinson-Guilford and Werner Progeria syndromes (HGPS) (Bonne 2003, De 
Sandre-Giovannoli 2003, Eriksson 2003) and restrictive dermopathy. (Navarro 2004)  
EDMD types 1, 2 and 3 can be distinguished clinically and by their inheritance pattern. 
Although the clinical course is similar, cardiac involvement is an invariable finding in 
EDMD2, which usually occurs by the second to third decade of life. This includes atrial 
and ventricular arrhythmias and conduction defects, followed by complete heart block 
or atrial paralysis but also affecting the left ventricle directly in the form of dilated 
cardiomyopathy. (Morris 1999, Becane 2000) Recently, it has become apparent that 
cardiac involvement in EDMD2 may be more severe that in other forms of muscular 
dystrophy. (Funakoshi 1999, Sanna 2003, van Berlo 2004) There are only a few 
previous studies (Zacharias 1999) reporting pathological endomyocardial autopsy 
findings in EDMD2 with unique atrial pathology and adipose tissue infiltration with 
deposition of antihuman IgG. The investigation of cardiac involvement in EDMD2 has 
mainly been based on two-dimensional echocardiography (2DE) and 24 hour 
ambulatory ECG (Sanna 2003) and it has been postulated that rhythm or conduction 
disturbances are the primary cardiac involvement in these patients. 
3.2.1.4 Clinical features 
Skeletal involvement in EDMD is less severe than in DMD or BMD, which are caused 
by a mutation in the gene coding for the protein dystrophin, found in the muscle and 
brain sarcolemma. Muscle weakness in EDMD is slowly progressive and the 
distribution is scapulo-humero-peroneal. Muscle contractures are typical of the 
syndrome and these can occur before muscle weakness. The major cause of mortality 
and morbidity is however cardiac involvement, which is nearly always present. 
Whereas skeletal muscle symptoms are often mild in EDMD, cardiac involvement may 
be profound, usually manifesting by the second or third decade. Cardiac involvement in 
autosomal dominant EDMD2 is an invariable finding and may be more severe than in 
other muscular dystrophies with a very high percentage of pacemaker dependence and 
sudden death. (Funakoshi 1999, Sanna 2003, van Berlo 2004) These abnormalities 
range from ventricular arrhythmias and conduction defects to complete heart block, 
atrial standstill and cardiomyopathy. (Morris 1999, Becane 2000) Cardiac disease 
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usually presents after the onset of skeletal muscle weakness. Patients often present with 
syncopal episodes in the second/third decades. The fact that so many require pacing has 
made CMR based long term follow-up or investigating patients with established cardiac 
disease virtually impossible. Later findings include atrial and ventricular 
cardiomyopathy. In EDMD1, 10-20 % of female carriers have conduction defects and 
are at risk of sudden death. 
In DMD and BMD cardiac abnormalities are characterised by systolic dysfunction with 
regional wall motion abnormalities (RWMA) which are usually infero-lateral. These 
RWMAs are associated with myocardial fibrosis which can be seen with late 
gadolinium enhancement (LGE) using CMR. Based on the findings and with the 
paucity of in-vivo studies of cardiac function in EDMD in the literature, we 
hypothesised that myocardial fibrosis could play a role in this patient cohort and 
examined this hypothesis with a CMR study. 
3.2.2 Anthracycline cardiotoxicity 
The anthracyclines doxorubicin and epirubicin remain the mainstay of anti-tumour 
therapy for many malignancies including soft tissue tumours, lymphomas and 
leukaemias. They are also used for both advanced breast cancer and as adjuvant therapy 
in early disease. For advanced disease, the long term effects of therapy are less 
important than palliation being compromised by early toxicity. For adjuvant therapy 
however, where the aim of therapy is a cure or long term remission, long term effects 
are an important factor.  
Breast cancer is the most common cancer in the UK accounting for 31% of all cancers. 
The lifetime risk of developing breast cancer is 1 in 8 for women in the UK and is it the 
second most common cancer in women under 35. Survival rates have been improving 
over the last 30 years. For women in England and Wales diagnosed between 1996 and 
2000 the 5 year survival is now over 80% and it is 73% for 10 years. (Cancer Research 
UK on line) This improved survival means the long term sequelae of anti-cancer 
therapy are a major concern. Aside from the toxicity of the anthracycline therapy itself, 
with an aging population the incidence of co-morbidity such as hypertension or 
coronary artery disease is more likely. Additional radiotherapy can augment 
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cardiotoxicity and the synergistic anti-cancer effects of newer targeted agents such as 
trastuzumab also exacerbate cardiomyocyte damage. 
3.2.2.1 Anthracycline pharmacology 
Anthracyclines are a group of antibiotics originally derived from a soil bacterium, 
Streptomyces. They are have been used for anti-cancer chemotherapy for about 40 
years and were first termed anti-tumour antibiotics. They act by causing cell damage 
and inhibiting cell replication. Anthracyclines consist of a planar, hydrophobic 
tetracycline ring with a glycosidic link to daunosamine sugar. They are positively 
charged and intercalate with unravelled strands of DNA during the process of cell 
division. Topoisomerases are enzymes that control the winding of DNA to permit the 
synthesis of proteins and DNA replication by creating transient breaks in the strands 
(i.e. they change the topology of the DNA molecule). Topoisomerase I and III are 
classified as type I enzymes as they cleave a single DNA strand. Topoisomerase II 
enzymes are classified as type II enzymes as they cut both DNA strands and are 
believed to play a role in the separation of daughter DNA strands and structural 
remodelling. Topoisomerase poisons which include anthracyclines, block this catalysis 
by binding to the DNA, the topoisomerase itself, or both molecules. Anthracyclines are 
believed to inhibit topoisomerase II by intercalation. This structural modification of the 
DNA thus causes functional changes which block transcription. Anthracyclines also 
bind to mitochondrial DNA inhibiting basic cellular function resulting in ATP 
depletion. Sensitivity to topoisomerase poisons occur in cells where the repair of DNA 
double strand breaks is defective. This property gives anthracyclines their cancer 
cytotoxicity but may be implicated in cardiotoxicity.  
Anthracycline molecules also possess quinone moieties which through electron transfer 
reactions generate oxygen free radicals which cause intra and extra-cellular damage. It 
is believed that ferritin is converted into an oxidative form producing oxygen 
superoxides and hydrogen peroxide resulting in oxidative stress damage to DNA, 
mRNA proteins and lipids. Oxidative stress can also affect mitochondrial calcium 
transport causing tissue damage and impaired contractility. Increased lipid peroxidation 
and free radical generation has been documented after anthracycline administration. 
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(Myers 1977, Doroshow 1983, Jackson 1984, Rajagopalan 1988) The cytotoxic actions 
of anthracyclines have the potential to affect all cells, especially rapidly dividing cells 
hence their antineoplastic effect. Cardiomyocytes are particularly susceptible to 
oxidative stress, possible due to the relatively low levels of anti-oxidant enzymes in the 
heart. Catalase activity is low in the heart therefore the myocardium relies on 
glutathione peroxidase to detoxify hydrogen peroxide. Anthracyclines however deplete 
glutathione. Concomitant iron chelation with dexrazoxane has been shown to reduce 
cardiotoxicity, possibly by blocking the free radical producing redox reaction. 
(Takemura 2007) Its use is associated with myelosuppression which further potentiates 
cardiotoxicity and trial results have been contradictory. (Basser 1994, Swain 1997, 
Swain 2004) Chelation therapy with dexrazoxane has been reported to reduce anti-
cancer efficacy although again published findings are conflicting, so it does not tend to 
be used in adjuvant therapy where anthracycline dosage is low. The role of 
dexrazoxane as an anti-oxidant has also been challenged recently. (Simunek 2008, 
Simunek 2009) What is clear is that cardiotoxicity is cumulative and dose dependent.   
3.2.2.2 Mechanisms of anthracycline cardiotoxicity 
Cardiomyocytes are believed to have a limited mitotic capacity after the embryonic 
phase of proliferation. Cardiomyocyte replication virtually ceases during the early post-
natal period and renewal only occurs if mediated by stem cells. In other words they are 
usually considered terminally differentiated. Young adults have approximately 8.2 
billion cardiomyocyte nuclei but on average 0.6% are lost per annum. (Olivetti 1991) 
Ventricular wall thickness is maintained by cell volume increase, but overall ventricular 
mass decreases with cell death. Response to cell injury therefore is limited to 
remodelling and or cellular hypertrophy, thus their regeneration capacity is limited with 
an increase in vulnerability throughout the normal aging process. The incidence of 
cancer increases with population age. In addition long term survival rates are improving 
due in part to adjuvant chemotherapy in early disease. This has lead to a cohort of long 
term cancer „survivors‟, with the added corollary of how to deal with long term 
treatment toxicity. In addition to dose dependency risk of cardiotoxicity is influenced 
by patient age (advanced or young age) duration of survival and the presence of 
cardiovascular comorbidity. Treatment with anthracyclines carries the greatest risk of 
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acute and late cardiotoxicity. Rarely cardiac toxicity can be acute, occurring during or 
immediately after exposure and is more frequent if administered is bolus or rapid 
infusion. Arrhythmias are common during the first 24 hours post dosing, usually in the 
form of increased ventricular ectopy. According to reports this is not associated with 
long term sequelae. (Lefrak 1973, Steinberg 1987) These studies however did not use 
sensitive markers of ventricular function to follow long term outcome. Other symptoms 
include vasodilatation, hypotension.  A rare but more serious complication is acute 
myocarditis/pericarditis, which was more common in early trials using high single 
doses.  This syndrome tends to occur 1-3 days post administration and can result in 
ventricular dysfunction and sudden death. (Bristow 1978b, Ettinghausen 1986, Towns 
2008, Pfeffer 2009) Heart failure is very rare in patients with no risk factors and at low 
dosages. Damage is now believed to occur during exposure, particularly as troponin 1 is 
released post administration. (Eschenhagen 2011) Sub-acute cardiotoxicity tends to 
occur up to eight months after the last cycle, typically peaking at three months. Chronic 
AMC is considered “early” if onset of ventricular dysfunction and heart failure is 
within a year of exposure, otherwise it is termed “late onset”, typically developing after 
a prolonged asymptomatic period. It is the late onset form of AMC that is becoming an 
increasing problem, with an ageing population and the improvement in the long term 
survival of cancer patients. It is known to be related to cumulative dosage and 
culminates with a dilated cardiomyopathy and heart failure which tends to develop by 
2-5 years after the last dose. As the risk of heart failure is known to increase with 
cumulative dosage LVEF is measured prior to each cycle. The pathogenesis of 
anthracycline induced CM is not fully understood but pathological appearances include 
a dilated heart with endomyocardial fibrosis and hypertrophy of surviving myocytes. 
(Mortensen 1986) Endomyocardial biopsies show sarcoplasmic reticulum dilatation, 
vacuole formation, myofibril loss and necrosis. (Floyd 2005) At lower dosages 
(<400mg/m
2
) the incidence of heart failure is low but increases rapidly at doses > 
550mg/m
2
 with a 50% risk at doses ≥1g/m2. The risk increase is non-linear and 
suggesting there is no „safe-dose‟ for anthracyclines. Some patients appear to be able to 
tolerate very high dosages whereas myocardial dysfunction has been reported at low 
cumulative doses implying individual sensitivity.  Sub-clinical abnormalities have been 
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identified using non-invasive imaging modalities in asymptomatic patients. Once heart 
failure is establishes prognosis is poor.  
Doxorubicin was the first anthracycline drug to be widely used as an anti cancer drug. 
Its association with cardiotoxicity however lead to the search for an analogue with an 
improved therapeutic index as long term survival depends not only on anti-cancer 
efficacy but also treatment induced irreversible side effects. Epirubicin is an analogue 
of doxorubicin and has a similar mode of action in binding to DNA thus inhibiting 
replication and protein synthesis. It does have a more favourable therapeutic index 
being associated with a significantly lower incidence of cardiotoxicity than 
Doxorubicin and is as effective as doxorubicin in the adjuvant setting. 
3.2.2.3 Trastuzumab cardiotoxicity 
The growth factor receptor gene, human epidermal growth factor receptor (HER2) is 
over-expressed in 25-30% of breast cancer cases in whom abnormally high levels of the 
encoded protein is found in the malignant cells. The disease is more aggressive in these 
patients who subsequently have a poorer prognosis. (Slamon 1987, Slamon 1989, 
Slamon 2001) Trastuzumab (Herceptin) is a recombinant humanised monoclonal 
antibody specific to the HER2 protein. It has been shown to inhibit tumour growth and 
enhances the anti-tumour effect of anthracycline therapy. (Baselga 1998, Popat 2008) 
Trials have concluded that adding trastuzumab to adjuvant therapy improves survival of 
HER2 positive women by approximately 33%, the risk of disease recurrence being 
reduced by about 50%. (Piccart-Gebhart 2005, Romond 2005, Smith 2007) 
Trastuzumab is usually well tolerated however it is associated with cardiotoxicity, a 
side effect not discovered until late in clinical trials, especially when combined with 
anthracycline therapy. (Schneider 2002) Cardiotoxicity with anthracyclines is estimated 
to be about 10% however this rises to 28% with the addition of trastuzumab with a 
concomitant rise in the incidence of NYHA class III/IV heart failure from 3 to 16%. 
(Suter 2004) The mechanism of cardiotoxicity appears different to those of 
anthracycline injury and is not dose dependent. Cardiac dysfunction is not associated 
with myocyte loss or troponin release. Clinical trials have reported cardiac dysfunction 
persisting for 20-25 days (the half life of trastuzumab) but then returning to normal in 
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most patients and recent data suggests there should be no long term adverse effects. 
(Eschenhagen 2011) There is however a paucity of long term follow-up studies. The 
likely pathogenesis is due to the blockage of HER2, which is expressed in low levels in 
most body tissue including the heart and is important for myocyte repair and adaption 
to stress. (Crone 2002, Cardinale 2010a, Ewer 2010) Gene deletion of HER2 or HE4 
has lead to CM in mice. (Crone 2002) This is more marked following anthracycline 
therapy, possibly due to anthracyclines altering the configuration of surface HER2 
receptors or interfering with cell signalling pathways. (Schneider 2002) There is less 
evidence of trastuzumab mediated cardiotoxicity when combined with regimens other 
than anthracyclines. In essence the synergistic anti-cancer properties are reflected in the 
effect on the heart therefore the issue of cardiotoxicity in this group of patients is likely 
to be an increasing problem. 
3.2.2.4 Early biomarkers and functional assessment 
Anthracycline mediated cardiomyocyte damage is now believed to occur mainly during 
exposure, this hypothesis has been supported by the release of troponin I after 
administration. (Eschenhagen 2011) Presentation is usually much later, maybe due to a 
lack of compensatory mechanisms, with heart failure occurring late in disease 
development. A normal LVEF does not necessarily mean the absence of a toxicity 
reaction. (Ewer 2008) The possibility of a genetic predisposition to cardiotoxicity is 
being increasingly explored. (Wojnowski 2005) What is clear is that there is a need for 
formalised follow-up studies looking at biomarkers for the prediction of toxicity and 
more sensitive indicators of functional change to better characterise myocardial 
damage. In this thesis, I examined this issue using CMR, and allowed for the 
complicating factor of HER2 treatment. 
3.2.3 Iron overload cardiomyopathy 
3.2.3.1 Iron metabolism 
Iron plays a pivotal role in many biological processes. Free iron is however toxic to 
cells. Damage is related to the production of reactive oxygen species (ROS) formed as 
levels of labile iron rise, which cause oxidative damage to membranes and 
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mitochondrial respiratory chain enzyme dysfunction. As mentioned previously, 
cardiomyocytes are possibly more susceptible to oxidative stress due to relatively low 
anti-oxidant and catalase activity. In the healthy state iron within the organism is 
conserved and recycled by a complex series of interactions. Ferritin is a protein found 
in all cells which acts as an iron buffer by binding iron in a safe format for storage and 
transportation. Iron is stored in the core of the ferritin molecule as Fe3+ in a crystalline 
solid. Each ferritin molecule can hold about 4500 Fe3+   ions. To remove the iron from 
ferritin, the Fe3+ is reduced to Fe2+ and hydrated thus allowing the iron to pass from 
the ferritin lattice. Haemosiderin is an intra-cellular iron storage complex composed of 
ferritin, denatured ferritin and other material. It is usually found in phagocytes and is 
abundant following haemorrhage and in the presence of iron overload. Iron from 
haemosiderin is not readily released. Transferrin is an iron transporter. Its major role is 
the carriage of iron from the duodenum and macrophages to all, and particularly 
erythropoietic, tissue.  
3.2.3.2 Iron overload and toxicity 
As iron levels accumulate due to erythrocyte catabolism this recycling network is 
saturated. With no other means of iron excretion, iron accumulates as toxic non-
transferrin bound iron (NTBI) in the plasma. This then accumulates mainly within 
parenchymal tissue and the reticulo-endothelial system. In the pituitary gland this can 
cause a wide range of endocrine disorders including growth retardation, delayed sexual 
maturity and infertility. Excess iron in the thyroid may lead to hypothyroidism and 
musculoskeletal problems, and diabetes is common due to excess iron in the pancreas. 
Hepatic iron overload can cause fibrosis and cirrhosis and hepatocellular cancer. 
However the major cause of death worldwide in chronically transfused patients is 
cardiac iron overload. (Olivieri 1994) This has been increasing as haemoglobinopathy 
patients live longer. Iron overload cardiomyopathy (IOC) is the result of the 
accumulation of iron within the myocardium and is characterised by the presence of 
systolic and diastolic cardiac dysfunction. This cardiomyopathy has been shown to be 
reversible with timely and adequate medical intervention with chelating agents. 
(Hahalis 2005) 
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3.2.3.3 The thalassaemias 
In the early 20th century, investigators including Cooley described a severe anaemia 
with associated splenomegaly and bony changes. The disease was first termed Cooley‟s 
anaemia and later thalassic anaemia as the first cases identified were of Mediterranean 
origin. The name was ultimately shortened to thalassaemia and incorporates the Greek 
words for sea and blood (thalassa =sea, haema =blood). (Olivieri 1999, Weatherall 
2004) This has turned out to be a misnomer as the thalassaemias are now known to 
include a heterogeneous group of inherited haemoglobinopathies in patients of different 
ethnicities with the majority of cases in South East Asia. (Cohen 2004) Although 
folklore attributes its spread eastward to the travels of Alexander the Great and his 
army, the fact that there are many mutations makes this unlikely. More plausible is that 
the heterozygote offers some protection against the malarial parasite Plasmodium 
falciparum and de novo mutations have occurred in different regions. (Weatherall 2004, 
2005) Recent migratory patterns have expanded disease distribution to north Europe, 
North and South America and Australasia. 
 
Figure 3-1 The orange shaded area highlights the endemic distribution of 
thalassaemia. It follows a wide band through southern Europe, North Africa and 
the Nile delta, the Middle East, the Indian sub-continent and south-east Asia. 
These areas are, or were in the past, malarial zones. 
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Haemoglobin is a tetramer comprising four sub-units. Each sub-unit contains haem, a 
porphyrin ring that holds a ferrous ion (Fe2+) at its centre by four covalent bonds. This 
group reversibly bonds with oxygen and gives the molecule its characteristic colour. In 
human adults the haem groups are held within four globular protein units designated the 
α and β chains. The three dimensional folding of these chains produces steric hindrance 
preventing the oxygenation of the Fe2+ iron to its ferric (Fe3+) state. 
 
Figure 3-2 Diagrammatic representation of a normal haemoglobin molecule. The 
Fe2+ ion to which oxygen reversibly binds is at the centre of the haem group 
which is held within the globular protein chains. 
There are more than 200 mutations of the β-globin genes, found on chromosome 11, 
which cause the β-thalassaemia phenotype and more than 80 mutations and deletions of 
α-globin genes on chromosome 16 causing α-thalassaemia. If the synthesis of these 
proteins is imbalanced, normal erythrocyte function is disrupted resulting in anaemia. 
The α-globin mutation is more common in South East Asia and Africa whereas the β-
globin mutation is prevalent in Southern Europe and the Middle East. 
 The thalassaemias are the commonest single gene disorders worldwide. It is estimated 
that about 7% of the worldwide population have the mutation. Β-thalassaemia is 
endemic to Southern Europe and is now prevalent to the UK via migratory patterns. 
Approximately 60,000 children are born every year with the homozygous β-
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thalassaemia major (TM). (Weatherall 1996, Weatherall 2005) and is consequently of 
medico-economic importance within the European Union. 
The β-thalassaemias are classified according to phenotype and genetic profile. Fetal 
haemoglobin consists of two α and two γ globin chains. During the first year of life the 
synthesis of fetal haemoglobin declines with a switch to adult haemoglobin production. 
The mutation of both β-globin genes in TM leads to a marked reduction or absence of 
β-chain synthesis which in turn leads to a relative excess of unbound α-chains causing 
ineffective erythropoiesis and damage to the cell membrane and haemolysis. The 
resultant microcytic anaemia induces bone marrow expansion (causing the 
characteristic bony abnormalities) and splenomegaly.  The increased plasma volume 
caused by the shunting through the expanded marrow space exacerbates the anaemia. 
Further adaptive mechanisms include extra-medullary haematopoiesis and erythroid 
hyperplasia. Without regular blood transfusions patients usually die during early 
childhood. Thalassaemia intermedia (TI) patients are also homozygotes but they present 
later and many do not require transfusion therapy as the β-chain mutations are less 
severe, however pulmonary hypertension is a frequent complication due to chronic 
anaemia. Thalassaemia minor (often referred to as thalassaemia trait) is the 
heterozygous state which results in mild anaemia which is usually asymptomatic. 
Blood transfusion therapy became standard therapy for patients with TM during the 
1960s. (Modell 1983) If the haemoglobin level is kept above 9g/dL the bone marrow is 
suppressed with a reduction in hepato-splenomegaly, extra-medullary haematopoiesis 
and bony abnormalities. (Olivieri 1999) This improves the short term clinical status and 
outlook for these patients, however this therapy comes with a longer term problem of 
tissue iron overload, which is the most important complication of TM worldwide. Even 
in patients not receiving transfusional therapy, iron overload has been described in 
patients with severe anaemia and erythroid expansion. (Pootrakul 1988, Olivieri 1999) 
This is due to reduced hepcidin production caused by the increased ineffective 
erythropoiesis. Hepcidin is produced by the liver and regulates iron absorption and 
recycling. It internalises and degrades the iron export protein ferroportin, found on the 
surface of duodenal enterocytes, hepatocytes and macrophages. The iron is then 
excreted at the end of the cell life span. A reduction in hepcidin leads to increased iron 
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absorption and its subsequent deposition in parenchymal tissue. (Ganz 2005) In TM 
patients regular transfusions exacerbates this iron accumulation as each unit of blood 
contains about 200-250mg of iron. 
Iron chelation therapy can reduce tissue iron levels and cardiac complications.  Prior to 
iron chelation therapy, patients died from the complications of iron overload, usually by 
the second or third decades of life.  The hexadentate iron chelating agent deferoxamine 
was the first used clinically and it became standard therapy in the 1970s. It has a high 
affinity for iron but is a large positively charged lipophobic molecule and is poorly 
absorbed by the digestive system. It also has a short plasma half life. (Kushner 2001, 
Porter 2001) These factors make it ineffective via oral transmission and administration 
needs to be intra-venous or sub-cutaneous. It is advised that patients with dangerously 
high levels of iron or those who develop important symptoms receive 24hour 
continuous intra-venous chelation therapy. For longer term therapy administration is 
sub-cutaneous, typically overnight five times per week. (Porter 2001) This optimises 
therapeutic efficacy but at a financial cost (the pumps and attachments are expensive). 
The demanding regime associated with parenteral therapy has inherent psychosocial 
and practical issues which modulate compliance and therefore efficacy, especially in 
adolescents and young adults. Poor compliance should be suspected if indices of iron 
overload increase unexpectedly. There are also drug related toxic effects including 
sensory neural loss leading to deafness and sight impairment. (Olivieri 1986, Porter 
1989) 
Use of the orally active bidentate iron chelator deferiprone (L1) in humans was first 
reported in 1987. (Kontoghiorghes 1987b) It has a much smaller neutrally charged 
lipophilic molecule which allows good gastrointestinal absorption and cellular access. 
(Kushner 2001, Porter 2001) The plasma half life is longer allowing oral administration 
with three doses per day (Kontoghiorghes 1987a) It is cheap to produce, does not 
require infusion equipment and has shown superior efficacy to deferoxamine in the 
removal of cardiac iron and improvement in LV systolic function. (Anderson 2002, 
Pennell 2006, Maggio 2009, Pepe 2011) Although deferoxamine is a very efficient 
chelator with a high iron affinity, its large molecular size limits its potential for 
intracellular chelation. Deferiprone is a small lipophilic molecule and therefore has 
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better access to intra-cellular iron. The cause of the enhanced improvement in LV 
function with deferiprone over deferoxamine therapy is not fully understood, however 
superior antioxidant potential has been demonstrated in a number of in vitro and in vivo 
studies. (Kontoghiorghes 2009) Other possible explanations are the reduction of 
reactive oxygen species and the restoration of normal mitochondrial function. (Kakhlon 
2008, Kontoghiorghes 2009) Agranulocytosis and neutropenia have been reported to be 
associated with deferiprone therapy but are usually reversible with discontinuation. 
Previously reported findings of hepatic fibrosis (Olivieri 1998) was not reproduced in a 
later large study and was probably due to the presence of iron and chronic hepatitis C. 
(Wanless 2002) The drug is still however not licensed in North America. Some patients 
do not achieve optimal iron balance with deferiprone monotherapy and there are 
tolerance issues. The combination of deferoxamine with deferiprone improves iron 
balance in a significant proportion of patients compared with monotherapy with either 
drug. (Anderson 2002, Daar 2006, Tanner 2007, Porter 2009) This can be either by 
simultaneous administration or by alternating the drugs. If both chelators are present a 
synergistic „shuttle‟ effect may be achieved by combining the strong iron affinity of 
deferoxamine with the ability of deferiprone, the weaker chelator, to penetrate cells. 
(Link 2001)   
Deferasirox is a relatively newly developed orally active tridentate ligand which has a 
half life of 8-16 hours permitting once daily (or sometimes twice daily) administration. 
Unlike deferiprone it is licensed in North America, is well tolerated and has shown 
efficacy in reducing iron burden. (Nisbet-Brown 2003, Cappellini 2006, Cappellini 
2007) The recent large multicentre EPIC (Evaluation of Patients Iron Chelation with 
Exjade) cardiac sub-study has shown its efficacy in removing iron from the heart over 
one and two years although LVEF remained unchanged. (Pennell 2010, Pennell 2011) 
A study by Wood et al (Wood 2010) showed a significant reduction in cardiac T2* over 
18 months in 48% of patients however there was a clear demarcation between 
responders and non-responders. Deferasirox was effective in patients with a moderate 
cardiac and liver iron burden but not in those with severe overload which would 
indicate more aggressive therapy for these patients. 
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3.2.4 The right ventricle in cardiomyopathy 
The role of the right ventricle (RV) has been relatively under-investigated in the study 
of the pathophysiology of cardiac disease, being often regarded as a passive conduit.  
(Voelkel 2006) The relative success of the Fontan procedure and tricuspid 
valvulectomy for endocarditis supported this view to some extent. With many imaging 
modalities the description of RV structure and function is limited by its complex 
geometry, proximity to the chest wall and being obscured by the lungs and sternum 
although the use of CMR has overcome these limitations and normal ranges for 
functional indices have now been established. (Maceira 2006b)  
The RV consists of an inlet section which includes the tricuspid valve, chordae 
tendineae and papillary muscles, the trabeculated distal myocardial segment, and the 
infundibulum section (or outflow tract). Although biventricular function is closely 
interlinked, it is apparent that the left and right ventricles are inherently different. 
(Strniskova 2006, Wang 2006) Morphogenesis studies have shown that the left and 
right ventricles have different progenitor cells and arise from different regions during 
early development. The mammalian heart develops from the primary heart tube from 
which the LV arises.  Right sided myocardial cells are derived from myocardial 
precursors anterior to the primary heart tube known as the anterior heart field. (Thomas 
1998, Cai 2003, Zaffran 2004, McFadden 2005, Verzi 2005) 
The ventricles are linked by sharing the septum, epicardial fibres and the pericardial 
space. The epicardial layers are arranged circumferentially and are in continuity with 
those of the LV. The deeper fibres are arranged longitudinally from base to apex in 
continuity with the septum. Under normal conditions the stroke volume of the RV is the 
same as the LV however as pulmonary vascular resistance is low the RV has 
approximately 25% less stroke work and is consequently more compliant with much 
thinner walls. The RV has considerably less contractile reserve than the LV and is 
therefore more sensitive to afterload due to reduced muscle mass and chamber 
geometry. A change in chamber geometry alters the normal orientation of muscle fibres 
which impairs contraction. (Bronicki 2010)  
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Right ventricular dysfunction may occur as a result of numerous mechanisms. Primary 
lung disease and LV dysfunction may lead to increased pulmonary vascular resistance 
thus increasing RV afterload. Pulmonary hypertension (PHT) plays a large role in RV 
pathology. The initial response to pressure overload is hypertrophy followed by 
functional impairment and compensatory dilatation. This is further exacerbated by 
tricuspid regurgitation due to annular dilatation which in turn can produce RV 
dysfunction. The precise mechanism of RV failure secondary to PHT is not fully 
understood although ischaemia, microvascular endothelial dysfunction and myocyte 
apoptosis may be implicated. (Voelkel 2006) 
Myocardial ischaemia and myopathic processes can affect both ventricles. In addition 
LV dysfunction may cause reduced RV perfusion.  Right ventricular dysfunction can 
further exacerbate LV dysfunction by reducing LV preload. Reports on RV 
involvement in myocarditis, MI and DCM all cite RV dysfunction as both a 
complementary and independent predictor of outcome stressing the importance of 
assessing RV function in cardiac disease. (Mendes 1994, Juilliere 1997, de Groote 
1998, Larose 2007, Miszalski-Jamka 2010)  Patients with severe heart failure but 
maintained RV function have better survival and exercise capacity. (Di Salvo 1995, 
Karatasakis 1998) RVMI occurs in approximately 50% of patients with inferior MI and 
10% of patients with anterior MI. (Cabin 1987, Zehender 1993) I therefore assessed the 
effect of chelation therapy on the RV in thalassemia in this thesis, which has not 
previously been explored. 
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Chapter  4: CMR Methods for Imaging Cardiomyopathy 
4.1 Determination of ventricular volumes and mass 
Ventricular volumes, mass and ejection fraction are the most commonly cited 
parameters for cardiac functional assessment and follow-up. Normal ranges indexed to 
age, gender and BSA have been established for the left ventricle (Maceira 2006a) and 
the right ventricle. (Maceira 2006b) This aids the identification of early disease as 
functional changes frequently precede clinical symptoms in cardiomyopathic 
conditions. (Keeling 1995, Baig 1998) Early detection permits early therapeutic 
intervention and potentially an improved outcome. Ventricular volumetric data are also 
common surrogate end points for pharmacological trials. The accuracy and 
reproducibility of CMR are superior to other imaging modalities, which makes CMR 
the technique of choice for longitudinal follow-up and pharmacological trials as study 
sample sizes can be reduced. (Bellenger 2000) In direct comparison trials, the inter-
study reproducibility of CMR for dilated, hypertrophied and remodelled hearts is 
superior to 2D echocardiography. (Grothues 2002) Right ventricular anatomy and 
function can be assessed with confidence which is a challenge for other modalities. 
(Grothues 2004, Maceira 2006b) This is particularly important as the role of the right 
ventricle as a predictor of outcome in heart disease is being increasingly recognised. 
(Mendes 1994, Juilliere 1997, de Groote 1998, Larose 2007, Miszalski-Jamka 2010) It 
is also possible to assess diastolic function with CMR. The scan time is long however 
in order to acquire images from sufficient cardiac phases for adequate temporal 
resolution. Echocardiography with its higher temporal resolution is still preferred by 
many centres for looking at diastolic physiology. Myocardial tagging is used for 
systolic strain analysis to investigate regional abnormality. The only major challenges 
to obtaining good quality CMR cine images are arrhythmias (as cine images are 
averaged over a number of cardiac cycles) and inadequate breath-holding. Real time 
acquisition where the whole image is acquired within a single heart beat can 
compensate for acquisition problems, but the frame rate and spatial resolution is poor. 
Navigator sequences monitoring the diaphragm allow free breathing acquisitions, and 
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arrhythmia rejection sequences are available, but both these techniques prolong the 
acquisition. In practice however, CMR is readily able to provide a set of geometrically 
correct long axis and contiguous short axis cines with excellent boundary definition 
using SSFP sequences, which with their improved blood to myocardial contrast are 
almost universally utilised. The resultant data set provides a three dimensional 
representation of cardiac chambers from which cardiac boundaries can be delineated 
and blood and myocardial volumes calculated. 
4.1.1 Volume and mass calculation by manual planimetry 
Cardiac volumetric and mass data can be derived by the manual planimetry of 
endocardial and epicardial boundaries. Particular care must be taken with the placement 
of the basal slice during acquisition if using planimetry. During endocardial contouring, 
the blood pool below the AV valves should be included and basal regions with thin, 
non trabeculated muscle should be considered atrial and excluded from ventricular 
assessment. Papillary muscles are excluded from the blood pool and included as mass. 
(Hudsmith 2005) The blood pool and myocardial volume are calculated by using 
Simpson‟s rule. Myocardial mass is derived by multiplying myocardial volume by its 
specific gravity (1.05g/mL
3
). Stroke volume and ejection fraction are derived from the 
calculated diastolic and systolic volumes. 
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Figure 4-1 Ventricular contours can be manually planimetered and the blood pool 
and myocardial volumes calculated by using Simpson’s rule. 
4.1.2 Volumes measured by CMRtools 
Although manual delineation of cardiac parameters is an important technique, it suffers 
from being slow to perform and the treatment of blood pool in relation to the AV valves 
can be operator dependent. Therefore semi-automated software is preferred. For the 
purpose of this thesis, I used software called "CMRtools" (Cardiovascular imaging 
solutions, London, UK), a commercially available multi-function DICOM 
viewing/analysis package which carries a class 1 CE mark and has FDA clearance. 
"LVtools" is the plug-in of this package which allows the calculation of functional 
indices. This semi-automated analysis package has been shown to have very high inter 
and intra observer reproducibility when compared with other contouring 
methods.(Miller 2010) A multi-dimensional Catmull-Rohm spline interpolation 
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algorithm is interactively applied to provide an approximation for surface temporal and 
spatial definition. Points of attachment are applied to the insertion points of AV and VA 
valves for diastole and systole to allow valve tracking throughout the cardiac cycle 
which provides a three dimensional model of valve plane motion. The valve planes are 
utilised to represent the interfaces between the ventricles, atria and great arteries 
ensuring that only blood volume associated with the ventricles is used for analysis. 
Data reformatting is used to identify the motion of the surface in long axis and temporal 
views. An interactive thresholding tool is then applied to define solid structures. 
 
Figure 4-2 Using LVtools cardiac borders are roughly contoured. Fine detail is 
achieved using thresholding. The result is a 3-D ventricular model with displayed 
phase-volume curves and derived indices. 
The first step is to identify and load the cine images needed to create the model. This 
comprises a stack of SAX cines covering both ventricles from base to apex and four 
long axis projections depicting the valves. The centre of the LV blood pool is identified 
by the operator and the endocardial surface roughly delineated for the selected diastolic 
and systolic cardiac phases. Using the appropriate long axis images, the valve plane is 
84 
 
identified for diastole and systole, and more reference points can be set if diastolic 
filling curves are desired. To finely differentiate between solid structures and blood 
pool a mid-ventricular short axis slice is selected and the thresholding tool is utilised to 
highlight operator defined solid tissue. The first selected threshold is automatically 
applied to all SAX slices but subsequent fine-tuning of separate slices is possible. To 
obtain mass measurements the LV epicardial surface needs to be defined accurately as 
this step does not utilise thresholding. This process is repeated to derive right 
ventricular parameters but this time approximating the centre of the blood pool to the 
septum as the program subtracts all previously defined LV structures. A separate 
window displays the volume/phase curves for systole and diastole with the calculated 
functional indices. 
One advantage of the 3-D model over manual planimetry is that the valve plane 
tracking removes uncertainty about inclusion of the most basal slice which may be 
partially within the atrium due to incorrect piloting 
4.2 Assessment of inflammation (non-contrast). 
Inflammatory or myocarditic changes often precede myopathic changes. (Feldman 
2000) Myocarditis has been described in up to 12% of young adults dying suddenly. 
(Virmani 2001, Doolan 2004, Puranik 2005, Fabre 2006) Between 5-10% of patients 
with myocarditis have been reported to progress to a dilated cardiomyopathy. (Fuster 
1981, Kawai 1999) Early identification could permit early therapeutic intervention with 
the potential for reducing long term sequelae. The identification of myocarditis can be 
problematic and is often reached only by exclusion. Patients may present with chest 
pain, ECG changes resembling infarction and a troponin rise. Ventricular function may 
appear normal if inflammation is focal. (Mahrholdt 2004, Mahrholdt 2006) Myocardial 
biopsy is invasive and localised and areas of infiltration may be missed. It would be 
advantageous to be able to predict possible long term myocardial damage by 
identifying early inflammatory changes in the scenario of known myocardial insult. An 
example of this is for planned anthracycline chemotherapy which is known to be 
cardiotoxic and is associated with long term cardiac functional impairment. CMR is 
ideally suited for looking for inflammatory changes by virtue of its intrinsic contrast 
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properties and by the utilisation of an injected contrast agent which can be used to track 
hyperaemia and fibrosis. The fact that the entire myocardium is visualised means that 
focal abnormalities can be identified. Transient increases in myocardial wall thickness 
and volumes have been described using echocardiography and CMR. (Hiramitsu 2007, 
Friedrich 2009) SSFP cine imaging is ideally suited for this purpose to obtain baseline 
and follow-up data from patients who will receive known cardiotoxic substances. STIR 
sequences highlight areas with increased fluid which would be expected in areas of 
inflammation with myocardial hyperaemia, increased capillary permeability and loss of 
cell membrane integrity. An increase in signal intensity (SI) has been noted using a 
contrast enhanced T1 weighted sequence in the setting of acute myocarditis. (Friedrich 
1998) A small study of patients prior to and also 3 days post the first cycle of 
anthracycline chemotherapy showed increased contrast enhancement of the 
myocardium compared with skeletal muscle using a T1 weighted fast spin echo 
sequence, and this correlated with a later reduction in LVEF, with the enhancement 
returning to normal by 6 months. (Wassmuth 2001) As myocardial hyperaemia is a 
feature of myocardial inflammation it is likely that imaging the early wash in kinetics 
of gadolinium contrast agent would exhibit an accelerated signal increase. For 
myocardial perfusion imaging a rest-stress protocol is utilised where the baseline status 
is compared with a pharmacologically induced hyperaemic state. For this thesis a 
perfusion acquisition was performed at baseline and 3 days post first cycle in patients 
undergoing adjuvant chemotherapy for early breast cancer. 
4.3 Myocardial perfusion, hyperaemia and fibrosis with gadolinium contrast. 
For CMR, gadolinium contrast dynamics can be divided into 3 phases: 1) perfusion; 2) 
early enhancement at 1-2 minutes; and 3) late enhancement at 10-15 minutes. First pass 
imaging is performed as a bolus of gadolinium contrast is injected. Image data is 
acquired before the bolus (baseline) and throughout delivery. Resultant processed data 
can give information about tissue perfusion. Early enhancement allows assessment of 
hyperaemia, and late enhancement highlights damaged tissue as the gadolinium contrast 
agent has a slower wash-out than in normal areas. 
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Figure 4-3 The contrast arrives rapidly into the blood pool and then the normal 
myocardium when first pass image acquisition is performed. After approximately 
10 minutes the contrast has largely washed out of normal tissue but remains in 
fibrosed tissue giving delayed contrast. 
4.3.1 Early enhancement 
Myocardial perfusion CMR is performed during the first pass of the contrast agent. 
During this time blood T1 is reduced approximately 50 fold. It is used to detect regional 
impairment of myocardial blood flow during rest and stress. Most commonly 
hyperaemia is induced by an intravenous infusion of adenosine at a rate of 0.14 mg/kg/ 
minute over three minutes. In the normally perfused myocardium, blood flow will 
increase several fold (usually with an associated increase in heart rate) which is termed 
the myocardial perfusion reserve. However, haemodynamically significant lesions 
restrict this and a comparison between rest and stress perfusion represents the 
myocardial perfusion reserve.  A rapid acquisition sequence (particularly as the heart 
rate can be high at peak stress) is necessary to obtain a series of T1 weighted images 
per cardiac cycle to image the contrast agent wash in to the myocardium. With such a 
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demanding imaging protocol, there is a trade-off between image quality and spatial and 
temporal resolution, as well as how many slices of the heart can be visualised. 
Depending on the heart rate, usually 3 short axis slices are visualised which adequately 
represents all coronary territories. The acquisition sequence used is usually 
turboFLASH, TrueFISP or hybrid echo planar imaging (EPI). The FLASH sequence 
has a short TR with a spoiler gradient and therefore a low flip angle which limits SI and 
SNR. The TrueFISP sequence has an improved signal intensity and S/N but artefacts 
are problematic. As the EPI sequence collects multiple lines after each RF pulse data 
acquisition is faster potentially reducing artefacts.  
The myocardial signal intensity curve (signal intensity/time) representing the change in 
SI can be obtained at rest and stress. The ratio of stress to rest perfusion reflects the 
myocardial perfusion reserve index. There are quantitative methods available which 
involve the measurement of multiple variables and the accurate description of arterial 
input, usually derived from the LV cavity or aortic root. (Christian 2004) Perfusion 
Tools is a plug-in of CMRtools and uses a model-based approach for first pass 
perfusion assessment with Fermi deconvolution. The software features include the 
definition of arterial input and provide multi-slice perfusion quantification at rest and 
stress giving a segmental assessment of perfusion indices. 
For early enhancement imaging at 1-2 minutes after gadolinium injection, which shows 
myocardial hyperaemia and capillary leak in inflammation, T1 weighted inversion 
recovery imaging is used. The increased blood volume in the affected area causes an 
increase in contrast uptake in the early vascular phase. (Friedrich 2009) 
4.3.2 Late enhancement 
Late gadolinium enhancement (LGE) reflects the delayed washout of the contrast agent 
from the myocardium where the interstitial space is increased due to fibrosis or protein 
deposition, or due to loss of myocyte membrane integrity from myocardial damage and 
inflammatory changes. Myocyte damage along with lymphocyte infiltration and 
oedema are characteristic of acute myocarditis. The contrast washes through normal 
myocardium fairly rapidly (as it does not cross the normal cell membrane) but 
accumulates in damaged areas. Using a segmented gradient echo inversion recovery 
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sequence, the TI can be set to show optimal contrast between normal myocardium, 
blood pool and the contrast enhanced abnormal tissue. In effect the signal from normal 
myocardium is nulled. This is usually best achieved between about 15 and 30 minutes 
after the contrast injection when the concentration of contrast in damaged tissue is still 
high but has reduced significantly in the blood pool and normal myocardium. (Kwong 
2006) This is particularly important in the case of spatially heterogeneous areas of 
damage, for example sub-endocardial defects or the infarct periphery. (Schmidt 2007) 
The TI needs to be constantly adjusted to compensate for the normal washout kinetics 
of viable tissue. 
4.4 T2* assessment of myocardial iron 
Myocardial T2* is measured using a well described gradient echo sequence, with a 
constant TR (to avoid T1 effects), and progressively incremental TE. (Anderson 2001, 
Westwood 2003) To measure myocardial T2*, a mid-ventricular septal region of 
interest (ROI) is selected avoiding blood pool and proximal vessels. Using the septum 
avoids susceptibility artefacts from tissue interfaces. Myocardial SI is inversely 
proportional to TE which are plotted against each other and fitted to a mono-
exponential curve (SI=P0•e-TE/T2*). The rate of decay increases with iron burden. In 
heavily iron overloaded patients, the SI for higher TEs may fall below background 
noise causing the curve to plateau and underestimating T2*. Curve fitting can be 
improved by adding a constant offset or truncating later echo times. The latter method 
is more reproducible and gives values closer to those obtained by the DIR sequence. 
(He 2008) ROIs can be drawn and plotted manually or an off-line analysis package 
utilised. All analysis for this thesis was performed using Thalassaemia tools, a plug in 
of CMR tools. This program allows rapid ROI delineation which is propagated 
throughout all TEs. The curve is fitted automatically and truncated by the operator if 
necessary. 
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Figure 4-4 Thalassaemia tools is an off-line automated analysis program that 
allows rapid isolation and propagation of ROIs through all echo times and fits 
points to a mono-exponential decay curve. This patient has a T2* of 17.85 which 
indicates mild myocardial iron overload. 
90 
 
 
Chapter  5: Emery Dreifuss muscular dystrophy (EDMD) 
5.1 Introduction 
Due to the high incidence of cardiac involvement and sudden death in EDMD2 early 
detection of cardiac abnormalities is important in conditions associated with CM to 
select the best therapeutic strategy with the aim to slow any cardiac remodelling and the 
onset of cardiac related symptoms. Timely intervention with steroid and ACE inhibitor 
therapy has been reported to be effective in patients with DMD. (Duboc 2005, 
Ramaciotti 2006, Kwon 2012)The hypothesis that fibrosis may play a role in the 
development of cardiomyopathy (CM) in EDMD2 was tested by using late gadolinium 
enhancement (LGE). Functional assessment was by CMR cine imaging and 
echocardiography. CMR myocardial tagging and echo myocardial velocity gradients 
(MVG) were used to image early changes in strain patterns that may occur before 
global dysfunction. 
5.2 Methods 
Eight consecutive genetically proven EDMD2 patients were enrolled from patients 
attending the regular outpatient clinics of the Dubowitz Neuromuscular Centre and 
invited to participate in the study. Patients with a contraindication to CMR such as 
cerebral clips, implantable devices and in particular cardiac pacemakers were not 
included. As the disease incidence is low and many patients do have implanted 
pacemakers, the potential study population was correspondingly low. Six patients were 
male, the age range from 7-42 years (mean 18.5). The table below summarises the 
clinical profiles of the patient group. All patients had muscle weakness associated with 
mild to severe mobility impairment. Of the patients studied, one was in atrial flutter and 
one had right bundle branch block. Patients were asked to undergo detailed 
echocardiographic imaging and 24 hour EGC at the Hammersmith Hospital and CMR 
imaging at the Royal Brompton Hospital on separate days for their convenience. The 
time between scans ranged from two weeks to three months. 
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An age matched control group was obtained from 8 healthy volunteers. It was not 
possible to match the controls for body surface area as the patient group had lower body 
weights than could be found in healthy volunteers. The study was approved by HH and 
RBH ethics committees and informed written consent was obtained from each subject 
or subject‟s guardian before entering the study. 
5.2.1 Standard echocardiography 
A comprehensive standard echocardiographic examination was performed using a 
commercially available diagnostic ultrasound system (HDI 5000, Philips Medical 
Systems, Crawley, UK) with a 4-2 MHz multifrequency transducer and second 
harmonic imaging capability for better endocardial border detection. Left atrial (LA) 
size and left ventricular (LV) dimensions at end-diastole and end-systole were 
measured to provide an overall assessment of LV function. LV end-diastolic wall 
thickness was measured and used to calculate left ventricular mass using the Devereux 
formula. (Devereux 1986) Cardiac dimensions were corrected for body surface area. 
Valves and great vessels were subjectively assessed for structural abnormalities. 
Doppler blood pool velocities were measured across the mitral valve in diastole to 
assess diastolic filling from early (E-wave) and late (A-wave) transmitral velocities. 
(Ommen 2003)  
5.2.2 Tissue Doppler echocardiography (TDI) 
From the apical projection, pulsed wave TDI velocities were measured in systole and 
diastole at the atrio-ventricular ring level. Samples were taken from the lateral, septal, 
anterior and posterior walls using apical four and two chamber projections. These 
velocities reflect the longitudinal vector of shortening of the myofibrils and provide an 
estimate of the ventricular function along the longitudinal axis. From the parasternal 
long axis view, an M-mode trace was obtained depicting the endo and epicardial 
boundaries. Onto this trace, a colour coded tissue velocity map was superimposed 
showing spatial and temporal velocity differences during systole and early and late 
diastole from which the MVG between subendocardium and subepicardium could be 
calculated and thus, the radial LV function estimated. The angle of the M-mode beam 
was aligned to be perpendicular to the myocardium (≤5 degrees). Aliasing was 
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eliminated by appropriate PRF settings and grey scale gains were adjusted to provide 
clear delineation of the endocardial and epicardial borders. The ECG was continuously 
recorded in all cases. 
Data captured in freeze frame were downloaded onto a PC with specially designed 
software (HDI Lab, Philips Medical Systems, Best, The Netherlands). Myocardial 
borders (endocardial and epicardial) of the left ventricular posterior wall were defined 
and traced by an experienced echocardiographer. The MVG was definable as the slope 
of linear regression of myocardial velocity along each M-mode scan line throughout the 
myocardium. (Palka 2000) This may be considered equivalent to radial strain rate of the 
myocardium. 
5.2.3 Cardiovascular magnetic resonance 
The CMR was performed using a 1.5 T scanner (Magnetom Sonata, Siemens AG 
Medical Engineering, Erlangen, Germany) using front and back surface coils and 
prospective ECG triggering. Images for all but one patient were acquired during breath-
hold. All anatomical imaging was performed using a prospectively gated steady state 
free precession (SSFP) sequence, typically flip angle 60, echo time 1.55 and slice 
thickness 7mm. The acquisition window and TR were adjusted according to the R-R 
interval. Segmentation was adjusted to provide ≥ 20 phases. From the scout images 
ventricular long axis views were obtained to depict valve motion. Using the long axis 
cines as scouts a full set of SAX slices, fully covering the ventricles and atria, were 
obtained.  Accurate assessment of ventricular diastolic and systolic volumes and left 
ventricular mass was facilitated using semi-automated segmentation (CMRtools, 
Cardiovascular Imaging Solutions, London, UK). Papillary muscles were included in 
LV mass and subtracted from LV blood pool. Atrial size was similarly measured during 
full atrial diastole. All cardiac dimensions were corrected for body surface area. Turbo 
spin-echo imaging with T1 and T2 weighting with and without fat suppression was 
used to show the presence of fibro-fatty replacement. Turbo spin-echo is a sequence 
used for tissue characterisation and can detect fibrous of fatty infiltration within the 
myocardium. Fat appears brighter due to increased contrast.  Axial cuts optimally 
showing right ventricular myocardium and short axis cuts through the base, mid-
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ventricle and apex were obtained to exclude the presence of myocardial fat. Typical T1 
weighted parameters included slice thickness 8mm, TE 6.7, TR according to R-R 
interval, flip angle 180° and for T2 weighting with fat suppression slice thickness 8mm, 
TR twice R-R (triggering on alternate pulses) TE 60, TI 170. Gadolinium-DTPA was 
given as a peripheral intravenous bolus (0.1mmol/kg bodyweight) to test whether 
fibrosis plays a role in cardiac involvement in EDMD. Contrast enhanced images were 
acquired using a segmented inversion recovery sequence after 10 minutes. The slice 
thickness was 8mm, TE 4, flip angle 20°, trigger pulse 2. The TR was adjusted for the 
R-R interval and the TI was constantly adjusted from 300 to 440 to compensate for 
normal contrast washout dynamics. Areas of late gadolinium enhancement, if seen, 
were to be expressed as a percentage of normal tissue. (Kim 2000, Moon 2003)  
Magnetic resonance tagging sequences spatially modulate longitudinal magnetisation at 
end-diastole thus creating a grid of tag patterns that when analysed revealed local and 
global cardiac motion patterns. The harmonic phase method (HARP) uses the fact that 
image phase is related to myocardial motion and spatial derivatives are calculated for 
each pixel to produce displacement maps. (Kuijer 2001, Sampath 2003) This analysis 
method overcomes the time constraints of conventional processing and tracking of tags. 
The tag sequence produces sinusoidal tag patterns at particular spatial frequencies. 
Myocardial deformation produces localised frequency variations which are used to 
calculate components of Eulerian and velocity fields. Fourier transformation of the 
tagged image produces central spectral and harmonic peaks, the location of which are 
determined by the tag pattern. Band-pass filtering is applied to eliminate phase 
cancellation and isolate the selected spectral peak, typically the lowest harmonic 
frequency. This filter is then applied to all the images. The resultant image consists of a 
harmonic magnitude image which is used to isolate the myocardium and a harmonic 
phase image which describes myocardial motion. The derived „angle‟ image is used 
track the phase of the tags by subtracting the baseline tag. (Osman 1999, Axel 2005, 
Ibrahim 2011) Two long-axis and 3 short-axis projections were acquired to give good 
coverage of all myocardial segments and depicting longitudinal, radial and 
circumferential motion. From this data, we calculated minimal principal strain for 
controls and study patients.  Minimal principal strain is defined as maximal shortening 
parallel to the fibre direction and correlates with circumferential strain patterns. 
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5.2.4 Statistics 
Descriptive statistics are presented as mean ±1 standard deviation. The relationships 
between sets of continuous variables were examined using unpaired student t-test. All 
tests were two-tailed and p<0.05 was considered statistically significant. 
5.3 Results 
5.3.1 Clinical characteristics 
The table below summarises clinical findings including cardiac and respiratory data for 
the time of the study. All patients carried a heterozygous LMNA gene mutation. The 
average patient age was 18.5 years±12 (range 7-42). There were 2 females and 6 males. 
They were all asymptomatic from the cardiac viewpoint and none was on any 
medication. Six patients had normal sinus rhythm with no conduction abnormalities on 
24 hour Holter monitoring. One patient was in atrial flutter, while another had first-
degree atrio-ventricular block. Musculoskeletal symptoms started at an average age of 
2.75±1.25 (range 1-4) years. All patients were ambulant with mild to marked limitation 
of functional capacity. One patient could only walk with crutches and another was able 
to walk short distances independently with difficulty.  
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Table 5-1 Patient demographics including clinical and functional characteristics. 
  
I: Walking independently, WC: Walking with crutches, WD: Walking Independently with difficulty, E: 
Elbow, H: Hips, TA: Achilles Tendon, HS: Hamstrings, UL: Upper Limbs, LL: Lower Limbs, TF: Trunk 
Flexors, >: more than, =: equal  FS: Fractional Shortening, AV: Atrioventricular, FVC, forced vital 
capacity, NIV: Non-invasive ventilation 
 
The body mass index (BMI, kg/m
2
) of the patient group was lower than in controls 
(15.2±3.43 g/m
2
 vs. 18.1±2.4 kg/m
2
, p=0.076). This was due mainly to the fact that the 
adults and older children in the patient group had very low body weights. In the control 
group only the younger children had low BMIs. The normal adult range for BMI is 19-
25 kg/m
2
. This low body weight was accredited largely to muscle wasting. There was 
no difference between the BSA of the two groups, although the BSA of the patients was 
below the expected values for age. (Mosteller 1987) 
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5.3.2 Echocardiographic findings 
Echocardiographic imaging was optimal in all 8 patients with clear endo and epicardial 
border delineation. Patients had normal left ventricular function at the time of 
examination with a fractional shortening ranging from 33-37% (mean 35%). There was 
no difference between patients and controls for LA size, left ventricular size and 
fractional shortening. LV mass was similar between patients and controls. There were 
no differences in LV mass as calculated by echo or CMR (63.3±12 g/m
2
 for echo and 
60±18 g/m2 for CMR, p=0.95).  Mitral E and A wave diastolic velocities were similar 
for both groups as were the annular E to A wave ratios. TDI velocities were normal in 
all mitral annular regions and were similar between patients and controls. The mitral E 
to annular E‟ wave ratio was also normal. 
Table 5-2 Echo derived parameters 
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MVGs were similar between patients and controls during systole. In early diastole 
however, during the rapid filling time, the early diastolic gradient was lower in patients 
than in controls suggesting early myocardial dysfunction (4 ± 1.2 s-1 vs.  7.1 ± 2.7 s-1, 
p=0.02). 
5.3.3 Cardiovascular magnetic resonance 
All patients tolerated the CMR scan well. The youngest patient (age 5 years) could not 
be cannulated via superficial access and he therefore could not be given Gd-DPTA. 
This patient also could not breath-hold adequately therefore a TrueFISP real-time 
acquisition sequence was utilised. Resolution was not as good as the breath-hold 
sequences but adequate for boundary definition and planimetry. Good quality breath-
hold images were obtained for all but this one patient, slice thickness 5-7mm according 
to BSA. Another patient had severe spinal contractions, which made breath-holding 
difficult and had to be brought out of the scanner during the examination due to 
discomfort. This prolonged overall scanning time but adequate images were obtained 
with minimal patient stress. 
Table 5-3 CMR findings 
 
Left and right ventricular (RV) ejection fractions were within normal limits for both 
patient and control groups. LV and RV volumes corrected for BSA were also within 
normal limits. There was no significant difference between the corrected ventricular 
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volumes between the two groups. Mean LV mass when corrected for body surface area 
was below the published normal value of 87±12 g/m
2
. (Lorenz 1999) The corrected 
mass for the control group was also below the normal range. Some of these differences 
may be explained by the relative youth of both patient and control samples when 
compared with the age range of the previously described group (8-55 yrs, mean 28±9) 
versus 7-42 yrs mean 18.5 and 6-30 yrs mean 15. The EDMD2 group did however have 
a particularly low corrected LV mass, which may be further explained by their relative 
physical inactivity due to mobility limitations. LV mass was similar between the two 
groups. RV mass was not measured due to difficulties with reproducibility in children.  
The LA volume CMR was greater in both patient group and controls compared with 
previously published data. (Poutanen 2000) This group did not however include the 
atrial appendages in their volume measurements and used FLASH sequences for their 
acquisitions. No patient showed areas of late gadolinium enhancement. There was 
however a significant reduction in inferior wall strain as determined by HARP tagging  
at -0.062 + 0.024 versus -0.094 + 0.032 in the control group (p=0.048).    
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Figure 5-1 Minimal principal strain pattern in the inferior segment of the mid-
cavity LV determined by CMR tagging. The dashed line is the minimum principal 
strain for EDMD patients, while the solid line is the average strain for the age-
matched normal volunteers.  
 
5.3.4 Follow-up 
Patients were re-assessed clinically two years after completion of the study. In brief, 
LV function remained normal as defined by conventional echocardiographic criteria, 
but one patient had developed atrial ﬁbrillation. 
5.4 Discussion 
This is the ﬁrst study to identify subclinical myocardial dysfunction in consecutive 
patients with the autosomal dominant form of EDMD The small series of patient 
reports available, selected on the basis of speciﬁc cardiac abnormalities, suggest that 
the evolution of AV block in the X-linked form seems to evolve slowly, culminating in 
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complete heart block or atrial paralysis for which pacing is indicated to prevent sudden 
death. (Dreifuss 1961, Emery 1966, Wyse 1987) The severity of conduction 
disturbances appears greater in the dominant form of the disease and ventricular 
ﬁbrillation may occur. This might explain the relative high frequency of sudden death 
in this group of patients despite pacing or ICD insertion. LV dysfunction may occur in 
the form of apparently isolated dilated cardiomyopathy, especially in EDMD2. One 
study described 54 living members of one family with a lamin A/C mutation of whom 
17 presented with cardiomyopathy and cardiac conduction system disease. (Becane 
2000) It is also possible that some individuals undergoing cardiac transplantation for 
idiopathic cardiomyopathy may in fact have undiagnosed EDMD. (Merchut 1990) It is 
therefore important in this group of patients to risk stratify for pacing/ICD insertion and 
to predict progressive myocardial disease allowing early pharmacological intervention. 
Only one study to date (Sanna 2003) has described the range of cardiac abnormalities in 
unselected population and found that only 3 of their 10 patients had evidence of 
ventricular dysfunction on the basis of conventional 2 dimensional echocardiography. 
Whether EDMD leads primarily to conduction abnormalities as opposed to myocardial 
fibrosis and dysfunction has remained unknown. In the current study we hypothesised 
that patients may develop primary myocardial dysfunction, which will subsequently 
lead to conduction abnormalities.  
TDI is a relatively new echocardiographic modality, which has been used to describe 
global and regional ventricular function. It has been used to describe early changes of 
myocardial function when conventional echocardiography remains normal. (Dutka 
2000) TDI requires modification in signal processing of the returned Doppler signals 
during which the higher velocities obtained from the blood pool are filtered out. The 
great advantage of TDI is the high frame rate which increases the sensitivity of this 
technique.  (Nagueu 1997, Rambaldi 1998, Sutherland 1999, Price 2000, Waggoner 
2001). In addition, information on myocardial deformation using the MVG from 
subendocardium to subepicardium can be obtained, furthering the assessment of 
myocardial function. Several groups have reported myocardial abnormalities in sub-
clinical conditions leading to cardiomyopathies. (Dutka 2000, Meune 2004)  In this 
study, early diastolic MVGs were abnormal in a homogeneous group of autosomal 
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dominant EDMD patients while conventional echocardiography failed to identify any 
abnormalities.  
The most often quoted indices of ventricular function, stroke volume and ejection 
fraction, are unavoidably load and heart rate dependant; therefore, the measurement of 
ventricular volumes in a non-controlled setting is arguably open to error. While LA 
dimensions can be measured by echocardiography, CMR can accurately deﬁne atrial 
volumes and function. Interestingly, these were normal by both echocardiography and 
CMR. Atrial volumes were not increased in comparison to the controls for this young 
patient cohort. This perhaps would refute any primary atrial dysfunction in these 
patients. Few reports of cardiac muscle pathology in EDMD are available but 
myocardial changes with focal degeneration and fatty fibrous replacement have been 
described. (Yoshioka 1989)  
CMR has been used to depict fatty and ﬁbrous inﬁltration in patients with myotonic 
dystrophy but not using newer technology including TSE, late enhancement imaging or 
tagging. (Vignaux 2002) There was no evidence of late enhancement of the 
myocardium with gadolinium and no evidence of ﬁbro-fatty replacement using the TSE 
sequences. There does however need to be signiﬁcant loss of cellular integrity over a 
macroscopically visible area to detect this. Nevertheless, there was a signiﬁcant 
difference in inferior wall strain as determined by HARP tagging suggesting early 
abnormalities of ventricular function. Although our patient numbers were limited by the 
rarity of the disease, these ﬁndings support those of other studies of patients with 
systemic degenerative disease. Studies on patients with Friedreich‟s ataxia and 
restrictive cardiomyopathy have shown that the MVG at early diastole is the most 
sensitive marker of early changes in myocardial function. (Dutka 2000, Palka 2000) 
The relationship between physical immobility and measurements of cardiac function, 
including MVGs is not established, but this should have no more affect that the 
opposite phenomenon, athletic training. A recent study has demonstrated a relationship 
between long-term athletic training and the diminution of age related changes in early 
diastolic function. (Palka 1999)  
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These results suggest that cardiac dysfunction precedes signiﬁcant ﬁbrosis and that the 
pathogenesis for the cardiac involvement in EDMD2 is different from that observed in 
DMD and BMD. These findings are in keeping with recent observations on the cardiac 
involvement in the animal model with targeted inactivation of the LMNA gene. 
(Nikolova 2004) Both CMR tagging and MVG by tissue Doppler consistently showed 
myocardial dysfunction in the infero-posterior LV wall. Relevant ﬁndings in this 
animal model were early (by 2 weeks of life) cardiac dysfunction with thin-walled, 
dilated and globular-shaped LV, with a lower mass than in control mice. In similarly 
aged mice, no evidence of myoﬁbril hypertrophy, necrosis or interstitial ﬁbrosis was 
found. Despite the lack of signiﬁcant histological changes, the contractile properties of 
single LV myocytes were studied and signiﬁcantly reduced shortening was 
demonstrated. At least part of the observed abnormality was related to disruption of the 
physiological links between desmin at sarcomeres and lamin. Desmin ﬁlaments are 
directly linked between the nuclear surface and the cytoskeleton, and it is possible that 
lamin contributes to this linkage. Our data and the experimental animal work favour 
therefore a model in which intracellular cardiac defect are an early finding in the 
process of the disease. This is followed only at a later stage by myocyte loss mostly by 
apoptosis and eventually fibrosis. (Nikolova 2004) This observation has important 
implication for the understanding of the pathogenesis of the cardiac involvement in 
EDMD. 
5.5 Clinical implications 
Early detection of myocardial dysfunction in patients with EDMD may potentiate early 
introduction of ACE inhibition or other treatment in advance of permanent pacemaker 
implantation. This could delay the latter while reducing or delaying LV remodelling. 
5.6 Study limitations 
Although our study involved a relatively small number of patients, this study is unique 
in that patients were carefully characterized, genotyped and were selected because they 
had no evidence of underlying cardiomyopathy and/or pacemakers, while all previous 
studies involved patients who already had an established cardiomyopathy or conduction 
system disease. In addition, the fact that so many patients have a permanent pacemaker 
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inserted precluded many from our study, as this currently constitutes a contraindication 
to CMR. This meant that we were unable to study older patients in whom myocardial 
abnormality may have been more readily detectable. CMR compatible pacemakers are 
now available and therefore in the future such patients would not be precluded from 
CMR. Myocardial dysfunction was assessed in the anterior septum by CMR tagging 
and posterior wall using tissue Doppler. This was due to data optimization for both 
imaging techniques. Nevertheless, abnormalities were found by both, CMR and tissue 
Doppler suggesting perhaps a diffuse process of myocardial involvement. T1 mapping 
(MOLLI) is an emerging acquisition protocol for the quantification of diffuse fibrosis. 
This technique was not available at the time of this study. 
5.7 Conclusions 
This study suggests that, unlike DMD or BMD, cardiac involvement in EDMD does 
not appear to involve myocardial ﬁbrosis in the early stage of the disease. The frequent 
implantation of pacemakers into patients with EDMD has unavoidably restricted the 
study of a larger patient population in the past, including those with cardiac symptoms. 
While global systolic function may be normal using conventional echocardiography, 
there appears to be subtle myocardial abnormalities manifested as a reduction in early 
diastolic myocardial gradients by echo and systolic strain patterns by CMR. Routine 
measurement of these may be useful in the early detection of cardiac involvement in 
EDMD. CMR studies with paced patients (Martin 2004) and the increased availability 
of MR friendly pacing systems opens the possibility of ongoing assessment of these 
patients even after the implantation of permanent pacing systems.
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Chapter  6: Anthracycline cardiotoxicity 
6.1 Introduction 
As detailed in chapter 3, cardiotoxicity due to anthracycline exposure can occur at any 
time during or post treatment. Although there is no consensus regarding the 
classification of anthracycline mediated cardiotoxicity (AMC), it is generally divided 
into 2 forms, with an acute or a chronic onset which is further sub-categorised into 
early and late onset. The increasing incidence of late onset  AMC highlights a need for 
cardiac assessment prior to and during chemotherapy and in addition long term follow-
up with more prospective longitudinal trials. Oncologists are now avoiding high doses 
of anthracyclines but as not all patients are susceptible to long term cardiac damage 
some patients are potentially being denied optimal anti-cancer therapy which flags the 
need for an “early warning system” to identify the patients at risk. (Cardinale 2004)  
6.1.1 Pharmacogenetics of anthracycline cardiotoxicity 
There are a number of studies reporting inter-individual differences in cardiac response 
to a uniform anthracycline challenge. (Lefrak 1973, Von Hoff 1979, Grenier 1998, 
Ciotti 2001, Wassmuth 2001, Kremer 2002, Nousiainen 2002, Sorensen 2003) It has 
been postulated that the inter-individual response differences to an extrinsic stimulus 
result from genetic differences. (Montgomery 1997, Brull 2001, Jamshidi 2002, 
Dhamrait 2003) The fact that susceptibility has been found to differ according to gender 
and race adds support to these findings. (Trachtenberg 2011) The identification of a 
relationship between genotype and phenotypic response using accurate characterisation 
would help the identification of patients at risk of AMC and allow timely intervention 
and optimal individual therapy tailoring. There are CMR techniques which could 
potentially help with this characterisation. The basic measurement of left ventricular 
volumes, mass and function are essential, but in addition there are 2 specialised CMR 
techniques of interest.  
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6.1.2 CMR in anthracycline cardiotoxicity 
The first CMR technique has potential to detect the acute cardiotoxic effects of 
anthracyclines including myocardial inflammation and dysfunction. (Bristow 1978b) 
CMR is widely used in the assessment of acute myocardial injury, and changes in tissue 
signal characteristics have been shown to reflect events associated with cellular 
jeopardy. (Friedrich 1998) Increased early gadolinium relative enhancement (EGRE), 
which compares cardiac with skeletal contrast uptake, is associated with myocardial 
hyperaemia, oedema and capillary leakiness. (Friedrich 2009) It has been shown to 
increase in acute infective myocarditis and is associated with a long-term decrease in 
LVEF. (Friedrich 1998, Wagner 2003) A pilot study by Friedrich‟s group of 22 patients 
undergoing anthracycline chemotherapy showed that an increase in EGRE on the 3rd 
day after commencing treatment was related to a decrease in EF at 28 days post onset 
of treatment, although there was only a modest correlation with LVEF at 6 months. 
(Wassmuth 2001) Nineteen of the patients had received a second course of therapy 
before the 28 day scan. The number of chemotherapy cycles was not stated but is 
usually 6 and therefore the results did not really reflect late onset AMC. The study did 
however suggest a use for EGRE in the prediction of late onset AMC. We hypothesised 
that an increase in EGRE early in treatment could predict long term outcome in patients 
receiving anthracyclines. We also explored the use of STIR imaging in the study, 
because of its use in identifying myocardial oedema. 
A second possible CMR technique of interest is the assessment of myocardial iron. 
Increased intracellular iron loading has been described in cell and rat models of AMC. 
(Kotamraju 2002, Kwok 2003, Miranda 2003) The iron chelator dexrazoxane has been 
shown to ameliorate AMC although deferasirox has been reported to afford no 
cardioprotection against AMC, (Xu 2005) and mechanisms other than iron scavenging 
have also been proposed. (Lyu 2007) Although we would not expect to see iron levels 
in the concentration found in iron overloaded transfusion-dependent patients such as 
thalassaemia major, we hypothesized that CMR T2* sequences might detect a rise in 
myocardial iron in patients who go on to develop AMC.  
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6.1.3 Other biomarkers of cardiotoxicity 
Finally, markers of cardiac damage and dysfunction, troponins and natriuretic peptides 
rise after anthracycline administration. (Cardinale 2010b) As much of the literature 
supports a major role for oxidative stress it would be expected that markers such as F2-
Isoprostanes, which are formed by the peroxidation of fatty acids by free radicals, 
would also be elevated. We hypothesised therefore that the early CMR markers would 
correlate with biomarkers of cardiac damage and oxidative stress which could be used 
as a predictor of late AMC instead of the more complex cardiac imaging. 
6.1.4 Study objectives 
In order to test these hypotheses, we participated in the Breast Cancer, Early disease: 
Toxicity from Therapy with adjuvant Epirubicin Regimens Cardiac Assessment and 
Risk Evaluation (BETTER-CARE) sub-study B performing CMR before 
chemotherapy, at 3 days post-chemotherapy and at 12 months follow-up. 
6.2 Methods 
6.2.1 Patient selection into the main BETTER-CARE study 
Patient recruitment for the main BETTER-CARE study was mediated via the NCRN. 
Approximately 1700 UK women per year are newly diagnosed with breast cancer and 
seen in the local cancer networks, 45 to 60% of whom require adjuvant chemotherapy. 
Based upon the experience of the oncologist principal investigators, it was predicted 
that approximately 18% of patients would fulfil study recruitment eligibility and be 
willing to participate. It was initially calculated that 276 patients were required to detect 
a 2% change in LVEF with treatment. Allowing for dropouts the initial target number 
for the main study was 296. The original age range was 30-60 years and estimated 
recruitment was around 200 patients per annum and that the target number would be 
achieved within 18 months. As it became apparent that recruitment was significantly 
slower that predicted (see limitations) the age range was changed to ≥ 18 years and the 
sample size reduced to 189 subjects. A target of 247 recruited study subjects was 
therefore set which would allow for patient withdrawal and the introduction of 
Trastuzumab for HER2 positive patients. Final eligibility criteria therefore included: 
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female sex, early breast cancer, > 18 years old, epirubicin based chemotherapy and no 
previous cardiovascular disease as outlined in table 6.1. 
Table 6-1 Eligibility criteria 
 
6.2.2 Patient selection into the CMR substudy 
Initially patients were referred to the RBH CMR unit from the oncology clinics of 10 
London hospitals. Due to slow recruitment, provisions were later made for patients to 
also be recruited and scanned locally at the Mount Vernon, Glasgow and Oxford 
centres. This included visiting the sites and training them in the desired methodology. 
All subjects scanned at RBH were invited to participate in the day-3 CMR sub-study. 
The primary endpoint of the CMR substudy was the change in EGRE in patients who 
developed chronic AMC. The EGRE study involved returning on the 3rd day following 
cycle 1 of epirubicin if well enough for an additional CMR scan, and we included blood 
and urine sample collection at this time.  
Patients were approached during their outpatient appointment to discuss chemotherapy 
by their oncologist. Interested patients were given a copy of the patient information 
sheet and signed consent was obtained for all participants. A patient information DVD 
was also available. Eligibility was checked against the study criteria by the oncologist 
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or NCRN research nurse and subsequently recorded in a case report form (CRF). 
Patients were eligible to take part in BETTER-CARE if they were enrolled in other 
studies provided they would receive 300-450mg/m
2
 of epirubicin. Information about 
the patient at enrolment and their subsequent course of treatment was noted in the 
oncology CRF. The NCRN nurse then contacted the study coordinator or the CMR unit 
directly to schedule the scans. All study participants were given an appointment for a 
baseline CMR assessment which was usually four to ten days prior to commencing 
chemotherapy. Patients went on to have their course of treatment as prescribed by the 
oncologist. This could include radiotherapy and/or trastuzumab. Follow-up was 
arranged for 52 weeks after the final dose of epirubicin and 3 months after the final 
dose of trastuzumab if given.    
6.2.3 CMR acquisition 
CMR, scans were acquired using 1.5 T Sonata and Avanto systems (Siemens Medical 
Systems, Erlangen, Germany). Using long and short axis localisers, left and right 
ventricular LAX inflow and outflow cines were acquired ensuring accurate depiction of 
each AV and VA valve motion from two views. Using the long axis cines to define the 
SAX plane, contiguous SAX cines were acquired with a 10mm offset from base to apex 
(slice thickness 7mm with a 3mm gap). All cines were acquired using a SSFP 
(TrueFISP) sequence. Retrospective ECG gating with 50 calculated phases ensured 
coverage of the entire cardiac cycle. A mid ventricular STIR image, slice thickness 10 
mm, TR adjusted for HR was acquired to test whether changes in SI at day 3 predicted 
long term change in EF. A T2* acquisition with 16 echo incremental times but constant 
TR was performed to measure myocardial iron, using both the white blood and the DIR 
preparations, (chapter 7) prior to contrast administration. To compare relative contrast 
enhancement between the myocardium and skeletal muscle a TSE sequence with 
TR=RR, TE 44, base resolution 192, phase resolution 100, echo train length 17 and 
slice thickness 20mm was used. A mid ventricular SAX slice, adjusted to optimally 
visualise both myocardium and left latissimus dorsi, was imaged with the chest coil 
turned off (to compensate for posterior and lateral signal loss when using the chest coil) 
prior to and after contrast injection. A 0.1mmol/Kg bolus of Gd-DTPA (Magnevist, 
Schering) was given via a peripheral vein using a power injector at a rate of 7 mL/Sec 
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followed by a bolus of normal saline. To test for myocardial hyperaemia an interleaved 
segmented hybrid EPI perfusion sequence was applied to measure myocardial contrast 
enhanced signal intensity upslope however technical difficulties lead us to abandon this 
approach. (See limitations) The relative enhancement sequence was applied at 30 
second intervals from 60 to180 seconds post injection to ensure optimal imaging of 
tissue contrast dynamics. For the tissue characterisation images, care was taken to 
image the same mid papillary region for all examinations at all time points. At baseline 
and end of study, long and short axis late gadolinium enhancement (LGE) images were 
acquired using a segmented IR turbo flash sequence between 5 and 20 minutes post 
contrast injection with a slice thickness of 8mm, offset 2mm and pixel size 1.8 x 
1.8mm. All CMR image analysis was performed using plug-ins of the viewing/analysis 
package CMRtools described in chapter 4. Changes in myocardial and skeletal signal 
intensity post contrast EGRE images were processed according to the methodology 
described by Wassmuth et al. (Wassmuth 2001) CMR derived markers of inflammation 
were measured blinded to volumetric changes. Measurement of volumetric parameters 
was performed by Dr P Kotwinski, UCL, London as part of the main study blinded to 
time point and changes in CMR derived inflammatory markers. 
6.2.4 Adjustments for trastuzumab therapy 
During the course of the study significant advances were made in adjuvant therapeutic 
regimens for patients with early breast cancer. The most important was the introduction 
of trastuzumab for HER2 positive patients. Trastuzumab was licensed in the UK for 
early breast cancer in 2006. Synergistic cardiotoxicity complicates therapy although the 
mechanism is different to anthracycline cardiotoxicity and it is usually reversible. 
Clinical trials have shown that cardiac dysfunction persists for 20-25 days (the half-life 
of trastuzumab) with cardiac function returning to normal in the majority of patients. 
(Ewer 2005, Guarneri 2006) The original study design was therefore modified to allow 
recovery time after treatment. 
6.2.5 Serum and urine biomarkers 
Plasma, serum and urine were collected at each time point for analysis of F2 
isoprostanes, troponin T, hsCRP and NT-pro BNP. The ratio between urinary F2 
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isoprostanes and creatinine was measured by Professor Kevin Moore, UCL, London 
using high pressure liquid chromatography. Contractual issues have delayed the CRP, 
troponin T and BNP assays. 
6.2.6 Statistics 
Power calculations showed that a change of 0.35 in EGRE with a SD of 0.9 (estimated 
from the literature) would yield a power of 80% at p=0.05 to detect a difference 
between the cardiotoxicity and non-cardiotoxicity groups with a sample size of 51 
patients. Data are presented as mean ± standard deviation (SD). Urinary F2-isoprostane 
data were log transformed to give a normal distribution. Changes in log values were 
then transformed back and presented as the geometric mean. Initial analysis of CMR 
data used a random effects model adjusted for age, BMI, systolic and diastolic blood 
pressure, radiotherapy and time from end of therapy. These factors did not change the 
results significantly therefore difference between values were analysed using a paired t-
test with a threshold 0.05 for statistical significance. Correlations were using Pearson 
correlation coefficients. 
6.2.7 Ethics 
The study was performed with full ethics approval from the South East Multi-Regional 
Ethics Committee. Study Reference: 04/MRE01/79. Site specific approval was obtained 
from the local ethics committees at all participating sites. Written consent was obtained 
from all study subjects. 
6.2.8 National Cancer Research Network (NCRN) Support 
The study was accepted into the NCRN local portfolio. Study Name: The Breast 
Cancer, Early disease: Toxicity from Therapy with adjuvant Epirubicin Regimens – 
Cardiac Assessment and Risk Evaluation (BETTER-CARE), NCRN Trial ID 1516. 
6.3 Results 
The first patient was scanned in November 2005 and the last baseline scan was April 
2009. Recruitment was closed in May 2009 due to time and financial restrictions. A 
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total of 191 patients had a baseline scan at RBH. All patients received epirubicin based 
chemotherapy treatment regimes. The majority received 
fluorouracil/epirubicin/cyclophosphamide (FEC) or FEC/docetaxel (82%). Other 
regimes were FEC/methotrexate, epirubicin/cyclophosphamide/ paclitaxel/gemcitabine 
(NEO-TANGO) and epirubicin/capecitabine (TACT-2). All patients included in the 
analysis received between 300 and 450 mg/m² epirubicin (cumulative dose). No patient 
received dexrazoxane or other cardioprotective medication. Other chemotherapy agents 
administered have not been reported to be associated with cardiotoxicity. The majority 
of patients had radiotherapy (87.3%) and 19.3% received trastuzumab. Two patients 
attended for CMR, but did not complete the scan due to claustrophobia. The final 1 year 
follow-up scan took place in June 2011. Of the patients approached for a day three scan 
for the CMR substudy, 61 agreed and were well enough to return. Six did not return for 
a one year follow-up scan including one patient receiving long term trastuzumab 
therapy for metastatic disease and there was one non cardiovascular death. One patient 
was discovered to have sustained a MI during chemotherapy and was subsequently 
excluded from the analysis. In 3 patients the EGRE data for either baseline or day-3 
was technically inadequate for analysis. We therefore report data on the 51 patients 
who completed the CMR substudy protocol with acceptable data quality. 
Table 1.2 shows the mean values and changes between time points for all parameters 
measured at baseline, day 3 and one year follow-up for the patients taking part in the 
day 3 study who returned for follow-up. No significant differences were found between 
the patients receiving trastuzumab and those not (p>0.1) therefore the patient results 
were combined. ERGE mean values and changes are for baseline and day 3 only. 
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Table 6-2 EF, LV mass and inflammatory imaging changes in the 51 patients who 
successfully completed the protocol 
 
For the whole group of 51 patients, there was a significant reduction in mean LVEF (-
2.6% p=0.0002) from baseline (72.7 ±4.7%) to 1 year follow up (70.1 ±5.2%). Mean 
RVEF fell from 67.9 ±5.4% at baseline, to 66.5 ±5.3% at follow up (-1.4%, p<0.006). 
LV mass showed a significant increase from baseline (105.6 ±12.3 g/m2) to 109.1 
±12.9 g/m2 at day 3 (+3.5g/m2, p= 0.00004) but returned to baseline by the one year 
follow up. RV mass was not measured due to poor reproducibility. The mean increase 
in EGRE was significant (+0.38 ±0.9, p=0.003) from 2.36 ±0.8 at baseline to 2.74 ±1.1 
at day 3. Mean STIR signal intensity showed a trend towards increase (p=0.07) from 
63.3 ±19.8 at baseline to 67.1 ± 0 at day 3.  
There was a significant correlation between changes in EGRE from baseline to day 3 
and a reduction in LVEF at follow up (R=0.34, p=0.01). There was also a weaker 
correlation between the increase in STIR SI between baseline and day 3 and reduction 
in LVEF at follow up (R=0.27, p=0.05) as shown in figure 1.1. 
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Figure 6-1 Graph showing the correlations between Changes in EGRE and STIR 
from baseline to day 3 and the change in LVEF from baseline to follow up. 
For patients with a ≥5% reduction in LVEF from baseline to follow up (n=22, mean 
reduction 7.8% ±3.6, p<0.00001) mean ERGE increased from 2.23 ±0.7 at baseline to 
2.95 ± .1 at day 3 (p=0.002) and STIR SI increased from 63.8 ±20.8 to 73.6 ±24.5 
(p=0.003). In the remaining patients (n= 29), there was a mean increase in LVEF from 
baseline to follow up of 1.7% ±3.2 (p=0.01), and the mean EGRE and STIR showed no 
significant change, (2.46 ±0.95 to 2.58 ±1.20 at day 3, p=0.39; and 63.2 ±19.5 to 63.3 
±16.2, p=0.98 respectively). 
No relationship was found between the changes in EGRE or STIR and change in RVEF 
at follow up. There was no correlation between increase in LV mass at day 3 and 
reduction in LVEF at follow up (R=0.05, p=0.77). There was a significant increase in 
cardiac T2* between baseline (31.7 ± 3.6ms) and day 3 (33.0 ± 4.4ms) p= 0.02. There 
was no significant between the baseline value and follow-up (30.8 ±5.0, p=0.3) 
Urinary F2-isoprostane/ creatinine mean values showed a trend towards decrease from 
0.106 ±0.063 at baseline to 0.096 ±0.064 at day 3 (p=0.17).  There was a negative 
correlation between the value at day 3 and both EGRE at day 3 (R=0.39, p=0.005) and 
an increase in EGRE from baseline to day 3 (R=0.32, p=0.03). There was a negative 
correlation between F2-isoprostane levels at day 3 and RVEF at day 3 (R=0.32, p=0.03) 
There was also a weak negative relationship between F2-isoprostanes at day 3 and a 
reduction in LVEF from baseline to follow up (R=0.26, p=0.06) 
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6.4 Discussion 
AMC has long been recognised as an unwanted corollary of successful cancer 
treatment. With ongoing improvements in anti-cancer therapy and an increasingly 
ageing population we can only expect the incidence to increase. Early diagnosis can 
either guide modulation of the therapy regime or flag the need for cardiological 
intervention, however the identification of patients at risk before commencing anti-
cancer treatment would be the optimal approach. This would permit different individual 
therapeutic strategies to give the best chance of cancer cure or long remittance but at 
the same time avoiding the risk of cardiac pathology, in other words tailoring treatment. 
The results of this study have shown a significant relation between EGRE, which is a 
CMR marker of myocardial hyperaemia and a late deterioration in left ventricular 
function. The relation is however only moderate and further work will be needed to 
establish whether such a test could be used to predict chronic ACM. Of interest is that 
the CMR oedema marker of STIR imaging also predicted the reduction in left 
ventricular function, but with lower power. 
Wassmuth reported that an increase in EGRE at day 3 post first chemotherapy cycle 
related to a later decrease in LVEF in a pilot study of 22 patients with diverse 
oncological diagnoses. (Wassmuth 2001) In this study patients were scanned prior to 
and then 3 days and 28 days post first cycle, and 18 patients were also scanned 6 
months after the start of treatment. The group found that an increase in EGRE by a 
factor of >5 at day 3 correlated strongly with a decrease in LVEF at 28 days and 
weakly with the change at 6 months. As most chemotherapy courses last for 6 months, 
the changes described cannot be considered chronic but the findings led us to believe 
there may be a use in this methodology for predicting late events, and we therefore 
designed our trial to have greater power to show an effect, to have a more 
homogeneous patient cohort, and to have longer follow-up which is clinically relevant 
to the development time of ACM after chemotherapy. Treatment regimens were 
carefully monitored and markers of inflammation and cardiac damage assessed. We 
also collected samples to measure markers of inflammation and cardiac damage to be 
subsequently related to genetic markers although the DNA and serum biomarker data is 
not available to date. The changes in EGRE in our patients were much lower than those 
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described by Wassmuth. This could be due to the anthracycline regime used, as 
anthracycline dosage tends to be lower in adjuvant therapy. They stated that there was 
no correlation between chemotherapy dose and myocardial signal intensity or 
functional changes in their patient group (data not included in the publication) however 
their cohort included patients with cancers with a poorer prognosis and the majority 
received doxorubicin therapy which is associated with a higher incidence of AMC. 
(Hortobagyi 1989, Pfeffer 2009) They used a 1.0 T (Siemens Impact Expert) MR 
scanner, but the scan sequence used was similar and we applied the same formula for 
calculating EGRE as in their study.  
It was expected that the urinary F2-isoprostane to creatinine ratio, as a marker of 
oxidative stress, would increase at day 3 but in fact there was a reduction. Furthermore 
this reduction related to changes in EGRE between baseline and day 3. Il‟yasova et al 
found that oxidative stress biomarker mean values, including F2-isoprostanes, were 
increased one hour after treatment administration in a group of women with early breast 
cancer but that they had normalised 24 hours later. (Il'yasova 2010) A more recent 
study by this group however noted two distinct patterns of response. One group showed 
an increase in biomarkers one hour post treatment with a subsequent decrease at 24 
hours and the other showed a mixed response with a reduction in some biomarkers one 
hour post administration and this group had higher baseline biomarker levels. (Il'yasova 
2011) In both studies they did not measure biomarker levels after 24 hours post 
anthracycline exposure. The authors postulated that differing mechanisms including 
antioxidant defence and homeostatic redox control may be implicated and relate to an 
individual‟s susceptibility to AMC. The decreased levels of F2-isopostanes at day 3 in 
our study may be a reflection of overshoot of the defence mechanism that is more 
marked in patients who are more susceptible to AMC. The fact that the decrease 
correlates with a subsequent increase in EGRE may indicate a longer equilibration 
process for macroscopic changes. 
Although it was hypothesised that a rise in myocardial iron might be identified by a 
reduction in T2* at day 3, in fact there was an unexpected increase in T2*. This may 
have resulted from the confounding effect of an increase in tissue oedema, prolonging 
spin-spin relaxation and therefore T2*. Tissue oedema would increase myocardial 
116 
 
volume and the increase in LV mass at day 3 would support this proposition, as does 
the increased STIR signal which we found at day 3. Zagrosek et al reported a parallel 
change in LV mass in myocarditis patients showing a transient increase in 
myocardial/skeletal signal intensity ratio. (Zagrosek 2008) We found a significant 
increase in LV mass at day 3, but somewhat surprisingly this did not correlate with a 
reduction in LVEF at follow up indicating that oedema might be generic response to 
anthracycline treatment, rather than being indicative of specific damage likely to 
ultimately result in loss of ventricular function. The patients were scanned a year post 
completion of treatment yet there is an increasing risk of heart failure for at least 5 
years. (Eschenhagen 2011) Prolonging the follow up period may identify a relationship. 
6.5 Limitations 
It was originally intended to restrict recruitment to women aged 30-60, of white-
European ethnicity, receiving 360-450mg/m
2
 epirubicin, receiving either no 
radiotherapy or only right-sided radiotherapy; who had who had a booking BP <140/90, 
BMI <30 and no history of cardiovascular disease or diabetes. However we found only 
7.5% of patients with planned adjuvant chemotherapy fulfilled these criteria and they 
were modified in June 2005. It was subsequently decided that all patients over 18 years 
could be included plus those with planned left-sided radiotherapy as around 80% of 
patients with early breast cancer receive radiotherapy therefore exclusion would have 
significantly hampered enrolment. Moreover modern radiation therapy is much less 
likely to be associated with cardiac damage. (Barrett-Lee 2009) Indeed a random 
effects model of volumetric changes with adjustment for variables including age, 
trastuzumab and radiotherapy showed no significant difference from the unadjusted 
changes.  
Other modifications included increasing the booking BP (<160/100) and BMI (<35) 
and reducing the epirubicin dose to 300-450mg/m
2
 to better reflect the range of 
regimens used at the participating centres. Due to the extended length of the study, 
several scanner upgrades occurred which meant non standard sequences needed to be 
modified. There is no evidence that this impacted on the CMR measures, but we cannot 
exclude this possibility. Due to the prolonged duration of the study, contracts which 
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were in place for performing the biochemical assays expired, therefore this data will 
only become available in the future and cannot currently be reported. 
6.6 Conclusions 
This study has shown a relationship between early tissue changes detected by CMR 
after anthracycline exposure and a long term reduction in left ventricular ejection 
fraction.  Furthermore the CMR derived tissue changes were related to changes in 
markers of oxidative stress which supports the role of oxidative stress in the 
development of AMC which may help the characterisation of patients susceptible to 
AMC. It would be interesting to follow these well characterised patients for a longer 
period to better understand the pathophysiology of AMC and the significance of early 
biomarkers and mid-term phenotypic changes in long term outcome. Further work is 
needed to establish whether these promising results with EGRE could have a clinical 
role in predicting late ACM. 
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Chapter  7: Optimisation of CMR Sequences for assessment of Iron 
Overload 
7.1 Introduction 
Although transfusions improve short term health and survival in TM patients, the 
consequent tissue iron deposition leads to organ damage in the long term. Those treated 
only with transfusions usually die early from cardiac failure secondary to myocardial 
siderosis. (Modell 1982, Borgna-Pignatti 2004) Myocardial dysfunction is directly 
linked with cardiac iron burden, (Kirk 2009) but often occurs late and can be hard to 
reverse once established. Direct, accurate assessment and early treatment of iron 
loading is pivotal in the management of these patients, along with tailored cardiac 
chelation therapy which may reverse or prevent myocardial dysfunction. (Wolfe 1985, 
Brittenham 1994)  Over the last decade, there has been a marked reduction in deaths 
attributable to tissue iron overload within the UK which coincides with the introduction 
of T2* cardiovascular magnetic resonance (CMR) as a diagnostic tool. (Modell 2008) 
The first T2* sequence developed was a multi breath-hold, white blood, end-diastolic 
acquisition. (Anderson 2001) This technique was time consuming and was 
compromised by miss-registration due to inconsistent breath-holding. A single breath-
hold sequence was subsequently developed to reduce scan time and improve image 
registration between images, and this improved reproducibility. (Westwood 2003) This 
technique became the standard for evaluation and follow-up and has been installed on 
CMR scanners from different vendors at multiple sites throughout the world (Kirk 
2010) and is still being used to investigate the cardiac efficacy of chelating agents. 
(Pennell 2006, Tanner 2007, Tanner 2008, Pennell 2010, Pennell 2011) Despite its 
success however, the white blood technique has some undesirable characteristics: the 
contrast between blood pool and myocardium may be suboptimal, and despite flow 
compensation, artefacts from motion and blood flow may compromise measurement 
accuracy.  
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More recently, a double inversion recovery „black blood‟ sequence has been reported 
which suppresses the blood signal, and a preliminary comparison with white blood T2* 
imaging suggested good reproducibility. (He 2007) The aim of study A was therefore to 
compare inter and intra-observer reproducibility between the established white blood 
sequence and the newer black blood sequence in a large group of patients, and to 
evaluate the interstudy reproducibility and artefacts when using the black blood 
sequence. For study B, we examined the possible role of performing T2* imaging in 
systole instead of diastole. 
7.2 Methods for study A: black blood imaging  
100 TM patients were studied to compare the black blood and white blood acquisitions. 
The cohort included 50 consecutive patients with cardiac siderosis (T2* <20ms) and 50 
consecutive patients with no cardiac iron (T2* >20ms) as measured using the 
conventional white blood T2* acquisition. Cardiac T2* values ranged from 4.5 to 
43.8ms across all patients. The age range was 11–50 years (mean 27) and 51% were 
female. All patients underwent both the conventional white blood and the new black 
blood T2* scan to test intra and inter-observer reproducibility. To test inter-study 
reproducibility, 23 patients with T2* values from 6.9 to 46.1 ms had a second scan for 
both black and white blood acquisitions on the same day.  
All patients were scanned using a 1.5 T scanner (Siemens Sonata, Erlangen, Germany) 
with a 6 channel phased array cardiac receiver coil and ECG gating. A mid-ventricular 
short axis slice was obtained for all scans. The white blood acquisition used a multi-
echo gradient-echo sequence (flip angle 20°, matrix 128x256 pixels, sample bandwidth 
810 Hz/pixel, slice thickness 10mm and field of view 40cm). The short axis images 
were acquired within a single breath-hold at 8 echo times from 2.54 to 17.90 ms at 
approximately 2 ms increments. For white blood diastolic imaging, the images were 
acquired immediately after the R-wave. For the black blood acquisitions, a double 
inversion recovery (DIR) pulse was applied on the R-wave and the inversion time 
extended into diastole, generating a similar set of 8 images at increasing echo times. 
Image analysis was performed using Thalassaemia tools (a plug in of CMRtools, 
Cardiovascular Imaging Solutions, London, UK). A full thickness ROI incorporating 
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the ventricular septum was selected avoiding blood pool and cardiac vessels. (Reeder 
1998, Ghugre 2006) T2* was derived by using an exponential curve fit, SI = SI0.exp-
(TE/T2*), where SI is signal intensity, TE is the echo time and SI0 is a constant 
representing signal intensity at time zero. A truncation method was used to account for 
background noise at the longer echo times and improve curve fit, (He 2008) although 
this was not generally necessary for the black blood acquisitions 
 
Figure 7-1 Rapid signal decay in heavily iron loaded hearts causes the curve to 
plateau. Later points that fall below background noise level are removed to 
improve curve fit in frame a (red crosses). For the black blood acquisition (b) 
background noise is reduced thus the curve fit is good for the full range of echo 
times without truncation (R2 = 0.9995) which reduces the likelihood of analysis 
errors. 
 
Analyses for all sequences were performed by two experienced investigators. Each 
data-set was anonymised and presented to observers in random order. Intra-observer 
reproducibility was assessed using 2 sets of measurements derived by observer 1. To 
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test inter-observer reproducibility, the first read results were compared with those of 
observer 2. Inter-study reproducibility was assessed by observer 1 using data from the 
repeated studies. Analysis of image quality was conducted by 2 observers using the 
following 5 point scale:   
0 - Very poor image quality with unusable images;  
1 - Poor image quality, just able to make out the heart but a lot of artefact;  
2 - Average image quality, not all of septum clearly seen and a lot of artefact;  
3 - Good image quality with moderate septal artefact;  
4 - Very good quality, with minimal septal artefacts;  
5 - Excellent image quality with no significant septal artefact.  
To quantify the reproducibility, the coefficient of variance (CV) was calculated from 
the standard deviation of the differences between analyses divided by their mean. A 
paired, two-tailed Student‟s t-test was performed on the natural log transformation of 
squared differences between methods to assess differences in measurement variability 
between methods. (Moon 2002) Friedman‟s test was used to analyze the image quality 
scores. A p value of < 0.05 was considered significant. The local research ethics 
committee approved the study and patients gave informed consent. 
7.3 Results for Study A 
There was no significant difference between the mean cardiac T2* values for all 100 
patients for the black blood acquisition and the conventional white blood sequence with 
diastolic imaging (20.5ms vs 21.6ms; p=0.26). Differences between black and white 
blood acquisitions were also not significant for the iron loaded (n=50, p=0.31) and non-
iron loaded (n=50, p=0.081) subgroups. The scatter plot of white blood vs black blood 
T2* showed the values lay close to the line of identity (fig 7-2) 
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Figure 7-2 Bland-Altman plot (a) and scatter plot showing the line of identity (b) 
of myocardial T2* values obtained from white blood and black blood acquisitions. 
Agreement was good for patients with T2* ≤ 20 (iron overloaded) but discrepancy 
increased with increasing T2 
 
7.3.1 Inter and intra observer agreement 
The intra-observer CV across the full range of T2* values (n=100) was significantly 
lower using the black blood compared with the white blood sequence (1.47% vs 4.23%, 
p<0.001). 
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Figure 7-3 Bland-Altman plot (a) and scatter plot (b) shows blinded intra-observer 
T2* measurement reproducibility using the white blood acquisition. The 
improvement in agreement using the black blood sequence can be seen from plots 
c and d. 
 In patients with iron overload (T2* <20 ms) the CV was significantly lower for black 
blood than for white blood acquisition (1.68% vs 2.81%, p<0.001). In patients with no 
iron overload (T2* >20ms), the CV was also significantly lower for black blood than 
white blood acquisition (1.28% vs 3.88%, p<0.001). 
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Figure 7-4 Bland-Altman plot (a) and scatter plot (b) shows agreement between 2 
blinded observers T2* for the white blood acquisition compared with the black 
blood images (c and d). 
 The inter-observer agreement findings were similarly superior for the black blood 
acquisition, with a CV of 2.54% (black blood) compared with 4.50% (white blood) for 
all patients (p<0.001), 2.91% vs. 4.28% for iron overloaded patients (p=0.003) and 
2.16% vs. 4.02% for patients with no iron loading (p=0.03)  
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7.3.2 Inter study reproducibility 
For all patients (n=23), the CV for inter-study reproducibility was superior for black 
blood compared with white blood acquisition (4.07% vs 8.42%, p=0.001). In patients 
with a T2* <20ms (n=12) the CV was 2.21% for black blood and 7.04% for white 
blood (p=0.003). In the patients with no iron loading (n=11), the CV was 3.93% and 
7.87% respectively (p=0.15). 
 
Figure 7-5 Plots a and b show interstudy reproducibility for the white blood 
sequence and c and d show the improved reproducibility using the black blood 
preparation. 
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7.3.3 Artefact scoring 
The mean artefact score was superior for the black blood acquisition compared with 
white blood (4.57 vs 4.25, p<0.001). 
7.4 Discussion for study A 
In this study, we have shown improvement in intra and inter-observer variability 
together with inter-study reproducibility for black blood T2* imaging over the 
conventional white blood sequence in a large patient sample. For the conventional 
white blood sequence with no trigger delay, low signal contrast and the consequent 
difficulty in defining the myocardial/blood boundary may cause error in T2* 
measurement. This may result in white signal from the blood pool being incorporated 
into the decay curve for analysis. The errors may also be exacerbated by miss-
registered, high signal blood pool artefacts which can be superimposed on the ROI. 
Adding the double inversion recovery pulse to generate the black blood images 
removes most of the blood signal (and hence artefacts) from the myocardium, making 
the measurement of T2* more robust. Importantly, the greatest disparity between white 
blood and black blood T2* values was seen when testing inter-study reproducibility in 
iron overloaded patients where we found a three-fold difference in the coefficient of 
variation. This discrepancy may be due to different levels of artefact in the myocardial 
septum resulting in changes in the overall signal intensity in the region of interest 
between scans. Indeed analysis of artefact scoring showed significantly poorer artefact 
scoring for the white blood acquisition which could potentially impart significant errors 
in longitudinal evaluation.  
The improved analysis with reduced requirement for truncation of data points in 
patients with short T2* values, is an additional advantage in reducing analysis errors, 
particularly in less experienced centres. These findings combined with the improved 
reproducibility, suggest that the black blood technique should be used for routine 
clinical practice, providing centres can install a robust sequence as implemented by the 
scanner manufacturers. 
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7.5 Conclusions for study A 
In conclusion, this study shows improved reproducibility and reduced artefacts for the 
black blood sequence in comparison with the previously validated white blood 
sequence, and therefore the black blood sequence should be considered the imaging 
technique of choice. 
7.6 Study B: Systolic T2* imaging 
Although reproducibility is improved there are however some disadvantages to the 
black blood acquisition. Because of the time taken to achieve blood signal nulling, it is 
usually necessary to gate on alternate cardiac cycles, unless the RR interval is very 
long. This can make the acquisition and therefore the breath-hold long which may be 
challenging for the patient leading to respiratory artefact on the image. Also border 
recognition can be difficult in the presence of heavy iron loading. Introducing a trigger 
delay to acquire data in late diastole has been shown to improve inter-observer 
variability (He 2007) however, in patients with a short R-R interval, the early and late 
ventricular filling phases tend to merge giving no period of stasis.  During late systole, 
before the AV valves open, wall thickness is maximal, the ventricles are relatively 
static and surface trabeculations more compacted, reducing partial volume effects. As a 
result, we hypothesised that acquiring data during this phase of the cardiac cycle 
(systolic imaging) would provide an easily definable ROI. 
7.7 Methods for study B 
25 patients with myocardial iron overload underwent examinations with the 
conventional bright blood sequence with diastolic image acquisition, the black blood 
sequence and a modified bright blood sequence with systolic data acquisition. The 
timing of the trigger delay for systolic imaging was derived from the corresponding 
cine images. Data analysis was performed as described above. 
7.8 Results for study B 
Taking black blood imaging as the reference, systolic imaging (with the addition of a 
trigger delay to the bright blood acquisition) showed a better agreement than the 
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conventional bright blood sequence with no delay (CV 5.82% vs 9.12%). The CV also 
improved for both intra-observer (from 3.93% to 1.73%) and inter-observer 
reproducibility (from 5.43% to 3.19%). 
 
Figure 7-6 Frames a and b show T2* values using diastolic white blood vs black 
blood imaging and frames c and d show the improves agreement between systolic 
and black blood imaging 
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Figure 7-7 Systolic bright blood (a) and black blood imaging (b) show good 
agreement whereas flow artefacts in the diastolic bright blood image (c) cause 
overestimation of T2*. 
7.9 Discussion for study B 
Adding a trigger delay to the bright blood sequence to produce systolic images 
improved reproducibility of analyses by a factor of two with no scan time penalties. 
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Although we believe that the black blood DIR sequence is the examination of choice 
for the measurement of cardiac T2*, the major compromise is scan duration and in 
addition, it has not yet been possible to transfer this sequence to all makes of scanner. 
Bright blood systolic imaging with a trigger delay to allow data acquisition which 
coincides with peak systole appears to be a significant improvement on the 
conventional sequence acquired immediately after the R-wave. The septal ROI 
thickness is maximal at this phase of the cardiac cycle with minimal motion and there is 
a high degree of agreement with the black blood T2* results. Therefore, systolic 
imaging may be a good alternative where black blood imaging is not available. 
7.10 Conclusion for study B 
In conclusion, although we have found improved reproducibility across all T2* values 
for the black blood sequence in comparison with the previously validated bright blood 
sequence there are time penalties and some problems with boundary definition with a 
heavy iron burden. Adding a trigger delay to the bright blood acquisition gives systolic 
T2* images with a thicker ROI which improves reproducibility resulting in a better 
agreement with the black blood value suggesting that this technique is a valid 
alternative if black blood imaging is unavailable or in patients with severe iron 
overload. 
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Chapter  8: Right ventricular response to deferiprone and 
deferoxamine 
8.1 Introduction 
Deferoxamine was the first iron chelating agent licensed for clinical use. Deferoxamine 
is a large positively charged lipophobic molecule, is poorly absorbed by the digestive 
system and it has a short plasma half life. (Kushner 2001, Porter 2001) This means the 
drug must administered subcutaneously or intravenously. This can lead to poor 
compliance which combined with other factors results in inadequate chelation. (Tanner 
2006) Deferiprone is a much smaller neutrally charged lipophilic molecule which 
allows good gastrointestinal absorption and cellular access and therefore oral 
administration. (Kushner 2001, Porter 2001) Direct comparison trials show that 
deferiprone has greater efficacy than deferoxamine for reducing myocardial iron 
loading and improving LV systolic function. (Anderson 2002, Pennell 2006) However, 
there is a paucity of data related to the effects of these chelators on the RV, which is 
known to be an important independent predictor of outcome in dilated cardiomyopathy, 
(Juilliere 1997) and ischaemic heart disease. (de Groote 1998, Larose 2007, Miszalski-
Jamka 2010) Recent papers have established the normal ranges for RV volumetric 
parameters for non-iron loaded TM patients and shown a significant relation between 
T2* and RVEF, including a small percentage of patients with impaired RVEF but 
normal LVEF. (Alpendurada 2010, Carpenter 2010) In order to identify and compare 
the effects of deferiprone and deferoxamine, we reanalysed the CMR images for the 
LA16 trial, which was a randomized controlled trial (RCT) comparing the 2 drugs. 
(Pennell 2006) Our hypothesis was that deferiprone would improve RV function more 
than deferoxamine. 
8.2 Methods 
The LA16 RCT consisted of 61 regularly transfused patients with TM from 4 centres in 
Greece and Italy. (Pennell 2006) All patients were previously treated with subcutaneous 
deferoxamine monotherapy. Inclusion criteria included a T2* between 8 and 20ms and 
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LVEF greater than 56% based on the lower normal limit for non-anaemic subjects from 
previously published data. (Lorenz 1999) No patient had heart failure symptoms. 
Deferiprone was allocated to 29 patients (actual dose 92mg/kg daily) whilst 32 patients 
were allocated to continue with deferoxamine therapy (dose of 43mg/kg/day overnight 
for an average of 5.7 days per week). Written informed consent was obtained according 
to local ethics committee approval. 
Iron loading and cardiac function was assessed using CMR. The T2* sequences were 
installed at the local CMR facilities, Athens (GE CVi) and Cagliari (GE Signa). The 
technique was validated by scanning phantoms of known T2* and testing intra-site 
reproducibility by scanning 5 patients twice at the local centre. The same patients were 
scanned at the reference site in London (Siemens Sonata) for inter-site reproducibility.  
A coefficient of variation (CV) ≤15% was defined as acceptable. Site inter-study 
variability was 2.4% for Cagliari and 3.5% for Athens. Comparison with the reference 
site yielded CVs of 1.6% and 9.7% respectively. Volumetric data were acquired using a 
steady state free precession sequence (FIESTA). A set of contiguous short axis cines 
were acquired to give complete coverage of both ventricles. Care was taken to place the 
basal slice parallel to the atrioventricular groove. Slice thickness was 8mm with a 
spacing of 10mm.  No patient had a history of, and no CMR scan showed any features 
of pulmonary hypertension (normal pulmonary artery size, no right ventricular 
hypertrophy, no systolic septal flattening). Patients were scanned between 3 and 10 
days post transfusion at baseline, 6 months and 12 months after entering the trial. T2* 
values and LV volumetric data were assessed previously using a CMR viewing and 
analysis software package CMRtools (Cardiovascular imaging solutions, London, UK). 
(Pennell 2006) LV function was assessed in the RCT using an early version of the 
analysis package in which LV volumes are quantified manually using direct surface 
planimetry, and therefore for consistency we elected to use the same version of the 
software to analyze the RV thus eliminating the need for right sided valve tracking. 
Care was taken to include blood volume below the pulmonary valve. Basal regions with 
thin, non trabeculated muscle were considered atrial and were excluded. Papillary 
muscles were also excluded from the blood pool. (Hudsmith 2005) Although local 
blinding to the treatment arm was not possible due to the nature of drug administration 
(oral for deferiprone and subcutaneous for deferoxamine), all remote scan analysis 
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performed at the core-lab in London was fully blinded to treatment. Study treatment 
was unblinded on completion of LV and T2* analysis. For the analysis of the RV 
volumetric data, all data sets were anonymised and analysed in random order using the 
same analysis package by experienced operators blinded to treatment arm and LV 
response. To assess reproducibility, data-sets with an improvement in RVEF ≥ 5% at 12 
months were reprocessed blindly. 
8.3 Statistical analysis 
Continuous variables were compared using a paired t-test. T2* values were log 
transformed and changes expressed as geometric mean with coefficient of variation. 
Between groups comparison of drug effects were assessed using a repeated 
measurement ANOVA. Statistical significance was set at p<0.05. To quantify 
reproducibility the coefficient of variance (CV) was calculated. 
8.4 Results 
Full data on the LA16 study have been published including the patient demographics, 
(Pennell 2006) but the important trial summary findings are repeated here. In the 
deferiprone group 27 patients completed the study; 2 patients withdrew due to adverse 
events (elevated hepatic enzymes, in one case probably due to cytomegalovirus). In the 
deferoxamine group, 29 patients completed; 1 patient withdrew secondary to a 
reduction in LV function and 2 for personal reasons. The patient groups were well 
matched at baseline for cardiac T2*, LV volumes and function and RV volumes and 
function (table 8-1 below). 
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Table 8-1 Baseline values for cardiac volume and function parameters. Values are 
mean ±SD except for T2* where values are geometric mean with CV. 
 
Baseline RVEF was within the normal reference range for thalassaemia patients, 
(Carpenter 2010) except for one patient in the deferoxamine group (RVEF 1% below 
the normal range). Patient compliance was similar for both groups. Myocardial T2* 
improved by 18% at 6 months (p<0.001) and 27% at 12 months (p<0.001) in the 
deferiprone arm. The LVEF rose by 2.0% from 69.7% at baseline to 71.7% at 6 months 
(p<0.001) and by 3.1% to 72.7 at 12 months (p<0.001). With deferoxamine therapy, 
T2* improved by 9% at 6 months (p=0.003) and by 13% at 12 months (p<0.001) but 
LVEF was unchanged being 68.4% at baseline and 68.7 at 6 months (+0.52%, p=0.42) 
and 68.5 at 12 months (+0.32%, p=0.66). 
In the current analysis, the RV mean volumetric and T2* values are detailed below 
(table 8-2) 
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Table 8-2 RV volumetric parameters at baseline, 6 and 12 months (mean ±SD) in 
the 2 treatment arms. The T2* values show the geometric mean and CV. The p 
value reflects the change from baseline to 12 months. 
 
To summarise, in the deferiprone arm RV end-diastolic volume (EDV) was stable, RV 
end-systolic volume (ESV) decreased significantly from 37.7 to 34.2mL at 12 months 
(p=0.009); and RVEF increased from 69.6% to 72.2% (p=0.001). For the patients on 
deferoxamine therapy, the changes in RV parameters from baseline to 12 months 
showed no significant difference. Analysis of between drugs treatment effects was 
expressed using a repeated measurement ANOVA (table 8-3 below) 
Table 8-3 Between drug effect on RV volumetric parameters showing a significant 
difference in RV ESV and RVEF favouring deferiprone. 
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There were significant differences favouring deferiprone for the reduction of RV ESV 
(p=0.014 at 12 months, and improvement in RVEF (p=0.009 at 12 months, (figure 8-1 
below). 
 
Figure 8-1 The response in the 2 treatment arms for RVESV (left pane) and RVEF 
(right pane) showed a significant improvement for patients treated with 
deferiprone, which was not seen with deferoxamine (p=0.014 and 0.008 
respectively for 12 month difference between drugs) 
Non significant differences between drugs were found for RV EDV. With regression 
analysis, the change in RVEF was found to be inversely related to the baseline EF 
(p<0.001) with a significant difference between drugs favouring deferiprone by a mean 
of 3.5% (95% CI 0.8 to 6.3%; p=0.012). The reduction in RVESV over 12 months was 
also related to the baseline ESV value with borderline significance (p=0.051), and there 
was a significant difference between drugs favouring deferiprone by a mean of 4.5mL 
more than patients on deferoxamine (95% CI 1.2 to 7.8mL; p=0.009). Therefore the 
patients benefitting most from deferiprone treatment are those with the lower baseline 
values of RVEF. The CV for intra-observer study RVEF measurement was 2.4% at 
baseline and 2.0% at 12 months. There was no relation between change in RVEF and 
change in LVEF (r=0.3, p=0.9). 
8.5 Discussion 
RV volumetric and functional parameters have been difficult to measure using 
conventional imaging techniques due to the irregular geometry of the RV chamber, the 
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size and quantity of the RV trabeculae, and the proximity of the RV to the chest wall 
which impairs echocardiographic assessment. CMR suffers less from these drawbacks 
because of its inherent 3D nature and high blood to myocardium contrast and is 
therefore considered to be the most accurate and reproducible technique for assessing 
RV volumes and EF. (Grothues 2002, Grothues 2004)  Attention to correct definition of 
the basal slice during acquisition and subsequent analysis is however pivotal. The 
improved confidence of measuring RV volumes and function from CMR and other 
techniques has assisted the understanding the importance of the RV in cardiac disease. 
 RVEF is an important predictor of outcome in dilated cardiomyopathy, which is both 
independent of and incremental to LV EF. (Juilliere 1997) The predictive value of RV 
function has also been shown in congenital heart disease, (Gatzoulis 1995, Graham 
2000, Roos-Hesselink 2004) chronic systolic dysfunction, (Meyer 2010) and ischemic 
heart failure, (Di Salvo 1995, de Groote 1998, Ghio 2001, Larose 2007) with RVEF 
being shown to be an independent predictor of outcome. Accordingly, the effects of 
myocardial iron loading on RV function may be important in thalassaemia patients. 
In the current study, we found a significant improvement in RVEF (increase) and 
RVESV (reduction) with deferiprone therapy. These improvements parallel the 
previously reported LV response. (Pennell 2006) There was no significant increase in 
RVEDV suggesting loading conditions did not play an important role. A flat RV 
response was seen in the deferoxamine group, which again mirrors LV behaviour. The 
between groups analysis showed superiority for deferiprone over deferoxamine for both 
the reduction in RVESV and the increase in RVEF. The magnitude of improvement in 
RVEF and reduction in RVESV were greater for patients with a higher ESV and lower 
EF at baseline. Interestingly neither LVEF nor RVEF improved significantly in the 
deferoxamine group despite the improvement in T2*. The cause for this difference in 
functional response is not fully understood, but the explanation may lie in the additional 
effects of deferiprone on restoring normal cardiac mitochondrial function, (Kakhlon 
2008) possibly through effects on reducing reactive oxygen species. (Kontoghiorghes 
2009) 
138 
 
There is little other data relating RV function changes with the iron chelators, but a 
recently published abstract relating to a longitudinal trial of the efficacy of deferasirox 
in myocardial siderosis, (Smith 2009) showed a significant improvement in myocardial 
iron levels with an improvement in RVEF at 1 year, but there was no change in LV 
function at 1, 2, and 3 years of follow up (year 3 paper under peer review). (Pennell 
2010, Pennell 2011) The significance of this discrepancy between RV and LV response 
to deferasirox is not currently clear, though it is possible that the RV response is an 
early signal of myocardial iron clearance as LV compliance and filling pressure 
improves. The 3 year RV response to deferasirox therapy is describes in chapter 10. 
8.6 Limitations 
Data acquisition for this study was originally designed to assess the change in T2* and 
LV functional parameters in response to therapy. Therefore no RV long axis images 
were obtained to construct 3-dimentional models for volumetric analysis, but the 
requirement for this was removed by using direct manual planimetry for quantitative 
analysis of RV volumes. Pulmonary arterial pressure was not systematically measured 
using echocardiography of the tricuspid regurgitant jet, but here was no CMR evidence 
of raised pulmonary artery pressure in our patients, and pulmonary hypertension is rare 
in well treated thalassaemia major. (Aessopos 2004) Direct RV measurement of T2* 
would have been interesting in this population to compare with changes in RV volumes 
and function, however, it is challenging to measure T2* in the thin wall of the RV and 
this was not attempted in the randomized controlled trial. 
8.7 Conclusions 
This study has shown that RVESV decreased and RVEF improved with deferiprone 
monotherapy and this beneficial response was superior to deferoxamine. RV volumetric 
and function parameters have in the past been neglected when reporting the efficacy of 
iron chelators for myocardial iron overload, and may have independent prognostic 
importance, as they do in other cardiac conditions with impaired cardiac function. 
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Chapter  9: Right ventricular response to deferiprone/deferoxamine 
combination therapy 
9.1 Introduction 
Deferoxamine has good iron binding efficacy but its beneficial effects are tempered by 
poor bio-availability which requires cumbersome treatment regimes which may be a 
contributory factor to the frequently observed long term complications of heart failure 
and cardiac death. (Borgna-Pignatti 2004) Deferiprone is both hydrophilic and 
lipophilic enabling it to readily penetrate myocardial cells and has been shown to be 
superior to deferoxamine in removing iron from the myocardium with improved cardiac 
outcomes. (Modell 2000, Anderson 2002, Piga 2003, Borgna-Pignatti 2006, Pennell 
2006) It has less efficient iron binding than deferoxamine however and some patients 
fail to achieve iron balance with monotherapy. By combining deferoxamine and 
deferiprone more patients achieve iron balance than with either chelator alone. (Wonke 
1998, Daar 2006, Kolnagou 2006) Due to differences in their access to body iron pools, 
the use of a combination of the two chelators seems to have a synergistic effect on the 
removal of excess iron. (Wonke 1998) If both chelators are available in the body 
simultaneously they may interact by iron being “shuttled” from deferiprone onto the 
deferoxamine molecule. (Porter 2009) 
A recent randomised controlled trial comparing combination therapy with subcutaneous 
deferoxamine and oral deferiprone against deferoxamine monotherapy showed 
combination treatment to be superior in removing cardiac iron and improving LVEF. 
(Tanner 2007) The beneficial effects of combination therapy on LVEF have also been 
confirmed in patients with TM and severe iron loading. (Tanner 2008) However, 
despite this success for LV function, the importance of combination therapy on RV 
function has not been reported, even though the RV can be affected by the toxic effects 
of myocardial iron. (Hahalis 2002, Alpendurada 2010) We therefore compared the 
effects of combination treatment (deferoxamine and deferiprone) with deferoxamine 
monotherapy on RV function in TM patients with cardiac iron overload. 
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9.2 Methods 
In order to examine the effects of combination treatment on the RV, we reanalyzed 
imaging data from 2 previously reported trials. The first was a randomized, double-
blind, placebo RCT comparing combined therapy of deferoxamine with deferiprone 
against deferoxamine with placebo in mild-moderate myocardial siderosis. (Tanner 
2007) The second trial was a longitudinal open-label study of combination treatment 
(no comparison arm) in patients with severe cardiac siderosis and impaired LV 
function. (Tanner 2008) Both trials were run simultaneously in Cagliari Italy, with 
ethical permissions driving the separation of the patients into the 2 groups, as 
previously described. (Tanner 2007, Tanner 2008) To summarise briefly; 167 adult TM 
patients (75 males, mean age 30 ± 5.3 years) were screened for quantification of 
myocardial iron loading using myocardial T2*. Inclusion criteria for patient screening 
were: diagnosis of TM currently maintained on subcutaneous deferoxamine 
monotherapy; age >18 years; and maintaining pre-transfusion haemoglobin > 9 g/dL. 
Exclusion criteria were: patients who had received deferiprone for a total of >6 months 
over the last 5 years; patients with previous reaction to deferiprone; neutropenia 
(absolute neutrophil count <1.5 × 109/L) at screening; thrombocytopenia (<50 ×109/L) 
at screening; liver enzymes > 3 times upper limit of normal; any condition making 
CMR impossible or inadvisable. 
 Of the 167 patients screened, 108 had significant myocardial siderosis (T2* < 20 ms), 
of whom 22 (13%) had severe myocardial loading (T2* < 8 ms). Patients with mild to 
moderate cardiac iron loading who satisfied the trial entry criteria (myocardial T2* 8-
20 ms, n=86) were invited for further detailed assessment by CMR. Of these, 65 were 
subsequently randomized to receive either deferoxamine plus deferiprone (combined 
group; n=32) or deferoxamine plus placebo (deferoxamine group; n=33), and were 
followed-up for 12 months. Patients with severe cardiac siderosis (T2* < 8 ms) were 
excluded from the RCT and it was at the treating clinician's discretion to determine best 
clinical practice for chelation therapy. Of the 22 patients with severe myocardial 
siderosis, 15 (9 females, 28.9 ± 4.8 years) received open-label combination therapy 
according to locally developed protocols, and were followed prospectively over one 
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year. These patients were used in a secondary comparative analysis against patients 
from the randomised trial who were on combination therapy. 
9.2.1 Cardiovascular magnetic resonance 
A mobile 1.5 Tesla CMR scanner (Sonata, Siemens Medical Systems, Erlangen, 
Germany) was transported from the RBH to Cagliari, Italy for this research. Myocardial 
and hepatic T2* were assessed using the white-blood single breath-hold multi-echo 
technique as previously described. (Westwood 2003) T2* analysis was performed using 
Thalassaemia-Tools with curve truncation to correct for background noise. (He 2008) 
Right ventricular volumes were determined at baseline and at 12 months from long axis 
and contiguous short-axis SSFP cine images. (Maceira 2006b) LVtools was used to 
produce 3-D models for RV volume analysis. These measurements were performed by 
observers blinded to the patient‟s clinical details and chelation regime. 
9.2.2 Echocardiography 
Doppler echocardiography studies were performed at baseline and at 12 months to look 
for pulmonary hypertension. Pulmonary artery systolic pressures (PAP) were 
determined by peak velocity of the tricuspid regurgitation jet plus estimation of right 
atrial pressures using standard methodology. Pulmonary hypertension was defined as 
PAP > 40 mmHg. 
9.2.3 Biochemistry 
Laboratory measures included weekly full blood count (due to the risk of 
agranulocytosis with deferiprone),  serum ferritin (Abbott AXSYM System), B-type 
natriuretic peptide (BNP-Biosite Diagnostics Inc, San Diego, California), and liver 
function tests (alanine aminotransferase - ALT). 
9.2.4 Statistical analysis 
Categorical data are presented as frequency and percentage (%). Continuous variables 
are presented as mean ± standard deviation (SD), except for BNP, which is displayed in 
median and interquartile range; and for T2* and ferritin, which use the geometric mean 
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(anti-log of the mean of the log data) ± coefficient of variation (CV). Baseline 
characteristics of both treatment groups were compared using an unpaired two-tailed t-
test for continuous variables (except for BNP, which was compared by a non-
parametric test) and a chi-squared test for categorical variables. Analysis of variance 
(ANOVA) was used to compare changes in T2* and RVEF over 12 months with 
treatment and baseline measures entered as covariates. Changes in RVEF over 12 
months within individual groups were compared with a paired t-test.  Correlations of 
myocardial T2* with ventricular function were performed using the Spearman‟s rank 
test. Subgroup analysis was performed according to severity of myocardial iron loading 
with cut-offs of 8ms and 12ms used to define patients with mild (T2* 12-20 ms), 
moderate (T2* 8-12ms) and severe (T2* < 8ms) iron loading. Statistical significance 
was set at p <0.05. All statistical analysis was performed using Stata 10.1 software 
(StataCorp, Texas, USA). 
9.3 Results 
The baseline findings and the results of the RCT comparing combination treatment 
against deferoxamine alone for changes in myocardial T2* and LV EF have been 
previously published, (Tanner 2007) and are briefly summarized here. The patients 
randomized to combination therapy or deferoxamine alone were evenly matched at 
baseline (table 9-1 below). 
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Table 9-1 Baseline characteristics of the randomized controlled trial population 
according to treatment arm.  Values are presented as n (%), mean ± SD, geometric 
mean (coefficient of variation), or as median (25th – 75th percentile). RV = right 
ventricular; EDV = end-diastolic volume; ESV = end-systolic volume; PAP = 
pulmonary artery systolic pressure; BNP = B-type natriuretic peptide 
 
The prescribed dose of deferiprone in the combination arm was 75 mg/kg/day. The 
average dose of deferoxamine in the deferoxamine alone arm (43.4 mg/kg/day for 5 
days/week) was significantly higher than the combination arm (34.9 mg/kg/day for 5 
days/week, p=0.02). Four patients in the combination arm withdrew from the study (3 
due to adverse events), and 3 patients in the deferoxamine arm withdrew (1 due to an 
adverse event). Thus, 28 patients in the combination arm and 30 patients in the 
deferoxamine monotherapy arm completed the study. 
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Over 12 months, the combination treatment group showed superior improvement in 
myocardial T2* compared with the deferoxamine group (ratio of change in geometric 
means 1.50 vs. 1.24, p=0.02). 
In the combination group, RVEF increased from 60.2 ± 7.2% at baseline to 63.8 ±5.9% 
at 12 months (p<0.001) whereas in the deferoxamine group, RVEF did not change 
(61.0 ±7.1% at baseline vs. 61.7 ± 6.4% at 12 months, p=0.49). There was a significant 
difference in the RVEF response between groups favouring combination therapy (3.6 
vs. 0.7%, p=0.02) 
 
Figure 9-1 Change in myocardial T2* (left panel) and in RVEF (right panel) over 
12 months according to treatment arm. Vertical lines represent standard error. 
The improvement in RVEF in the combined group was mainly driven by a decrease in 
RV end-systolic volumes (60.8 ±24.2 ml to 50.6 ±17.3 ml, p<0.01) rather than a change 
in RV end-diastolic volumes (135.5 ±33.0 ml to 132.0 ±29.5 ml, p=0.10). There was no 
significant change in PAP between the combination vs. the deferoxamine arm from 
baseline to one year (-1.8 mmHg vs. +0.3 mmHg, p=0.19). 
The median myocardial T2* in the RCT at baseline was 12.0ms. This value was used as 
a cut-off to define patients with mild (myocardial T2* 12-20 ms) and moderate iron 
loading (myocardial T2* 8-12ms), and this was in accord with the cut-offs used in the 
original trials. Both subgroups were then analysed according to the chelation regime. 
Comparing the individual treatment arms, we observed a significant improvement in 
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RVEF in patients with T2* between 8 and 12 ms on combination therapy (58.5 ±6.9% 
at baseline vs 63.3 ±6.0% at 12 months, p<0.01), and borderline significant 
improvement in patients with T2* between 12 and 20 ms (62.1 ±7.3% at baseline vs. 
64.3 ±6.0% at 12 months, p=0.08). Conversely, patients on deferoxamine alone had no 
significant improvement in RVEF, whether the baseline T2* was 8-12ms (59.3 ±6.8% 
at baseline vs. 59.8 ±6.4% at 12 months, p=0.70) or 12-20ms (62.5 ±7.2% at baseline 
vs. 63.3 ±6.1% at 12 months, p=0.58). Comparison of the between groups effects 
showed that combination therapy was superior to deferoxamine alone in improving 
RVEF in patients with baseline T2* below 12ms (4.7% vs. 0.5%, p=0.01) but not in 
those with T2* above 12ms (2.2% vs. 0.8%, p=0.47. (figure 9-2). 
 
Figure 9-2 Change in RVEF over 12 months according to treatment arm and 
myocardial T2* at baseline (T2* 8-12 ms on left panel, T2* 12-20 ms on right 
panel). Vertical lines represent standard error. 
9.3.1 Longitudinal open label study in severe cardiac siderosis 
The baseline findings and the results of the longitudinal study in the 15 patients with 
severe iron loading (myocardial T2* < 8ms) evaluating combination treatment for 
changes in myocardial T2* and LVEF have been previously published, (Tanner 2008) 
and are briefly summarized in table 9-2 below. 
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Table 9-2 Baseline characteristics of the randomized controlled trial population 
(mild and moderate myocardial iron loading) vs. open-label combination therapy 
population (severe myocardial iron loading). Values and abbreviations presented 
as in the previous table. 
 
Two patients were in clinical heart failure, and both had BNP levels >100 pmol/l.  The 
mean prescribed doses of deferoxamine and deferiprone at baseline were 38.0 mg/kg 
for 5.3 days/week (equivalent to 40.7 mg/kg for 5 days/week) and 73.9 mg/kg/day, 
respectively. During the trial, doses were reduced to 20.3 mg/kg for 4.5 days/week and 
65.7 mg/kg/day respectively primarily due to reductions in ferritin. (Tanner 2008) All 
15 patients received unblinded combination therapy with deferoxamine and deferiprone 
throughout the study period. Over 12 months, there was a significant improvement in 
myocardial T2* (ratio of change in geometric means 1.31, p<0.01).  
In 12 of the 15 patients (80%), the baseline RVEF was low compared to a reference TM 
population with a normal T2*. (Carpenter 2010) The baseline RVESV was significantly 
raised and there was a trend for a higher RVEDV, resulting in a significantly reduced 
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mean RVEF (49.0 ± 9.4%) when compared to the population with less severe iron 
loading. Pulmonary artery systolic pressures were similar in both groups (22.0 ± 5.9 
mmHg vs 21.6 ± 5.2 mmHg, p=0.82). Over 12 months, there was a significant 
improvement in RVEF (10.5 ±5.6%, p<0.01), with no significant change in PAP (22.0 
mmHg vs 24.4 mmHg at 12 months, p=0.16). The two patients with heart failure at 
baseline were asymptomatic at the end of the study. 
When grouping the patients on combination therapy (the 32 patients from the 
combination arm in the RCT plus the 15 unblinded patients on open-label combined 
therapy), we found an inverse relation between myocardial T2* at baseline and 
improvement in RVEF over one year (figure 9-3 below). 
 
Figure 9-3 Breakdown of improvement in RVEF (%) for different groups 
according to chelation therapy and myocardial T2* baseline. Vertical lines 
represent standard error. 
Patients with severe iron loading had a greater improvement in RVEF than patients 
with moderate iron loading (10.5% vs. 4.7%, p<0.01). 
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9.3.2 Entire study cohort 
In the cohort of 80 patients with myocardial iron loading, a significant correlation was 
observed between baseline myocardial T2* and baseline RVEF (r=0.46, p<0.01) and 
baseline LVEF (r=0.50, p<0.01). Accordingly, there was a strong correlation between 
RVEF and LVEF at baseline (r=0.82, p<0.01). The improvement in RVEF during the 
study period also correlated with the improvement in LVEF (r=0.79, p<0.01); figure 9-
4. 
 
Figure 9-4 Correlation of change in RVEF with change in LVEF over 12 months. 
We also analyzed the change in RVEF with the change in cardiac iron as derived from 
recent human cardiac iron calibration data from Carpenter et al. (Carpenter 2011) There 
was a significant inverse correlation between the improvement in myocardial iron 
concentration and the improvement in RVEF (r=-0.42, p<0.01) . 
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9.4 Discussion 
In the first T2* publication by Anderson et al, normal T2* levels were associated with 
normal LVEF, but when T2* fell below 20ms, there was a progressive fall in LVEF, 
showing that increasing iron loading  is associated with worsening of LV function. 
(Anderson 2001) Similar observations have recently been made for the RV, 
(Alpendurada 2010) suggesting RV dysfunction may be a contributor to heart failure 
and cardiac mortality in TM patients, as has been found in other cardiac conditions. (Di 
Salvo 1995, Juilliere 1997, Ghio 2001, Larose 2007, Meyer 2010) However, to date, 
there has been little published data on the response of the right ventricle to chelation 
therapy, and no data at all on the most appropriate chelation regime in the presence of 
right ventricular dysfunction. 
Chelation with deferoxamine has been one of the cornerstones for the treatment of TM. 
It has been extensively studied over the past decades and has shown to decrease the 
total body iron burden, prevent complications of iron overload and improve survival in 
TM. (Zurlo 1989, Brittenham 1994, Olivieri 1994) However, long-term deferoxamine 
monotherapy has been hampered by poor compliance and failure of long term 
prevention of myocardial iron deposition, heart failure and cardiac deaths. (Modell 
2000, Anderson 2002) Deferiprone appears better able to penetrate cells and organelles 
than deferoxamine. This may in part explain why deferiprone is superior to 
deferoxamine for removing iron from the heart. (Pennell 2006) The combined use of 
these two chelating agents which exploits the relative merits of each drug, has been 
supported in animal models, and has become an attractive therapeutic option in severe 
cardiac iron loading or when negative iron balance has not been achieved by other 
methods. (Link 2003, Origa 2005, Tanner 2007, Tanner 2008) Observational, 
prospective and randomised controlled studies have demonstrated the efficacy of 
combined therapy in removing iron from the liver and heart, improving endothelial 
function and left ventricular function, (Tanner 2007, Tanner 2008) as well as endocrine 
function. (Farmaki 2010) Our current study compared the effects of combination 
therapy on RV function in TM patients with myocardial iron loading. Our findings 
from the RCT show combination therapy to be superior to subcutaneous deferoxamine 
alone in improving RV function in patients with mild and moderate iron loading. In 
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addition, our data from the longitudinal open-label study show that RV dysfunction is 
reversible even in patients with severe iron overload. It is of interest that the recovery in 
RV function was greatest in patients with a more severe degree of myocardial siderosis 
and RV dysfunction.  
 It is well recognized that RV performance depends not only on intrinsic contractility 
but also on RV afterload, which is the resistance that the RV has to overcome during 
ejection. Increased pulmonary artery pressures reflecting increased pulmonary vascular 
resistance may thus impair RV function. (Shekerdemian 1997) However, none of the 
participants in this study had pulmonary hypertension, in line with previous studies 
suggesting a low prevalence of pulmonary hypertension in regularly transfused TM 
patients. (Derchi 1999, Aessopos 2004) Whilst an improvement in myocardial T2* was 
associated with an improvement in RVEF, no significant changes in pulmonary artery 
pressures were observed throughout the study. Therefore, the improvement in RV 
function seen in this population was independent of pulmonary artery pressure thus 
eliminating a potential confounding factor for the evaluation of RV function.  
As in the previous study (chapter 8) the magnitude of recovery in RV function parallels 
the recovery in LV function, and this correlates with the response to chelation therapy. 
This is in keeping with the findings of other studies in non-ischaemic 
cardiomyopathies, where it has been observed that LV and RV function is usually 
affected in a similar way and to a similar extent. (Juilliere 1997, La Vecchia 2001) The 
close association seen between RVEF and LVEF and the increase of these parameters 
over time following successful myocardial iron chelation supports the concept that 
intrinsic RV myocardial contractility is predominantly affected by intracellular iron and 
plays a key role in RV performance in this toxic-induced cardiomyopathy model. 
(Alpendurada 2010) Finally, as right ventricular ejection fraction has incremental 
prognostic value which is additional to LVEF, (Di Salvo 1995, Juilliere 1997, Ghio 
2001, Larose 2007) it is reasonable to suggest that the improvement in RVEF seen in 
this study with the combined use of deferiprone and deferoxamine may contribute to 
improved outcomes. 
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9.5 Limitations 
This is a retrospective analysis of 2 trials designed to assess the change on myocardial 
T2* with iron chelation regimes in which RV parameters were not planned as primary 
end-points. Nevertheless, all data was prospectively collected and the current RV 
analysis was blinded to the patients‟ details and chelation regimes. 
9.6 Conclusions 
In the RCT of mild to moderate cardiac iron loading, combination treatment improved 
RV function significantly more than deferoxamine alone. Combination treatment also 
improved RV function in severe cardiac siderosis. Therefore adding deferiprone to 
deferoxamine has beneficial effects on both RV and LV function in cardiac siderosis, 
which may be relevant to the improved mortality reported with deferiprone. 
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Chapter  10: Response of the right ventricle to deferasirox 
10.1 Introduction 
Siderotic cardiomyopathy accounts for the majority of deaths worldwide in transfused 
TM patients. Deferoxamine is an efficient chelator but the route of administration by 
subcutaneous infusion often leads to non-compliance. Deferiprone is orally active 
which is more acceptable to patients thus improving compliance. It is associated with 
an improvement in LV and RV function probably due to its ability to access labile 
intra-cellular iron (LCI). It does not have approval for use in the USA however due to 
idiosyncratic agranulocytosis, and unfounded reports of liver fibrosis. (Olivieri 1995) 
There has therefore been a need for another orally available chelating agent. 
Deferasirox (Exjade®) is an orally active tridentate ligand with a long half life allowing 
once daily dosing. It had been in clinical development since 1998. Treatment with 
deferasirox has been shown to reduce body iron burden in patients with transfusion-
dependent anaemias. The removal of myocardial iron has been demonstrated in pre-
clinical studies and several clinical trials. (Cappellini 2006, Vichinsky 2007, Porter 
2008, Pennell 2010, Pennell 2011) In models using cultured cell preparations, including 
cardiomyocytes, Glickstein et al demonstrated that deferiprone and deferasirox, but not 
deferoxamine, gained cellular access and bound labile iron. (Glickstein 2005, 
Glickstein 2006) The production of reactive oxygen species (ROS) was subsequently 
reduced, excess cellular iron removed and myocyte contractility restored. The presence 
of ROS reduces nitric oxide availability leading to impaired endothelium dependent 
vasorelaxation. In addition, to these favourable cardiac effects, vascular effects have 
also been seen with iron chelators. Tanner et al demonstrated an improvement in 
brachial artery flow mediated dilatation in cardiac iron overloaded TM patients with 
deferiprone/deferoxamine combination therapy, (Tanner 2007) and Cheung et al 
reported similar findings with an associated decrease in carotid artery stiffness index in 
with deferasirox therapy. (Cheung 2008) These studies suggest that deferasirox may be 
effective in improving RV function. 
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The Evaluation of Patients Iron Chelation with Exjade (EPIC) cardiac sub-study was 
designed to assess the effects of long term iron chelation therapy with deferasirox, as 
prospective data on iron chelation for more than 1 year is limited. The objectives 
included the assessment of drug efficacy, safety and cardiac function using CMR T2* 
and cine imaging. The primary endpoint was change in cardiac iron burden, with LVEF 
as the secondary endpoint. One and two year data have already been published showing 
a continued significant reduction in myocardial iron loading in patients with iron 
overload, but no improvement in LVEF was seen. (Pennell 2010, Pennell 2011) 
Chapters 8 and 9 describe the improvement in RVEF with chelation therapy in patients 
treated with deferiprone monotherapy and also in combination with deferoxamine. In 
both studies, the improvement in RVEF was associated with an increase in LVEF and 
driven by an improvement in RV contractility as reflected by the reduction in RVESV. 
Based on the results for these trials an improvement in RV function with deferasirox 
would be unexpected however RV volumetric parameters were measured along with 
the LV and this chapter reports the effects over three years on RV volume, function and 
mass parameters with reference to the LV response. 
10.2 Methods 
10.2.1 Patients and dosing 
Study participants were a subgroup of patients with β-thalassemia major who were 
enrolled in the larger EPIC trial (Cappellini 2010) assessing deferasirox across various 
underlying anemias. The EPIC cardiac substudy was a prospective, open-label, single-
arm, multicenter study conducted initially over a core period of 1 year. The study was 
then extended for an additional 2 years, allowing continuous treatment with deferasirox 
for up to 3 years in patients who completed the 1-year core study. 
The methods and inclusion/exclusion criteria for the EPIC cardiac substudy have been 
reported in detail in the year 1 (Pennell 2010) and year 2 (Pennell 2011) cardiac 
substudy findings. Briefly, patients aged ≥10 years with TM who had CMR myocardial 
T2* >5 to <20ms, LVEF ≥56% (as assessed by CMR), serum ferritin concentrations 
>2500ng/mL, MRI (R2) liver iron concentration (LIC) of >10mg Fe/g dry weight (dw), 
and a lifetime minimum of 50 packed red blood cell transfusions were eligible for 
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inclusion in the cardiac substudy. In patients participating in the cardiac substudy, 
deferasirox was initiated at a dose of 30mg/kg per day for the first 4 weeks of treatment 
and this could be increased to 40mg/kg per day. Doses could be adjusted (by 5 10mg/kg 
per day) in the case of serum ferritin changes, increased serum creatinine 
concentrations, increased serum transaminases or adverse events (AEs). Dose increases 
up to 45mg/kg per day were considered in patients with minimal worsening of cardiac 
T2* (≤33% from baseline) or no improvement in T2* (≤25% from baseline) provided 
that LIC was ≥3mg Fe/g dw at the 6-monthly assessments and that there were no safety 
concerns. However, any dose increases beyond 40mg/kg per day had to be approved by 
the Study Monitoring Committee and study sponsor. Patients were withdrawn from the 
cardiac substudy if cardiac T2* decreased by >33% from baseline, or LVEF decreased 
to 50 <56%, with no improvement to ≥ 56% at a repeat assessment 3 months after the 
initial assessment. Patients completing the 1-year core study continued to receive the 
same dose of deferasirox when entering the extension study.  Patients who completed 
the second year could enter the third year of the study, continuing to receive deferasirox 
at the dose prescribed at the end of year 2. 
10.2.2 Assessments 
The primary efficacy endpoint of the cardiac substudy was the change in cardiac T2* 
from baseline, the 1 and 2 year results of which are reported elsewhere (Pennell 2010, 
Pennell 2011) The 3 year report is pending. This chapter describes the changes over 3 
years in RV function and mass, and includes the changes in LV parameters which were 
measured as secondary efficacy endpoints during the study. The following parameters 
were assessed using CMR for both RV and LV function: EF, end-systolic volume 
(ESV), and end-diastolic volume (EDV) and mass (M). All parameters were assessed at 
baseline and at 6-monthly intervals following initiation of deferasirox treatment, for a 
total period of 36 months. 
10.2.3 Statistical methods 
The patient population reported here are those patients who completed the 3-year 
extension study and had baseline and 36-month ventricular parameter measurements. 
Data from the intention-to-treat analysis are not included. The absolute changes from 
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baseline to 36 months in RVEF, LVEF, RVESV, LVESV, RVEDV, LVEDV, RVM 
and LVM values were summarized using descriptive statistics. Values for ventricular 
volumes and mass were corrected for body surface area (BSA; calculated from 
individual patients‟ body weight and height). All data are presented as mean ± standard 
deviation (SD). Statistical significance was examined using a paired Student‟s t-test at a 
two-sided α level of 0.05. 
10.3 Results 
10.3.1 Patient characteristics 
Of the 114 patients initially enrolled into the 1-year core cardiac substudy (Pennell 
2010), 105 completed this period and 101 entered the extension study.  A total of 86 
(85.1%) patients completed year 1 of the extension. Seventy-one patients elected to 
continue into the second year of the extension, of which 66 (93.0%) completed the 
overall 3-year study. Of these patients who completed the 3-year study, 27 were male 
and mean age at baseline was 20 years (Table 10-1). In patients with baseline cardiac 
T2* >5 to <10ms, there was a lower proportion of patients aged 10 to <16 years, greater 
percentages of Caucasian patients and patients who had hepatitis B and/or C, and fewer 
who had previously received deferoxamine monotherapy, as compared with patients 
who had baseline T2* 10 to <20ms (Table 10-1). However, transfusion characteristics, 
duration of chelation therapy and mean iron intake were similar for these groups. 
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Table 10-1 Patient characteristics 
 T2* >5 to <10ms 
(n=22) 
T2* 10 to <20ms 
(n=44) 
All patients 
(n=66) 
Sex    
Male, n (%) 8 (36.4) 19 (43.2) 27 (40.9) 
Female, n (%) 14 (63.6) 25 (56.8) 39 (59.1) 
Mean ± SD age at baseline, years 21.1 ± 6.5 19.4 ± 7.51 20.0 ± 7.2 
Age group, years, n (%)    
10 <16 5 (22.7) 15 (34.1) 20 (30.3) 
16 <50 17 (77.3) 29 (65.9) 46 (69.7) 
Race, n (%)    
Caucasian 8 (36.4) 12 (27.3) 20 (30.3) 
Oriental 13 (59.1) 30 (68.2) 43 (65.2) 
Other 1 (4.6) 2 (4.6) 3 (4.6) 
History of hepatitis B/C, n (%) 7 (31.8) 8 (18.2) 15 (22.7) 
Splenectomy, n (%) 12 (54.6) 21 (47.7) 33 (50.0) 
Mean ± SD duration of transfusion 
therapy, years 
20.0 ± 6.6 18.2 ± 8.0 18.8 ± 7.6 
Previous chelation therapy, n (%) 
Deferoxamine monotherapy 12 (54.6) 33 (75.0) 45 (68.2) 
Deferiprone monotherapy 1 (4.6) 0 1 (1.5) 
Deferoxamine + deferiprone
‡
 9 (40.9) 11 (25.0) 20 (30.3) 
Mean ± SD duration of chelation 
therapy, years 
13.5 ± 8.7 13.0 ± 7.2 13.2 ± 7.7 
Mean ± SD systemic blood pressure, systolic/diastolic, mmHg 
At 1-year core study baseline 105.1 ± 11.0,  
67.1 ± 10.0  
107.0 ± 11.6,  
66.0 ± 7.7 
106.4 ± 11.3,  
66.3 ± 8.5 
At start of 1-year extension  105.1 ± 11.2,  
66.6 ± 7.6 
105.4 ± 13.3,  
63.1 ± 8.5 
105.3 ± 12.6,  
64.3 ± 8.3 
At start of 2-year extension 100.9 ± 9.8,  
65.3 ± 9.7 
107.7 ± 11.0,  
63.4 ± 6.7 
105.4 ± 11.0,  
64.1 ± 7.8 
At end of 2-year extension 105.6 ± 12.9,  
67.5 ± 8.0 
107.0 ± 11.3,  
65.5 ± 7.3 
106.5 ± 11.8,  
66.2 ± 7.5 
Mean ± SD RBC intake
†
, mL/kg/day 
At 1-year core study baseline 
(mean for previous year) 
0.45 ± 0.72 0.23 ± 0.17 0.31 ± 0.44 
At start of 1-year extension  0.38 ± 0.18 0.30 ± 0.11 0.33 ± 0.14 
At start of 2-year extension 0.36 ± 0.14 0.29 ± 0.10 0.31 ± 0.12 
At end of 2-year extension 0.35 ± 0.12 0.29 ± 0.10 0.31 ± 0.11 
Mean ± SD iron intake, mg/kg per day 
During 1-year core study 0.41 ± 0.19 0.33 ± 0.12 0.35 ± 0.15 
During 1-year extension period 0.38 ± 0.15 0.31 ± 0.11 0.34 ± 0.13 
During 2-year extension period 0.37 ± 0.13 0.31 ± 0.11 0.33 ± 0.12 
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10.3.2 Iron intake and blood pressure 
Red blood cell (RBC) iron intake significantly increased from baseline in patients with 
baseline cardiac T2* 10 to <20ms at the end of the first year (month 7 to 12, 
+0.07mL/kg/day, P=0.012), but did not change significantly throughout the rest of the 
study. There were no significant changes in iron intake in patients with baseline cardiac 
T2* >5 to <10ms.  Diastolic blood pressure significantly decreased from baseline in the 
cardiac T2* 10 to <20ms group after 1 year (–2.9mmHg, P=0.024) and after 2 years (–
2.6mmHg, P=0.033), however, by year 3 there was no significant difference compared 
to baseline. Systolic blood pressure did not change significantly throughout the study. 
In contrast, systolic blood pressure significantly decreased from baseline after 2 years 
in patients with baseline cardiac T2* >5 to <10ms (–4.3mmHg, P=0.043), but was not 
significantly different after 3 years. Diastolic blood pressure did not change 
significantly. 
10.3.3 Deferasirox dosing 
For the 66 patients completing the 3-year study, mean overall deferasirox exposure 
(±SD) during the 3-year treatment period was 157.4 ± 2.2 weeks; 157.4 ± 1.9 for 
patients with baseline cardiac T2* >5 to <10ms and 157.4 ± 2.4 for patients with 
baseline cardiac T2* 10 to <20ms. The average actual dose received over the 3-year 
treatment period was 34.5 ± 5.9mg/kg per day; 35.9 ± 4.8mg/kg per day for patients 
with baseline cardiac T2* >5 to <10ms and 33.9 ± 6.3mg/kg per day for patients with 
baseline cardiac T2* 10 to <20ms. The majority of patients received average actual 
doses between 35 and 40mg/kg per day (n=33) and seven patients received doses >40 
to <45mg/kg per day. Final deferasirox dose at the end of the 3-year study was 30 to 
40mg/kg per day in 44 (66.7%) patients, 45mg/kg per day in six (9.1%) patients, while 
the remaining had <30mg/kg per day. All 66 patients who completed 3 years of the 
study received at least one dose adjustment. All patients had at least one dose increase, 
with a total of 246 dose increases, most commonly as per protocol (n=142, 57.7%) or 
due to lack of efficacy (n=85, 34.6%). Eighty-three dose decreases were recorded in 33 
patients (50.0%) most commonly due to laboratory test abnormalities (n=32, 38.6%) 
and adverse events (n=22, 26.5%). A total of 89 interruptions occurred in 49 patients 
(74.2%) mostly due to adverse events (n=37, 41.6%). 
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10.3.4 Effect of long term deferasirox therapy on ventricular function 
At baseline of the core 1-year study, mean RVEF significantly increased versus 
baseline in patients with baseline cardiac T2* 10 to <20ms at 1 year until the end of the 
study (P<0.001 at year 1, p<0.001 at year 2, p=0.0079 at year 3, Figure 10-1.A. Mean ± 
SD LVEF was 67.4 ± 5.9% (Figure 10-1,B). There were no significant changes in mean 
LVEF from baseline at years 1, 2 or 3. Mean ± SD baseline RVEF was 66.0 ± 5.9% for 
all patients. 
 
Figure 10-1 Mean ± SD ejection fraction of the right (A) and left (B) ventricle, 
according to baseline T2* 
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Overall mean ± SD baseline RVESV/BSA at the core study baseline was 24.2 
±9.6mL/m2 (Figure 10-2,A). This remained stable over the total study period, with the 
exception of a significant decrease from baseline to 1 year in patients with baseline 
cardiac T2* 10 to <20ms (2.6 ±7.9mL/m2; p=0.037). Mean ± SD LVESV/BSA was 
24.2 ±9.5mL/m2 at baseline (Figure 10-2,B). There was a significant increase from 
baseline to 1 year in patients with baseline cardiac T2* >5 to <10ms (+2.9 ±6.0mL/m2; 
p=0.037). LVESV then remained stable over the following 2 years. There were no 
significant changes in LVESV in patients with baseline cardiac T2* 10 to <20ms. 
 
Figure 10-2 Mean ± SD right (A) and left (B) ventricular end systolic volume 
(indexed for body surface area), according to baseline T2* 
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Mean ±SD RVEDV/BSA at core study baseline was 66.0 ±18.3 and 72.2 ±20.7mL/m2 
in patients with baseline cardiac T2* >5 to <10 ms and baseline cardiac T2* 10 to 
<20ms, respectively (Figure 10-3,A). Significant increases were observed in both 
groups at 2 years and these were maintained at the end of 3 years. Mean ± SD 
LVEDV/BSA for all patients was 75.5 ±19.1mL/m2 at baseline and was similar for 
both baseline T2* subgroups (Figure 10-3,B).  
 
Figure 10-3 Mean ± SD right (A) and left (B) ventricular end diastolic volume 
(indexed for body surface area), according to baseline T2* 
At the end of the core 1-year study, there were no significant changes from baseline in 
mean LVEDV/BSA. However, at year 2, mean LVEDV/BSA was significantly 
increased in both subgroups relative to baseline, with an overall mean ±SD change of 
5.6 ±11.6mL/m2 in all patients (p<0.001). At year 3, this increase was maintained in 
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patients with baseline T2* 10 to <20ms but not in patients with baseline cardiac T2* >5 
to <10ms. 
 Mean ±SD RVM/BSA at baseline was 33.2 ±7.8g/m2 in all patients (Figure 10-4,A). 
Significant reductions from baseline in mean RVM/BSA were observed after 2 years, 
and the downward trend continued up to 3 years of deferasirox therapy. LVM/BSA at 
baseline was 79.1 ±16.8g/m2 for all patients. At the end of 1 year, mean LVM/BSA had 
decreased significantly from baseline in both groups of patients with baseline cardiac 
T2* >5 to <10ms and baseline cardiac T2* 10 to <20ms. This decrease relative to 
baseline became greater over time in both sub groups, until the end of the 3-year study 
(Figure 10-4,B). 
 
Figure 10-4 Mean right (A) and left (B) ventricular mass (indexed for body surface 
area), according to baseline T2 
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10.4 Discussion 
This study reports a significant improvement in RVEF associated with a decrease in RV 
mass after 3 years of deferasirox therapy in iron overloaded TM patients. It is the first 
prospective study to assess the RV functional response to iron chelation with 
deferasirox. Previous reports of deferasirox treatment have described changes in cardiac 
T2* with LVEF as a primary endpoint. (Pennell 2010, Pennell 2011) Chapters 8 and 9 
describe the RV response to chelation therapy over the course of one year where an 
improvement in RVEF was seen with deferiprone monotherapy, and in combination 
with deferoxamine. In both cases however the changes were driven by a reduction in 
RVESV and there was an associated improvement in LVEF. With deferasirox the 
increase in RVEF was related to an increase in RVEDV and there was a reduction in 
RV mass with no reduction in RVESV. The mean baseline RVEF (66.0 ±5.9% for all 
patients) was very similar to that in a study by Carpenter et al (66.2% ±4.1). (Carpenter 
2010) The mean indexed RVEDV at baseline was 66.0 ± 18.3 mL/m2 in patients with a 
baseline cardiac T2* >5 to <10 ms and 72.2 ±20.7 mL/m2 in those with T2* 10 to 
<20ms. This is despite most of the patients in the severe group being in the older age 
category. These values are 33% and 26% less than the reference value (98.1 ± 17.3 
mL/m2) for non iron loaded TM patients. LVEDV also increased and there was a 
reduction in mass but there was no decrease in LVESV or increase in LVEF. Diastolic 
blood pressure decreased significantly in the mild to moderate group after 1 and 2 years 
of treatment and systolic blood pressure decreased after 2 years in the severe group. No 
significant differences were noted between baseline and 3 years however. These are 
very interesting findings suggesting a different pharmacological effect of deferasirox to 
that of deferiprone or deferoxamine. A recently published study by our group of ex-
vivo iron overloaded hearts, showed the RV myocardium had up to 21.9% less iron 
than the LV. (Carpenter 2011) The RV is however particularly susceptible to iron 
induced functional impairment, (Walker 2010) and has less contractile reserve. 
(Bronicki 2010) This does not explain why, with deferasirox therapy, the LVEDV and 
RVEDV both increased with mass reduction, yet systolic volumes remained 
unchanged. The changes may be reflecting an improvement in diastolic function, and 
restriction is considered a feature of myocardial iron accumulation. An echo TDI study 
showed diastolic functional impairment in a high proportion of iron overloaded patients 
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with a normal EF, (Vogel 2003) although a CMR based study by our group showed a 
weak correlation between LV diastolic filling parameters and T2* in a group of 67 TM 
patients of whom 46 had iron overload and 5 had an abnormal LVEF. (Westwood 
2005)  
Another possible mechanism for improvement in RV function might arise from relief of 
vascular dysfunction caused by iron overload. Haemolysis can cause depletion of the 
potent vasodilator nitric oxide (NO) and its precursor arginine. It also increases platelet 
activation and stimulates the release of the vasoconstrictor endothelin-1. (Gladwin 
2004, Gladwin 2005, 2008, Kato 2009, Machado 2010) These factors negatively impact 
upon vascular homeostasis and can lead to endothelial dysfunction, vasoconstriction 
and hypercoagulability. This can ultimately cause vascular disease, and indeed 
endothelial dysfunction is associated with the development of atherosclerosis. 
(Davignon 2004) Interestingly Duffy et al (Duffy 2001) reported an improvement in 
NO mediated endothelium dependant vasodilatation in patients with CAD when given 
intra-arterial deferoxamine. Arterial stiffness or loss of compliance is also important as 
it increases impedance to flow which in turn increases afterload. Using ultrasound 
Cheung et al showed an abnormal carotid artery stiffness index and brachial artery flow 
mediated dilatation (FMD) in patients with TM. These patients had a higher indexed 
LV mass compared with the control group but there was no difference in fractional 
shortening and no patient showed abnormal filling patterns. (Cheung 2002) Cheung 
also demonstrated an increase in carotid intima-media thickness compared with 
controls in a group of TM patients without diabetes mellitus or heart failure. (Cheung 
2006) Similar findings were reported by Hahalis et al who also found carotid plaques in 
three TM patients but none in the well matched control group. (Hahalis 2008) 
Endothelial dysfunction in TM patients, as measured by brachial artery FMD, has been 
shown to improve with deferiprone/deferoxamine combination therapy compared with 
deferoxamine monotherapy. (Tanner 2007) In a recent publication Cheung et al 
demonstrated an improvement in brachial artery FMD and carotid artery stiffness with 
deferasirox therapy. (Cheung 2008) There were no changes in echo derived LV 
functional indices. Changes in BP, LV mass and right sided parameters were not 
reported. They hypothesised that these findings may reflect the ability of deferasirox to 
bind labile iron in the vascular walls with subsequent improvement in endothelial 
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function. The changes were seen by 6 months therefore the authors suggested the 
observations may be due to a direct almost immediate effect on the arterial walls rather 
than the long term reduction of iron burden. Our findings would support this 
hypothesis. An improvement in endothelial function with deferasirox in TM patients 
would have an important clinical implication. The presence of the β-thalassaemia trait 
(heterozygote) has been associated with a reduced risk of developing coronary artery 
disease (CAD) due the protective effect of their lipoprotein and blood rheology profiles. 
(Tassiopoulos 2005) Thalassaemia trait however only causes a mild anaemia that does 
not require transfusion therapy. Life expectancy for TM patients is increasing. In 1970 
the average life expectancy was only 17 years but by 2000 over 80% of patients had a 
life expectancy of > 40 years. (Modell 2008) The risk of developing CAD increases 
with age. Hahalis et al reported premature atherosclerosis in 20 young TI patients but 
there have been no reports to date on the development of CAD in thalassaemia patients. 
(Hahalis 2008)The longer surviving TM patients are now entering the age of increased 
risk therefore we may see the incidence increase as patients survive longer. As 
endothelial dysfunction is an important factor in the development of vascular disease it 
would be interesting to see whether the different chelating agents influence its 
development. 
A further possible mechanism for improvement in RV function, might be through 
improvement in pulmonary artery pressure, and this might fit the finding of reduction in 
RV mass which we found in our study. The mean baseline RV mass in our patient 
cohort (33.2 ±7.8g/m
2
) was less than that quoted by Carpenter et al (38.8 ±7.9g/m2) in 
their study of TM patients without iron overload. (Carpenter 2010) They only included 
patients over 18 years whereas a significant number of our patients were children. 
Interestingly, RV mass in their TM patients tended to be higher than for normal 
controls. An increase in RV afterload, due to increase pulmonary vascular resistance 
would cause an increase in RV mass. Pulmonary hypertension (PHT) is a common 
finding in patients with haemoglobinopathies. (Vichinsky 2004, Aessopos 2005, 
Farmakis 2011) The pathogenesis of PHT in haemoglobinopathies is likely to be 
multifactorial but as with changes in the systemic vasculature haemoglobin released by 
chronic haemolysis can lead to vasoconstriction. Tissue hypoxia is compensated by a 
high output state, further exacerbated by bone marrow expansion, which in the presence 
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of increased pulmonary vascular resistance contributes to elevated pulmonary 
pressures. Iron overload is associated with interstitial pulmonary fibrosis and myocyte 
dysfunction which are additional contributory factors associated with increased 
pulmonary vascular resistance. Unfortunately pulmonary pressures were not recorded 
in our patient cohort. Although common in TI patients who usually do not require 
regular transfusions for survival, reports on the prevalence of PHT in TM are extremely 
polarized. (Grisaru 1990, Du 1997, Derchi 1999, Aessopos 2004) A large study of well 
treated Greek TM patients showed a very low incidence of elevated pulmonary 
pressures, however the authors did not state cardiac iron levels and patient with poor 
chelation compliance were excluded from the study. (Aessopos 2004) The two reports 
of very high incidences were in patient who were poorly treated and with a high 
prevalence of LV dysfunction, but the patient populations studies were small. (Grisaru 
1990, Du 1997) Pulmonary hypertension has been noted to be more frequent in 
haemoglobinopathy patients who have undergone splenectomy. (Hoeper 1999) It has 
been reported that splenectomy in patients with haemolytic disorders increases the 
likelihood of thromboembolism. (Cappellini 2000) This is possibly due to the loss of 
the filter function of the spleen resulting reduction in the clearance of abnormal red 
cells as this problem is not seen in patients splenectomised for other reasons. (Peacock 
2005) Only 19% of the patients in the study by Aessopos had been splenectomised. 
(Aessopos 2004) In our patient cohort 50% (54.6% in the severe group) had undergone 
previous splenectomy. In addition 22.7% had a history of hepatitis which may cause 
liver fibrosis which could play a contributory role. Liver fibrosis can lead to portal 
hypertension which is associated with pulmonary hypertension. 
10.5 Limitations 
Pulmonary artery pressures were not measured in this patient group as the primary 
endpoint was a change in myocardial iron content as measured by CMR T2*. It would 
have been interesting to see if pulmonary pressures were increased at baseline and to 
document any changes associated with therapy, and whether they correlated with 
changes in RV volume and mass. However, previous experience from our group 
suggests that pulmonary hypertension is very uncommon in well treated TM patients. 
CMR is not the modality of choice for the assessment of diastolic function. We did not 
166 
 
therefore assess diastolic function in these patients which would have provided a more 
sensitive marker of myocyte function. 
10.6 Conclusions 
This study has shown a reduction in RV mass in iron overloaded patients treated with 
deferasirox over a 3 year period, and an increase in RV EDV and RVEF. The findings 
suggest a different pharmacological effect of the chelator deferasirox to that of 
deferiprone in the possible direct improvement of endothelial function and reduction in 
pulmonary pressures. 
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Chapter  11: General discussion and conclusions 
11.1 Introduction 
Symptomatic heart failure is a common late manifestation of CM that is distressing for 
the patient and associated with high morbidity and mortality. Identification and 
accurate assessment of risk factors and early disease can guide therapy and improve 
outcome. Non invasive imaging plays a pivotal role in the identification and 
classification of CM. CMR in particular provides a comprehensive phenotypic 
description in patients with myocardial dysfunction. It is sensitive to early functional 
changes and often identifies the underlying pathology which is critical for rational 
treatment that is specific to the disease process. It also provides an accurate assesses of 
therapeutic efficacy. With this backdrop, the use of CMR in the accurate assessment of 
early disease features and the recognition of causative factors has been evaluated 
testing the hypotheses that myocardial fibrosis and strain abnormalities in EDMD 
precede systolic dysfunction and that inflammatory markers post anthracycline 
exposure predicts late cardiac functional changes. In addition the value of optimising 
acquisition sequences to improve reproducibility was addressed and the evaluation of 
chelation therapy with particular reference to the RV was explored. 
11.1.1 Emery-Dreifuss Muscular Dystrophy 
Though EDMD is rare, with relatively mild musculoskeletal manifestations, the high 
risk of cardiac involvement and sudden death has primed the interest of neurologists 
and cardiologists in trying to establish why this is the case and whether there are early 
signs of cardiac involvement that might guide therapy. Due to its rarity and the 
frequency of pacemaker insertion there were very few comprehensive reports in the 
literature, particularly using CMR, at the time of starting the work for chapter 5. Based 
on reports from other MD studies it was hypothesised that fibrosis would be implicated 
in the disease process. As changes in systolic function often occur late in disease 
process, strain imaging was performed using echo and CMR in an attempt to uncover 
early functional changes. Unfortunately sudden death is frequently the presenting 
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symptom in EDMD therefore careful cardiac evaluation and follow up is mandatory. 
Cardiac family screening has been advocated, including female heterozygotes with X-
linked EDMD who are also at risk of cardiac complications. (Fishbein 1993, Bouhouch 
2008). Differences between echo derived myocardial velocity gradients and CMR strain 
patterns compared with the control group were identified although statistical 
significance was weak, the rarity of the condition and high incidence of pacemaker 
implantation limiting cohort size. The LVEF derived by both techniques was within 
normal limits drawing attention to the fact that LVEF is not a sensitive marker of early 
functional change and that these patients require careful monitoring even if 
conventional markers of function appear normal. The original hypothesis that fibrosis 
would play a part in pathogenesis was not supported by our results. However the IR 
turbo flash LGE acquisition protocol available at the time would only depict 
macroscopic changes. Very small areas of fibrosis would be difficult to recognise 
however carefully the images were viewed and a more diffuse process would be 
missed. Using more recently developed T1 mapping protocols, with and without the use 
of a contrast medium might have detected diffuse myocardial changes and yielded a 
different result. Given the high risk of atrial and ventricular arrhythmias and sudden 
death in these patients, it would be worth pursuing further studies to look for diffuse 
ventricular and atrial fibrosis. The availability of CMR compatible pacemakers means 
long term evaluation of these patients who were previously lost to CMR follow-up may 
also be possible in the future. 
11.1.2 Anthracycline Cardiotoxicity 
Chapter 6 describes for the first time the relationship between an increase in EGRE 
detected shortly after initial anthracycline exposure, a change in urinary F2-
isoprostanes and a long term reduction in LVEF.  
Improvements in chemotherapy regimens have lead to an impressive reduction in 
morbidity and mortality in cancer patients. The mode of action of many cancer 
treatments however, can also lead to cardiovascular injury culminating in heart failure. 
Long term cardiotoxicity is less of a concern for patients with metastatic disease for 
whom the treatment is aimed at short term improvement in survival and quality of life. 
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For patients with a good chance of long term survival undergoing adjuvant therapy to 
reduce the risk of disease recurrence, it is a major factor. Rarely heart failure can occur 
acutely but more commonly the onset is delayed. Cell disruption and loss have been 
reported in patients undergoing endomyocardial biopsies early post anthracycline 
administration suggesting early myocyte damage. (Bristow 1978a) Elevation of 
biomarkers including BNP and troponins, which would reflect myocyte damage during 
treatment, correlates with an increased risk of developing late anthracycline mediated 
cardiotoxicity (AMC) but early changes in LVEF do not, which implies an early 
compensatory mechanism. (Ewer 2008) The heart has considerable contractile reserve 
making the detection of early sub-clinical damage difficult. Why some patients go on to 
develop heart failure but others do not, despite similar drug regimens and cumulative 
dosages, is one of the most intriguing conundrums faced by oncologists and 
cardiologists.  
In our study, the patients with a reduction in LVEF ≥ 5% at follow up showed a mean 
increase in EGRE of 46% compared with only 7% for other patients. A significant 
change in urinary F2-isoprostanes 3 days after anthracycline administration correlated 
with EGRE at the same time point and showed a relationship with a late reduction in 
LVEF. The negative correlation between EGRE and the urinary F2-isoprostane to 
creatinine ratio may be due to the fact that biomarkers of oxidative stress peak 1 hour 
post anthracycline administration. Future studies should therefore take this into account 
when collecting urine samples. There was also a relationship between STIR SI and late 
LVEF. There was no significant change in LVEF or RVEF at day 3 underlining the fact 
that functional changes do not parallel inflammatory markers. These findings should be 
useful in the further understanding of AMC. Interestingly, the mean reduction in LVEF 
one year after completion of adjuvant chemotherapy in patients with early breast cancer 
was approximately 2% irrespective of whether the patients also received trastuzumab. 
The fact that trastuzumab did not exacerbate long term change in ventricular function 
supports previous findings that its cardiotoxicity is generally reversible (Ewer 2005, 
Guarneri 2006) although data on cardiac function in our patient group during treatment 
was not available. RVEF also decreased but by a lesser degree (1.2%) after one year 
which is surprising given the lower cardiac reserve. I initially attempted to look at more 
sensitive functional parameters by measuring diastolic filling and myocardial tagging 
170 
 
patterns. Interim analysis of ventricular filling parameters in 30 patients proved not 
worthy of pursuit due to the high level of inter-group variability probably due to the 
wide age range and differences in body habitus throughout the cohort. Also diastolic 
parameters derived by evaluating volume changes during filling are highly preload 
dependent and the temporal resolution of CMR derived data is low compared with 
echocardiography. As with the EDMD group no LGE was seen at follow-up. This again 
could reflect a more diffuse process that may be detected using a different acquisition 
protocol. In addition the follow-up at approximately 1 year post completion of therapy 
is quite early. Failure to obtain suitable analysis software to perform the myocardial 
tagging analysis within the time restraints and the scanner upgrade issues led to this not 
being included in this thesis. This data may provide useful data when analysis software 
becomes available. 
11.1.3 Improving T2* Imaging 
CMR has become established as the technique of choice for the management of patients 
with myocardial iron loading and there has been a concomitant reduction in mortality 
from siderotic CM within the UK. (Modell 2008) Although the white blood technique 
developed in our unit has proved successful, with our group disseminating the 
acquisition sequence and training sites worldwide to perform diagnostic scans in iron 
overloaded TM patients, there are some reproducibility issues. Using a DIR sequence to 
null the blood signal chapter 7 described further improvements in the T2* CMR 
technique. The use of black blood T2* CMR was shown to improve the reliability of 
iron overload assessment, and this validation has lead to this technique being adopted 
for routine use at the Royal Brompton Hospital. It is also now being disseminated 
around the world.  
11.1.4 The Right Ventricular Response to Chelation Therapy 
Chapters 8, 9 and 10 are the first reports to describe the RV response to chelation 
therapy. Apart from ARVC, the assessment of RV function has historically not featured 
prominently in the follow up of patients with CM. There are a few reports in the 
literature citing the important role of RV function as a predictor of outcome in 
ischaemic heart disease and other cardiomyopathies (Juilliere 1997, de Groote 1998, 
171 
 
Larose 2007, Miszalski-Jamka 2010) and this caused us to examine the RV in 
thalassemia major, in which congestive heart failure is the commonest cause of death. 
There was a significant improvement in RVEF associated with the reduction in 
myocardial iron burden with both deferiprone monotherapy and 
deferiprone/deferoxamine combination therapy. No improvement was found with 
deferoxamine monotherapy in either study. In both trials there was a concomitant 
improvement in LVEF. In the post mortem study by Carpenter et al, it was noted that 
the RV wall iron concentration was up to 21.9% less than the global LV level. 
(Carpenter 2011) As a similar improvement in EF was found for the LV and RV with 
deferiprone or combination therapy, this may reflect greater sensitivity to iron toxicity 
or lower reserve in the RV. In this context, the cardiac response to deferasirox therapy 
described in chapter 10 was anomalous and of particular interest. No significant change 
in LVEF was seen with the reduction in cardiac iron, but the RVEF increased, and the 
LV and RV mass reduced. Furthermore, unlike the responses described with 
deferiprone, this was caused by an increase in RVEDV. Systemic blood pressure 
decreased in the first 2 years of treatment however there were no significant differences 
at year 3, perhaps reflecting a drug tolerance effect. The RV response might be 
explained by a reduction in pulmonary pressures or an improvement in RV compliance, 
which would suggest an interesting therapeutic potential worth exploring. Pulmonary 
hypertension has been reported to have a low incidence in TM in studies of well treated 
European patients. (Derchi 1999, Aessopos 2004) Of note is the fact that the 
deferiprone and combination trial patients were Italian or Greek patients and all were 
treated at expert centres. Patient recruitment for the deferasirox study was worldwide 
including patients of different ethnicities. The suggestion of pulmonary arterial pressure 
elevation at baseline may reflect either sub-optimal transfusional therapy before 
commencing the trial or genetic differences in response to iron overload which again 
has interesting implications.  
11.2 Limitations of this research 
The rarity of EDMD meant our patient study group was very small, despite 
collaborating with the Dubowitz Neuromuscular centre at Hammersmith Hospital. 
Although we found a significant difference in echo MVGs and CMR tagging strain 
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patterns between patients and controls a larger group of patients would have made the 
study more robust. Chapters 6, 8, 9 and 10 all report the results of longitudinal studies 
in which patient recruitment provided an initial challenge. For the anthracycline study 
(chapter 6) the number of eligible patients was greatly overestimated by the 
oncologists, as was patient willingness to travel to a separate site to be scanned. This 
had a negative impact on patient recruitment which took nearly four years rather than 
the predicted 18 months. This meant that there were a number of scanner upgrades 
during the study period, which affected the running of the sequences developed on site, 
and these had to be surmounted.  Early breast cancer patients were chosen as the 
disease is common and usually carries a good prognosis. Adjuvant chemotherapy 
however, uses relatively low anthracycline doses and the mean decrease in LVEF found 
was only ~2%, moreover no patient had an abnormal EF at follow up. Changes in EF 
would be expected to be greater in patients prescribed higher anthracycline doses (thus 
increasing study power) but this tends to associated with more aggressive malignancy 
that has a poorer prognosis and there would also be a higher likelihood of the need for 
heart failure medication. Children are more susceptible to AMC (Von Hoff 1977, 
Grenier 1998, Lipshultz 2008) however growth would confound long term follow up, 
and therefore these were not studied. 
The data for Chapters 8, 9 and 10 were obtained from international trials. The patients 
for the deferiprone/deferoxamine combination trial were scanned by our group, taking a 
mobile scanner from RBH to Italy. This meant all data quality was of high standard and 
as we were on site we had good access to clinical information. The deferiprone vs 
deferoxamine monotherapy trial used data obtained by the local site personnel. Our 
team travelled to the sites for training prior to the trial, but data sets missing adequate 
LAX cines were received for analysis which prevented 3D modelling as the preferred 
mode of volumetric analysis. Manual planimetry was used instead, which was slower 
and less objective. For the deferasirox trial the RBH thalassaemia team travelled to 
each participating site for training and strict acceptance criteria were applied to 
incoming data sets. Those judged incomplete or sub-standard were rejected. 
Consequently all included data was of good quality. We did not have the foresight 
however to measure baseline pulmonary artery pressure which could have derived from 
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the TR jet obtained by echocardiography and would have added useful clinical 
information. 
11.3 Conclusions 
To summarise, the original findings emerging from this work are as follows: 
 There was no evidence of macroscopic myocardial fibrosis in EDMD however 
strain abnormalities were detected using CMR tagging and echo derived MVGs. 
 EGRE correlates with changes in urinary F2 isoprostanes and a late decrease in 
ventricular function after anthracycline exposure. 
 Nulling the blood signal or adding a trigger delay improves the reproducibility 
of cardiac iron assessment. 
 Deferiprone monotherapy and in combination with deferoxamine shows 
superior improvement in RV function to deferoxamine monotherapy which may 
have prognostic significance. 
 Deferasirox monotherapy improves RVEF with an associated reduction in RV 
and LV mass but no improvement in LVEF suggesting a different 
pharmacological effect to deferiprone and the possible direct improvement of 
endothelial function. 
These novel observations have the potential to improve diagnosis in cardiomyopathy 
and provide ideas for new treatment approaches.  
Further work in these areas is described in chapter 12 (Future Directions). 
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Chapter  12: Future directions 
12.1 Technical advances 
During the course of acquiring data for this thesis there have been a number of 
advances in CMR technology and sequence design which can lead to improved 
phenotype description. An example would be the identification of patients for whom 
diffuse interstitial myocardial fibrosis might  be a substrate for myocardial dysfunction 
(EDMD and AMC) but no areas of late gadolinium enhancement are demonstrable. The 
availability of T1 mapping during equilibrium gadolinium infusion has created the 
potential to test this. (Flett 2010) We are now developing such sequences and validating 
their use for work with CM patients.  
The CMR unit at Royal Brompton Hospital (RBH) is continually working to optimise 
T2* sequences. Dr Taigang He is exploring the use of parallel imaging to reduce scan 
time for the inversion recovery sequence as the relatively long breath hold can be a 
limiting factor for some patients. As we now have the potential to scan at 3T (Siemens 
Skyra), future diagnostic protocols, including iron overload assessment, are being 
designed for high field work. Our group are currently adapting and writing sequences 
and validating measurements against previous work at 1.5T. We are also currently 
collaborating with Prof John Porter‟s team at UCH to improve the measurement and 
calibration of hepatic iron loading. 
12.2 Future collaborative work at RBH 
The NIHR Biomedical Research Unit at RBH opened in November last year. Available 
diagnostic technology includes 3T CMR equipment (Siemens Skyra), Phillips IE33 
echo equipment, a catheter lab, and genetics with next generation sequencing. The 
improved research potential of having this under one roof is significant. The 
anthracycline cardiotoxicity study (chapter 6) provided a lesson in the difficulty of 
collaboration between geographically remote units. A joint cardio-oncology clinic 
between RBH and the adjacent Royal Marsden hospital has recently been established. 
The primary objective is to provide optimal cardiac care for patients undergoing 
chemotherapy but lends the added potential for collaborative research between 
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oncology and cardiology into the mechanisms of cardiac toxicity associated with 
chemotherapy treatment. A full work-up for patients is planned including CMR, 
echocardiography and bloods for the genotyping of consenting patients. This provides a 
multi-modality phenotype description which can be related to the genetic drivers of LV 
dysfunction. The CMR protocol has been drafted taking into account our experiences 
with the Better-care study and will include bi-ventricular volumetric data, T1 and T2 
mapping and LGE imaging.  
Chapters 8, 9 and 10 described how chelation therapy not only improves LV systolic 
function but also RV and possibly endothelial function. Research into the RV response 
to cardiac iron overload is ongoing in our unit. In particular ways in which RV 
myocardial iron can be quantified are being explored using 1.5 and 3T field strengths 
lead by Dr M H Alam as part of his PhD thesis. The possibility of inter-individual 
response to iron burden is also being explored in a genetic study lead by Dr Alam into 
the drivers for cardiac iron loading. The availability of echo equipment opens the 
potential to measure parameters of diastolic function and assess PA pressures on site. 
12.3 International collaboration 
The thalassaemia team is currently participating in a worldwide training program 
sponsored by the Thalassaemia International Federation, Novartis and local health 
authorities. This involves travelling to sites to install T2* CMR sequences and train 
personnel in image acquisition and analysis leading to collaborative research 
opportunities. 
12.4 Ongoing prospective trials 
Research from our unit, including the improvements described in chapter 7, has helped 
establish CMR as the diagnostic tool of choice for the diagnosis and follow up of 
siderotic CM. Our unit is presently concluding a Novartis sponsored CMR driven 
randomized controlled trial comparing the efficacy of deferasirox and deferoxamine 
monotherapy in reducing cardiac iron burden in TM patients. We have also just 
commenced a 2 year trial evaluating the efficacy and safety of 
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deferasirox/deferoxamine combination therapy in severely iron overloaded TM patients 
looking at changes in T2* and bi-ventricular volume and mass changes. 
Chapters 6, 8, 9 and 10 describe how CMR can show small changes in ventricular 
function with either therapy or exposure to a cardiotoxic agent. The importance of 
assessing RV function is also emphasized and we are commencing a new ResMed 
sponsored trial investigating the bi-ventricular response to adaptive servo-ventilation in 
patients with chronic heart failure and central sleep apnoea. 
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Chapter  14: Appendices 
14.1 Personal contribution to the research 
For the EDMD study, I worked in collaboration with Professors Petros 
Nihoyannopoulos (Echocardiology) and Francesco Muntoni (Neuromuscular centre) 
from the Hammersmith Hospital. I participated in the design of the study and 
performed all the echo examinations and analyses including the myocardial velocity 
gradients. I scheduled the patient appointments at RBH and performed all the CMR 
scans working with Dr Sanjay Prasad. I performed all the CMR analysis with the 
exception of the myocardial tagging which was carried out by Dr Sharmeen Masood. 
For the Better-Care CMR protocol, I participated in the design of the study. I performed 
the scans for the main study and the day 3 sub-study either alone or with Dr Paul 
Kotwinski. I analysed all the EGRE, STIR and T2* data and participated in the 
volumetric analysis for the main study. The day 3 patient left ventricular (LV) 
volumetric assessment was performed by Dr Kotwinski to eliminate possible bias. 
For the black blood T2* study, I acquired all the CMR scans and performed the 
analysis.  
In the right ventricular response to deferiprone vs deferoxamine study I performed the 
original LV functional data analysis. The subsequent right ventricular (RV) analysis 
and interpretation was performed by myself and Dr Francisco Alpendurada. 
For the combination deferiprone plus deferoxamine trial, I travelled to Italy for all three 
time points and participated in data collection. I performed the original LV analysis 
with Dr Mark Tanner, and again I performed the RV analysis and interpretation in 
concert with Dr Alpendurada. 
The deferasirox study involved travelling to participating sites with Dr Taigang He and 
Professor Raad Mohiaddin to optimize the T2* sequence and train the imaging staff in 
CMR scanning techniques. Under the supervision of Professor Pennell, I performed all 
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T2* and volumetric analysis for both LV and RV and was responsible for the 
interpretation of the ventricular functional response. 
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